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ABSTRACT OF DISSERTATION

GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS OF
THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DRUGRESISTANT NON-SMALL CELL LUNG CANCERS
More than 80% of lung cancer patients die from drug-resistant, metastatic
disease. Our focus is to identify new drug targets and alternative therapeutic
strategies to improve outcomes for this majority of lung cancer patients. We aimed
to satisfy the need for new treatment approaches by leveraging the information
gained from the development of two multigene biomarker predictors of Epidermal
Growth Factor Receptor Inhibitors (EGFRI) response in Non-Small Cell Lung
Cancer (NSCLC). From these data, we first identified TGFβ signaling as a possible
modulator of EGFRI resistance and I hypothesized that TGFβ signaling
participates in the development and maintenance of erlotinib-resistance and sensitivity and regulates the gene expression of the miRNA comprising the
signature of response. To identify novel putative treatment strategies for
overcoming EGFRI resistance, we leveraged the raw data used to build the
EGFRI-response predictors of NSCLC cells with divergent EGFRI responses using
mathematical and protein-protein interaction modeling to identify a network of
deregulated proteins in EGFRI-resistant cells. From this analysis, we identified a
drug combination that is kills EGFRI-resistant NSCLC cells and further study will
confirm if this novel strategy translates into a clinically utilizable option for the
treatment of EGFRI-resistant NSCLC.
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CHAPTER 1

A. LUNG CANCER OVERVIEW

Overview of Cancer
Cancer is a group of genetic diseases that are caused by DNA damage and epigenetic
changes. These changes result in cells that are characterized by uncontrolled growth,
unchecked survival, and invasion into surrounding and distant tissues.
Cancers are classically characterized by six hallmarks with an additional two hallmarks
and two tumor-enabling characteristics that are increasingly recognized (1):
1)

Growth signal autonomy: Normal cells require direction of external growth

factors to drive replication. Cancers circumvent this need by mutational loss of
growth factor pathway regulation and sometimes autonomous secretion of and
response to growth factors.
2)

Genomic instability: This is a tumor-enabling characteristic. Tumor cells

gain increasing numbers of mutations and epigenetic changes that are selected
for by pressure over successive generations.
3)

Evasion of growth and proliferation inhibitory signals: The majority of the

body’s healthy cells are not actively dividing. This is due to their response to growth
inhibitory signals that are required to maintain homeostasis and prevent unwanted
growth. Cancers develop acquired mutations to evade these inhibitory signals.
4)

Tumor

promoting

inflammation:

This

is

another

tumor-enabling

characteristic. Pathways that respond to signals from the immune system that are
intended to induce cell death are co-opted by tumors to enhance tumorigenesis
and progression.
5)

Evasion of apoptosis, or programmed cell death: Normal cells undergo

apoptosis in response to events like DNA damage. Cancer cells evade apoptosis
generally through loss of apoptotic regulators.
6)

Avoiding immune destruction: The immune system can play a role of

identifying and destroying emerging neoplasias. Tumors develop methods of
locally disabling immune surveillance mechanisms.
1
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7)

Gain of unlimited replication potential: Normal cells are programmed to stop

dividing (senesce) or undergo apoptosis following too many rounds of DNA
replication and subsequent cell division events.
8)

Angiogenesis, or the formation of new blood vessels: All cells require blood

vessels to supply oxygen and nutrients and cancer cells induce the formation of
new blood vessels in order to supply their rapidly growing numbers.
9)

Deregulated cellular energetics: The perpetual proliferation of tumor cells

requires increased energy metabolism from a variety of sources (e.g.,
carbohydrates or lipids) to produce additional ATP demand to fuel growth. They
also require larger amounts of cellular building blocks like nucleotides. Tumor cells
adjust cellular metabolism pathways to meet increased energy requirements by
the tumor.
10)

Invasion and metastasis: The healthy cells only migrate for the purposes

of development and wound healing. Cancer cells exploit the pathways that regulate
these processes in order to invade surrounding tissues with the ultimate goal of
colonizing tissues at distant sites from the initial, primary tumor site.
Cancers are driven by a series of two types of mutations: 1) gain-of-function
mutations including amplification events resulting in oncogenic drivers, also known as
oncogenes, and 2) loss-of-function mutations resulting in loss of genes responsible for
regulating proliferation and survival, known as tumor suppressors (1). Proto-oncogenes,
or genes that can become oncogenic with a gain-of-function mutation in one copy of the
gene, are often involved in growth and proliferation pathways. Tumor suppressor genes
require the loss-of-function of at least one (for haploinsufficiency and lower gene dose),
but more often two copies of the gene (complete loss) in the genome. Tumor suppressors
are most often growth inhibitors, responsive to growth inhibitors, or related to DNA repair
or cell cycle check points (2). Cancers were initially described as having an “oncogene
addiction” when cell survival is dependent on the constant over-activation of oncogenic
signaling pathways (3, 4). However, it is growing increasingly evident that tumors are
incredibly heterogeneous. Therapeutically targeting only the “oncogene addiction” leads
to resistance arising from the selection of tumor cells that have alternative means of
functioning around the inhibited oncogene (4). Moreover, not all tumors have an evident
single “oncogenic addiction” and it is clear that successful tumor treatment will require the
therapeutic-targeting of multiple oncogenic drivers and sources of resistance
2
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simultaneously or sequentially (4). These specific aberrations in the cancer genome are
paramount to cancer genesis, adaptability and progression and will be described in depth
later in this chapter.
Cancer progression is marked by the extent of primary tumor invasion into the
surrounding tissues. In the later stages, after heavily invading surrounding tissues, tumor
cells gain the potential to survive beyond the stroma. This process primes them to enter
nearby blood vessels (intravasation) and be transported to distant organs via the
circulatory or lymphatic system (5). Following transport, cancer cells exit blood vessels by
a process called extravasation and either lie dormant or begin colonizing near the site of
exit (5). The colonization of distant organs is called metastasis and is a hallmark of the
latest stages of the disease most often resulting in death (1, 5). Lung cancers are
particularly deadly because the majority of patients present in the later stages of the
disease where metastatic colonization is already in progress or distant lesions have
already been confirmed (6).
Lung Cancer Epidemiology
Lung and bronchial cancers represent a significant health issue both in the United
States as well as abroad and are the number one cancer killer in the world (7). Around
14% of cancer diagnoses each year are lung and bronchial cancers (6, 8). Lung and
bronchial cancers are second in the number of diagnoses in both men and women in the
U.S. each year behind the gender specific cancers, prostate and breast (6, 8). However,
26-28% of the cancer deaths each year are attributable to lung and bronchial cancers in
both men and women, which exceeds that of any other cancer (6, 8). The high incidence
of lung cancer mortality correlates with the fact that 80-85% of patients present in the later
stages of the disease (6, 8).
The Commonwealth of Kentucky has one of the highest incidences of lung cancer
in the U.S. with an exceptionally high rate of lung cancer diagnoses in the rural,
underserved, Appalachian communities (9). Eighty-two percent of lung cancer deaths are
directly attributable to smoking (10). Frequent indirect smoke exposure also contributes to
lung cancer development (10). The Commonwealth of Kentucky has one of the highest
smoking rates in the U.S. (6, 7). Kentucky agriculture has historically relied heavily on
3
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tobacco as a major state crop. The federal deregulation of tobacco occurred in the mid2000s causing many local farmers to stop growing the crop while the local economy
suffered accordingly. Many Kentucky smokers still consider smoking to be a form of
boosting the local economy despite the decrease in working tobacco farms. Other
environmental sources of carcinogen exposure leading to lung cancer include radon,
chloromethyl ethers, asbestos, arsenic and other outdoor pollution namely by industry and
vehicles (11). Of these, high radon levels are also commonly seen in Kentucky (12).
Moreover, reliance on the rural industry of coal mining exposes many residents of
underserved Appalachia to additional industrial carcinogens including increased radon
levels and heavy metal exposure at jobsites (11, 13). The mining industry also introduces
these carcinogens into the environment where they are commonly found in the air, soil
and in water runoff further compounding the problem (13).
Lung cancers present as different histological subtypes that are broken down into
two broad categories: 1) Small Cell Lung Cancers (SCLC) and 2) Non-Small Cell Lung
Cancers (NSCLC) which encompass adenocarcinomas, bronchioalveolar carcinomas,
squamous cell carcinomas, and large cell carcinomas. Adenocarcinomas represent the
largest percentage of lung cancer cases (14).
Common Driver Mutations in Lung Tumors
Tobacco smoke is the main contributing factor to DNA mutagenesis leading to lung
cancer pathogenesis, but other environmental factors including radon, occupational lung
carcinogens and indoor and outdoor pollution contribute to lung cancer development (11).
The carcinogenic activity of tobacco smoke is largely caused by three specific groups of
chemicals: 1) tobacco-specific nitrosamines, 2) polycyclic aromatic hydrocarbons, and 3)
aromatic amines (15). As lung cancers are largely driven by carcinogen exposure resulting
in DNA damage and epigenetic alterations, they are highly heterogeneous and have one
of the highest numbers of somatic mutations among cancers (16, 17). This high level of
heterogeneity among lung tumors complicates molecular testing efforts for drug
assignment and leads to quick cancer evolution in response to treatment (18).
In recent years, an increasing number of driver mutations in lung cancers have
been identified. Growth promoting drivers of lung cancers currently known include Kirsten
4
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rat sarcoma viral oncogene homolog (KRAS), the epidermal growth factor receptor
(EGFR), BRAF, MEK-1, HER2, MET, multiple members of the PI3K/AKT/mTOR
pathways, ALK, ROS1, and rearranged during transfection (RET) (19). Prominent tumor
suppressors found to be inactivated in lung cancers that are currently known include p53,
phosphatase with tensin homology (PTEN), members of the p16INK4A/RB pathway and
STK11. Other less prevalent oncogenes currently being studied in NSCLC include
fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), MYC
family member amplification, and amplification of BCL2 (19).

The Oncogenic Drivers of the Hallmarks of Cancer in Lung Tumors
Most lung adenocarcinomas harbor known oncogenic driver mutations (20). The
activation of proto-oncogenes into oncogenes often occurs by gene amplification,
structural rearrangements forming fusion proteins with other genes, deletions and point
mutations (19). Signaling by oncogenes often results in “oncogene addiction”, making
those proteins ideal candidates for targeted therapy (3, 4). Unfortunately, the signaling
pathways regulated by oncogenes and tumor suppressors are commonly interconnected
and the mutational evolution of tumors in response to disease progression and/or
therapeutic selection pressure adds complexity to this increasingly intricate relationship
(19).
KRAS is a member of the RAS family of proto-oncogenes that include KRAS,
NRAS, and HRAS. RAS family members encode G-proteins that bind guanosine
diphosphate (GDP) in inactive form. Upon activation of an upstream receptor tyrosine
kinase (RTK), they switch to bind guanosine triphosphate (GTP) allowing the activation of
many downstream pathways (19). These pathways include the mitogen-activated protein
kinase (MAPK) pathway through ERK and phosphoinositol-3-kinase (PI3K)/AKT/mTOR
pathway (21). Activation mutations in KRAS are the result of mutations that alter the
GTPase function of the protein hindering KRAS-GTP from being inactivated into KRASGDP (19, 21). KRAS activation mutations occur in 25-40% of lung adenocarcinoma tumors
making them the most common oncogenic alterations in lung adenocarcinomas (19, 22).
Meta-analyses have shown that KRAS mutated tumors are resistant to EGFR inhibitors
(EGFRI) as KRAS signaling is downstream of the EGFR RTK (23). Mutations in HRAS
5
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Figure 1.1: Oncogenic driver mutations and percentage of occurrence in lung
adenocarcinomas.
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and NRAS are rare in lung adenocarcinomas (24). KRAS mutations are more common in
western populations, males and smokers (25, 26). KRAS driver mutations very rarely
occur in lung adenocarcinomas concurrently with EGFR activation mutations (27).
BRAF is a serine/threonine protein kinase that is downstream of KRAS signaling
in the MAPK-ERK signaling pathway (28). Activated BRAF activates MEK1/2, and MEK1/2
subsequently activates ERK1/2 which regulates transcription factors including c-Jun and
ELK1 (28). BRAF mutations only occur in about 3% of NSCLC with mutual exclusivity from
KRAS and EGFR mutations (19, 27). Similar to what is observed in melanoma and
colorectal cancers, 50-75% of BRAF mutations in lung adenocarcinomas are the V600E
activation mutation in the kinase domain of the protein (19, 29). Other BRAF mutations
observed in the kinase domain include D594G and L596R and mutations also occur in the
activation domain (G-loop) of the protein including G465V and G468A (28, 30).
MEK1 (also known as MAPK1) is a serine/threonine kinase downstream of RAS in
the MAPK-ERK signaling cascade (31). Somatic mutations resulting in activation of MEK1
are rare and found in less than 2% of lung adenocarcinomas. MEK mutations are most
often activation mutations in exon 2 that is not part of the kinase domain (32). Importantly,
NSCLC harboring these MEK1 mutations have been shown to be sensitive to anti-MEK
therapies (32).
Human epidermal growth factor receptor 2 (HER2/ERBB2) is a member of the
ERBB/EGFR family of receptor tyrosine kinases. HER2 does not commonly bind ligand
directly as most ligands have a low affinity for the HER2 receptor (33). Instead, HER2
binds to other ligand bound receptors of the same family and is a preferential
heterodimerization partner by other ERBB family receptors (33, 34). HER2 signals through
a variety of downstream signaling pathways including STAT, PI3K/ATK/mTOR, and
MAPK-ERK (35). HER2 mutations in NSCLC are observed as an overexpression in 20%
of cases, as an amplification in 2%, and activation mutations are only observed in 1-4%
of NSCLC (36, 37).
MET, also known as hepatocyte growth factor receptor, is a proto-oncogene that
encodes a membrane-spanning tyrosine kinase receptor (38). Like many other RTKs,
MET binds its ligand and homodimerizes, which results in the activation of the tyrosine
7
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kinase domain. It is able to activate Ras-MAPK-ERK, PI3K-AKT, and c-SRC pathways
(38). MET amplification is a common mechanism of acquired resistance to EGFR inhibitor
(EGFRI) treatment and is observed in ~20% (39, 40). MET amplifications are observed in
treatment naïve patients in approximately 1-7% of tumors (40, 41). MET amplification
occurrence has been reported as high as 21% in one study of a treatment-naïve cohort of
western Europeans (all non-Asian), 93% of whom were smokers (42). MET amplification
leading to acquired EGFRI resistance occurs by aberrant or unregulated PI3K-AKT
signaling. Tumors harboring a MET amplification have been shown to drive and maintain
the PI3K/AKT signaling cascade thereby bypassing EGFRI blockade (19). For this reason,
one of the mechanisms proposed to overcome acquired EGFRI resistance in NSCLC is
co-treatment with EGFRI and MET inhibitors (39).
The phosphoinositol-3-kinase (PI3K)/AKT and mTOR signaling pathways are
responsible for cell survival, proliferation, differentiation, adhesion and motility and are
also frequently mutated in NSCLC (43). Many of the receptor tyrosine kinases are able to
activate this pathway including EGFR, MET, HER2, insulin-like growth factor receptor,
platelet-derived growth factor receptor, and transforming growth factor receptor beta
(TGFβ) (44). Activated RTKs recruit PI3K to the membrane where it is responsible for the
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol
3,4,5-triphosphate (PIP3). Active PIP3 recruits AKT to the membrane where it can be
phosphorylated by PI3K and/or mTOR (45). RAS family members have been shown to be
able to activate PI3K directly contributing to the cross talk between PI3K/AKT/mTOR and
MAPK-ERK signaling cascades (45). The PI3K/AKT/mTOR signaling pathway is
commonly deregulated in NSCLC, and other cancers, with 50-70% of NSCLC harboring
PI3K pathway member mutations (22, 44). Oncogenic mutations in PI3K and AKT have
been reported with amplification of the PIK3CA gene, which encodes the alpha isoform of
the PI3K catalytic subunit, most commonly observed (44). PIK3CA mutations largely
involve the catalytic domain and occur in 1-3% of NSCLC (22). Mutations in AKT are rare,
only being reported in 0.5-2% of NSCLC (22). Loss of PI3K regulation by the tumor
suppressor component, PTEN, also occurs and will be discussed further below (45).
ALK is a receptor tyrosine kinase found commonly with a gain-of-function mutation
in NSCLC resulting in constitutively active ALK signaling (46). ALK mutations are most
commonly rearrangement mutations resulting in a fusion of the intracellular kinase domain
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with a different gene, echinoderm microtubule associated protein-like 4 (EML4) (47, 48).
ALK-EML4 fusion proteins come in a number of variants, but the most commonly
described is the fusion of exons 1-13 of EML4 joined to ALK exons 20-29 (47, 49). Other
partner genes besides EML4 have been described recently, but are less common (50).
Active ALK signaling results in cell proliferation and apoptotic evasion mediated by
JAK3/STAT3, RAS/MAPK-ERK, and PI3K/AKT signaling pathways (51). Oncogenic ALK
mutations are susceptible to ALK inhibition by crizotinib (52) and have been found in
approximately 4-8% of NSCLC (53). ALK rearrangements generally occur exclusively from
EGFR and KRAS alterations, but instances of ALK rearrangements occurring
concomitantly with EGFR mutations have been reported as a mechanism for EGFRI
resistance (20, 47).
ROS1 is a proto-oncogene encoding a transmembrane receptor tyrosine kinase.
Its kinase domain has high homology with that of ALK (54). Similar to ALK, ROS1
mutations are most commonly gene rearrangements resulting in fusion proteins and are
found in 1-3% of NSCLC (55, 56). A variety of fusion partners have been identified
including, FIG, KDELR2, TPM3, SDC4, LRIG3, EZR, SLC34A2, and CD74 (50, 56). Early
clinical evidence has suggested that NSCLC harboring ROS1 rearrangements are
sensitive to the ALK/MET kinase inhibitor, crizotinib (55).
Rearranged during transfection (RET) is a proto-oncogene activated by
chromosomal rearrangement resulting in oncogenic fusion RTK signaling (57). RET is
most commonly found fused with KIF5B and RET fusions have been identified in 1-2% of
NSCLC (58). Tumors harboring RET rearrangements are sensitive to several multi-kinase
inhibitors, and recent in vitro evidence suggests that tumors harboring KIF5B-RET fusions
are sensitive to RET inhibition (59).

The Tumor Suppressors Commonly Lost in Lung Cancer
Tumor suppressor genes are important negative regulators of cell growth and
proliferation, and a normal functioning cell requires two copies of these genes to function
(60). Tumor suppressor genes were famously described as “anti-oncogenes” by Alfred
Knudson in 1993 where he outlined a “two-hit” hypothesis describing how the loss of two
9
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copies of a tumor suppressor gene resulted in carcinogenic activity (60). The first allele is
most often lost by an inactivation mutation, epigenetic silencing or other aberrations, while
the second allele is most commonly lost by loss of heterozygosity (LOH) when a region of
a chromosome is lost by deletion, mitotic recombination, or non-reciprocal translocation
(19). The most common tumor suppressor genes inactivated in NSCLC are TP53, PTEN,
the p16INK4A/RB cell cycle regulating pathway, and serine/threonine kinase 11 (STK11).
Others have been noted, FHIT and RASSF1A, but they are less prevalent in NSCLC than
those listed and are discussed elsewhere.
The most commonly occurring gene mutation found in lung cancers is TP53. TP53
mutations are found in up to 80-100% of small cell lung carcinomas and in up to 65% in
non-small cell lung cancers, although a consensus on frequency varies (19, 61, 62). p53,
the protein product of the TP53 gene, is responsible for making cell fate decisions in
response to damaged DNA by upregulating genes responsible for DNA repair or apoptosis
accordingly (63). It is also a transcription factor for a host of other genes (19). In healthy
cells, DNA damage or other carcinogenic stress induces p53 expression, which promotes
DNA repair or cell cycle arrest by inducing the expression of cyclin-dependent kinase
inhibitors (64). For this reason, p53 plays a crucial role in determining cell fate between
whether to repair DNA damage or undergo apoptosis (65). TP53 loss is most commonly
due to a hemizygous deletion of the chromosomal locus in which it resides (19). TP53 loss
of function also occurs when missense mutations in the DNA binding domain occur (62).
TP53 mutations in NSCLC correlate with a history of smoking or environmental exposure
to smoke (64, 66). TP53 mutations can occur concomitantly with EGFR and KRAS
mutations (67).
A second commonly mutated tumor suppressor is phosphatase with tensin
homology (PTEN). As discussed earlier, PTEN is a lipid and protein phosphatase
responsible for inhibiting PI3K/AKT/mTOR signaling. It does this by dephosphorylating
PIP3 back into PIP2 (68).
STK11 (also known as LKB1) is a serine/threonine kinase responsible for inhibiting
mTOR (69). As described above, components of the AKT/mTOR signaling pathway have
been found to be deregulated in around 30% of lung adenocarcinomas (22). STK11
activity is inhibited by a variety of deletion or other somatic mutations leading to inactive,
10
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Figure 1.2: Tumor suppressors that are commonly lost in lung adenocarcinomas.
Percentage of lung adenocarcinomas with each tumor suppressor loss. Occurrence laid
over the oncogenic driver mutations in lung adenocarcinomas.
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truncated proteins (70). Inactivation of STK11 specifically occurs in 11-30% of lung
adenocarcinomas (22, 70, 71). STK11 inactivation mutations comprise the third most
common mutation observed in lung adenocarcinomas behind p53 and KRAS (19, 70). It
has been suggested that STK11 mutations correlate to smoking history. STK11 loss has
also been correlated with the existence of KRAS mutations. Smoking status, KRAS
mutations, and STK11 mutations are mutually exclusive of EGFR mutations (70, 71).
The p16INK4A/cyclin D1/CDK4/RB pathway is responsible for cell cycle progression
between G1 and S phase and members of the pathway are commonly mutated in lung
cancers (19). Retinoblastoma protein (Rb), encoded by the RB1 gene, mediates the G1/S
transition of the cell cycle by sequestering the E2F1 transcription factor required for Sphase entry until its phosphorylation (72). RB1 was the first tumor suppressor gene
described in lung cancer (73). It is found to be inactivated in around 90% of lung
carcinomas, but it is only inactivated in 10-15% of NSCLC (17). In NSCLC, perturbations
in this pathway most commonly come from members upstream of RB resulting in hyperphosphorylation of the protein leaving the G1-S transition to occur unchecked. In NSCLC,
these alterations occur in cyclin D1, CDK4 and the cyclin-dependent kinase inhibitor,
p16INK4A (74). In normal signaling, p16INK4A is responsible for inhibiting phosphorylation of
RB by cyclin D1 halting the cell cycle. p16INK4A is inactivated in approximately 80% of
NSCLC (75, 76). Overexpression of cyclin D1 by gene amplification, epigenetics, or
transcriptional upregulation is found in ~40% of NSCLC (77).
Targeted Therapies in NSCLC
Targeted therapies are quickly becoming standard of care for lung cancers
harboring oncogenic mutations. The majority of NSCLC patients present with tumors in
the advanced stages of the disease (78). Until very recently, patients with advanced stage
NSCLC were most often placed onto platinum-based chemotherapy regimens (29).
Clinical trials examining the efficacy of various platinum-doublet combinations have
revealed that improving the therapeutic benefit of conventional chemotherapies has hit a
plateau. This has spurred forward the development of therapies that target specific
oncogenic mutations to improve outcomes (29, 79). Several targeted therapies have
become the standard of care for advanced NSCLC harboring specific mutations and they
are described below. When paired with the development of diagnostic or companion
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biomarkers, these targeted therapies have greatly improved treatment for some patients
while the remainder are treated with the appropriate cytotoxic agents (29). Importantly,
EGFR is commonly targeted in lung adenocarcinomas and will be covered more in depth
in the EGFR section of this chapter. A discussion of the hallmarks of cancer with current
FDA-approved drugs targeting them in lung cancer is presented below.
Targeting Growth and Proliferation in NSCLC
Oncogenic KRAS mutations occur in 25-40% of NSCLC and are common in
pancreatic, colorectal, serous ovarian and thyroid cancers, making them a desirable
therapeutic target (80). Mutant KRAS is also an attractive target because it tends to occur
exclusively of other driver mutations (e.g., EGFR, ALK) (81). Over the last three decades,
attempts at targeting KRAS have been largely unsuccessful, and there are currently no
KRAS inhibitors approved or in trials. Current methods of “targeting” mutant KRAS involve
targeting the members of downstream pathways to eliminate oncogenic KRAS signal
through them (81). These include inhibitors of MAPK-ERK and PI3K/AKT/mTOR pathways
among others, and the FDA approved inhibitors of each of these targets are outlined below
(81).
Oncogenic ALK rearrangement mutations (described in the oncogenes discussion
above) were first described in 2007 and have been found to occur in around 4-8% of
adenocarcinoma patients (82). The first generation ALK inhibitor, crizotinib, was approved
in 2011 for use in patients with advanced NSCLC harboring a confirmed ALK
rearrangement mutation (83). A second generation ALK inhibitor, ceritinib, is 20 times
more potent than crizotinib and has demonstrated promise in patients who progressed on
crizotinib or were intolerant of crizotinib. It has also performed well in ALK-inhibitor-naïve
patients (84). The other second generation ALK inhibitor, alectinib, has shown activity
against the crizotinib resistance mutation (L1196M), reducing the size of both previously
treated and untreated brain metastases (29). Both of the second generation ALK-inhibitors
are indicated for use in patients who progressed on or were intolerant of crizotinib (29).
Importantly, NSCLC that harbor ROS1 rearrangements have also been shown to be
sensitive to crizotinib treatment, which suggests a possible dual role for the ALK inhibitor
although it is not currently FDA-approved for use in ROS1 rearrangements (29).
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BRAF mutations occur in approximately 2-3% of NSCLC and are also a therapeutic
target in lung cancers. Approximately 50-75% of the BRAF mutations observed in lung
cancer are the V600E mutation that also occurs commonly in melanoma (85). V600K also
occurs in 6-30% of melanomas (86), but it is very uncommon in NSCLC. Of the approved
BRAF inhibitors, vemurafenib and dabrafenib have demonstrated significant activity in
BRAF V600E and V600K mutant melanomas, so they are being explored for efficacy in
NSCLC both alone and in conjunction with the MEK inhibitor, trametinib (29). Initial Phase
II trials of trametinib combined with dabrafenib revealed an overall response rate of 63%
(29). Vemurafenib has also demonstrated activity in NSCLC patients harboring a BRAF
V600E mutation as a single agent (87, 88). While vemurafenib and dabrafenib are in trials,
none are currently FDA approved specifically for the treatment of NSCLC.
The tissue-type specific drug approval by the FDA for targeted therapies has
limited our ability to best match patients to targeted therapies (e.g., BRAF in lung). Offlabel use occurs, but this limits payment options leaving the majority of patients unable to
receive these therapies unless they have been specifically designated for their specific
tumor type and mutation status. An ongoing NCI trial, Molecular Analysis for Therapy
Choice (MATCH), is currently working to identify whether actionable variants of 143 genes
associated with cancer that match to 20 drugs in the study work in a non-tissue-specific
manner (89). The study specifically aims to assign targeted therapies independent of
anatomical tumor locations in any advanced or solid tumors or lymphomas that are
refractory or with no standard therapy (89). Of the drugs described above, crizotinib is
included for ALK and ROS1 rearrangements, while dabrafenib in conjunction with
trametinib and trametinib alone are included for BRAF mutations. The EGFR/HER2
inhibitor, afatinib (described in depth below), is also included for the treatment of
EGFR/HER2 mutations (89). Other oncogenic mutations found commonly in lung cancers
that are included are AKT and PIK3CA. Hopefully, this endeavor will end the “off-label”
use of targeted therapies across tissue types. This would allow patients whose tumors
harbor specific mutational statuses responsive to targeted therapies to receive them.
Targeting Angiogenesis in NSCLC
As stated earlier, loss of growth and proliferation regulation is not the only
commonality between tumors that allow them to grow and invade unchecked. One of the
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CHAPTER 2
drivers of lung cancer currently being targeted clinically is angiogenesis. Angiogenesis is
the process by which cancer cells stimulate surrounding blood vessels to grow into and
around a tumor supplying the oxygen and nutrients rapidly proliferating cells need to grow
– it is also imperative for the development of metastatic lesions (1). The development of
anti-angiogenesis therapies have been aimed at inhibiting the vascular endothelial growth
factor (VEGF) receptor on local endothelial cells. These inhibitors intentionally target
normal tissues is to prevent them from responding to stimuli coming from the tumor.
Importantly, the opportunity to target the healthy cells to minimize tumor growth is a
promising option because healthy cells are significantly less likely to develop resistance
to a drug. There are currently two FDA-approved drugs that target the VEGF receptor in
lung cancers: bevacizumab and ramucirumab. Both are monoclonal antibodies targeting
the extracellular, ligand-binding domain of the VEGF receptor (29).
Targeting the Immune Evasion Mechanisms of NSCLC
Immune evasion is also a commonality among tumors. In the past few decades, it
has grown increasingly evident that the role of the tumor microenvironment, namely the
interaction of the tumor cells with circulating immune cells, is critical for cancer growth and
progression (90). Therapeutic targeting of tumor cell immune evasion has recently gained
a lot of momentum as a first-line clinical option for patients with high PD-L1 expression
(90). Inhibiting both of these interactions between the tumor and its surroundings are
imperative to cutting tumors off from their resources and self-preservation methods.
Evasion of the immune system is a key step in cancer development, specifically for
NSCLC. Tumors overcome the immune responders (activated T cells, B cells, natural killer
cells monocytes and dendritic cells) by over-expressing PD-L1 or PD-L2 ligand on their
cell surface (90). The immune responder cells, CD4, CD8 and pro-B cells, express the
receptor (PD-1) on their surface. The interaction between the receptor on the immune cell
and the ligand on the tumor cell suppresses the anti-tumor immune response. This
process is also known as T-cell exhaustion (90). By blocking the interaction of PD-L1 with
the PD-1 receptor on immune cells, T-cell exhaustion is overcome allowing immune cells
to maintain their tumor-cell killing function (91).
There are currently three approved monoclonal antibodies targeting this interaction
between immune cell receptors and the tumor cell blockade of immune response:
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Drug

Specific
Mutations

Target

Stage

Drugs Targeting Growth and Proliferation

ALK

Rearrangements in
both
Rearrangements

Approved for
ALK
Approved

Alectinib

ALK

Rearrangements

Approved

Vemurafenib

BRAF

V600E and V600K

Dabrafenib

BRAF

V600E and V600K

Gefitinib

EGFR

Erlotinib

EGFR

Afatinib

EGFR/HER2/HER4

Dacomitinib

EGFR/HER2/HER4

EGFR Exon 19
Deletion or L858R
EGFR Exon 19
Deletion or L858R
EGFR Exon 19
Deletion or L858R/
EGFR T790M
EGFR T790M

Clinical trials
Clinical trials
alone and in
combination
with trametinib
(MEK inhibitor)

Neratinib

EGFR/HER2

EGFR T790M

Clinical trials

Osimertinib

EGFR T790M

EGFR T790M

Necitumumab

EGFR

None

Cetuximab

EGFR

None

Approved
Approved in
combination
with
gemcitabine
and cisplatin
Clinical trials

Crizotinib

ALK/ROS1

Ceritinib

Approved
Approved
Approved
Clinical trials

Drugs Targeting Angiogenesis
Bevacizumab

VEGFR

None

Approved

Ramucirumab

VEGFR

None

Approved

Drugs Targeting Immune Evasion Mechanisms
Nivolumab

PD-1

Pembrolizumab

PD-1

Atezolizumab

PD-L1

High PD-L1
Expression
High PD-L1
Expression
High PD-L1
Expression

Table 1.1: Targeted therapies in NSCLC.
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nivolumab, pembrolizumab, and atezolizumab. Pembrolizumab (marketed as
Keytruda) is an IgG4 isotype humanized monoclonal antibody targeting PD-1 molecules
expressed on the surfaces of the immune cells (92). Nivolumab (marketed as Opdivo) is
also a monoclonal antibody targeting PD-1 molecules on immune cell surfaces. It is a fully
humanized IgG4 isotype antibody (93). The final immune checkpoint inhibitor currently
approved for use in NSCLC is atezolizumab (marketed as Tecentriq) (90). Atezolizumab
is a fully humanized IgG1 isotype monoclonal antibody targeting the PD-L1 ligand on the
tumor surface rather than the PD-1 receptor on the surface of the immune cells (94). PDL1 expression levels are being investigated as a predictive biomarker with success in
some tumor subgroups, but it does not appear that PD-L1 levels have prognostic value
(90).
B. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
As stated earlier, EGFR is a common oncogenic driver of NSCLC. This body of work
stems from the Black laboratory’s work in identifying predictive biomarkers of EGFR
inhibitor success in NSCLC, and for this reason I have described it in depth below.

EGFR Activation and Signaling
EGFR is a transmembrane, receptor tyrosine kinase (RTK) that includes an
extracellular ligand binding domain and an intracellular tyrosine kinase domain (95). EGFR
is a member of the ErbB family of RTKs that are structurally similar. They consist of an
extracellular, ligand binding domain, a lipophilic membrane-spanning domain, and a
cytoplasmic tyrosine kinase domain (96). EGFR and other members of the ErbB RTK
family have varying affinities for multiple ligands. The extracellular growth factors with
which they interact include epidermal growth factor (EGF), transforming growth factor
alpha (TGFα), heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AREG),
epiregulin (97), and betacellulin (BTC) (98). Binding of the ligand results in receptor
homodimerization or heterodimerization with other members of the EGFR/ErbB family of
receptors resulting in autophosphorylation of the tyrosine residues of the kinase domain
(96, 99, 100).
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EGFR signal transduction occurs through MAPK-ERK, PI3K/AKT/mTOR, and
STAT signaling pathways (99, 100). Importantly, signal transduction through these
signaling pathways is not exclusively driven by EGFR in normal cells. Rather, EGFR
belongs to a network of other RTKs that can activate common effectors (101). The
complexity of these networks is growing constantly and the phenomenon is being
described as ‘crosstalk’ amongst the signaling pathways and RTKs (102). This improves
our understanding of compensatory signaling routes and the development and
maintenance of targeted therapy-resistance. However, it also underscores the need for
developing novel methodologies targeting multiple sources of tumor driving and drug
resistance generating pathways.
One of the pathways stimulated by EGFR activation is the MAPK-ERK pathway,
with members RAS/RAF/MEK/ERK. The MAPK/ERK signaling pathway is specifically
responsible for growth and proliferation, which is why it is commonly mutated in cancer
(28, 67). EGFR activates this cascade by phosphorylating the KRAS GTPase using
mediator proteins (e.g., SOS and GRB2) (103). Phosphorylated KRAS then
phosphorylates BRAF, which in-turn phosphorylates MEK1/2, and finally MEK1/2
phosphorylates ERK1/2. Phosphorylated ERK then translocates into the nucleus where it
activates transcription factors associated with growth and proliferation (e.g., ELK1 and
ETS1) (104). The MAPK-ERK pathway is ultimately responsible for regulating the
expression of genes that drive growth and proliferation of the cell (e.g., MYC and JUN)
(105, 106).
EGFR signaling also activates the PI3K/AKT signaling pathway. The initial steps
in PI3K/AKT signaling are described more in depth in the oncogenes and tumor
suppressor sections above. The important thing to note about this signaling pathway is
that AKT is able to activate a number of independent downstream pathways. In normal
signaling, one role of AKT is the phosphorylation of the Bcl-2 family member, Bad, which
ultimately leads to caspase activation and the induction of apoptosis (107). AKT can also
signal through the mammalian target of rapamycin (mTOR), sometimes referred to as
mechanistic target of rapamycin, which is responsible for regulating cell size and
proliferation in non-cancerous cells (108).
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Figure 1.2: EGFR Signaling Pathways.
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A third signaling pathway driven by EGFR is the signal transducers and activators
of transcription signaling pathway mediated by a family of STAT molecules (109). Until
rather recently, STAT signaling was believed to be activated only by cytokine signals (e.g.,
interferon and interleukin family members) with its activation being mediated by the Janus
Kinase (JAK) (110, 111). We now know that STAT proteins can also be indirectly activated
by EGFR via SRC-mediated phosphorylation (112). Phosphorylation of a STAT molecule
results in a homodimerization with a STAT family member of the same type, resulting in
translocation of the complex into the nucleus and gene expression regulation (112). STAT
family members are responsible for regulating the expression of genes promoting survival,
growth and proliferation, immune response, angiogenesis and wound healing (113, 114).
Importantly, these three signaling pathways do not encompass all of the signaling
events regulated by EGFR, just those that are best characterized and are relevant to the
contents of this dissertation.
EGFR Mutations in Non-Small Cell Lung Cancers (NSCLC)
EGFR action as an oncogene impacts many cellular functions including
proliferation, differentiation, invasion, survival, neovascularization and metastasis (100).
EGFR mutations are found in a number of tumor types including NSCLC (19). In lung
cancers, the majority of EGFR mutations occur in lung cancers of the adenocarcinoma
histological subtype (25, 67) and are also most commonly found in younger patients who
are female with no history of smoking (22, 115, 116). EGFR activation mutations have
been identified in 10-15% of unselected western patients (20, 25). However, EGFR
activating mutations occur more commonly in Asian populations and are observed in 3040% of lung tumors (67, 115). EGFR oncogenic mutations result in constitutive tyrosine
kinase activation (117).
In NSCLC, oncogenic mutations in the EGFR gene occur in the exons (18-24) that,
when translated, comprise the tyrosine kinase domain of the protein (19). The most
common of these mutations are the exon 19 frame deletion mutations, of which there are
over twenty different variants that account for around 45% of the EGFR mutations in
NSCLC (19). The second most common type of EGFR mutations are missense mutations,
most commonly L858R in exon 21, accounting for approximately 40% of EGFR mutations
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in NSCLC (67). Less common EGFR mutations (~5-10% of EGFR mutations in NSCLC)
leading to EGFR inhibitor (EGFRI) resistance often involve in-frame duplications of
insertions into exon 20 (26). Variant-III (EGFRvIII) mutations also occur (~3% of NSCLC)
where the extracellular binding domain of EGFR is deleted, which prevents the EGF ligand
from binding, but still results in aberrant downstream signaling (118). EGFRvIII, gene
duplication mutations, and over-expression of EGFR protein occur more commonly in
squamous cell carcinomas than in adenocarcinomas (119).
Acquired resistance mutations are most often selected for in patients undergoing
EGFRI treatments which lead to resistance. The most common of these is the T790M
point mutation in exon 20, which results in an amino acid change from a threonine to a
methionine. This interferes with the binding of reversible EGFRIs (120). The T790M
mutation is found in approximately 50-60% of patients who develop acquired resistance
to EGFRIs (120). Importantly, T790M mutations have been observed in treatment-naïve
patients, so they are not exclusively driven by EGFRI treatment (20). Other common
routes of EGFRI resistance occur through the activation of PI3K-AKT signaling pathway
and this is most commonly achieved by amplification of MET (39).
Mutations in EGFR are not the only mechanism by which aberrant EGFR signaling
occurs in lung cancer. EGFR has also been found to be over-expressed, generally as a
result of a genomic amplification event, with increased EGFR copy number observed in
up to 50% of lung cancers (121). EGFR over-expression can also occur as a result of
increased promoter activity or a decrease or loss of transcriptional or translational
regulation mechanisms (122). EGFR over-expression results in increased EGFR activity
with and without activating mutations present suggesting that the increased activity is likely
due to the high volume of receptors in the membrane spontaneously dimerizing with one
another at the cell surface (122, 123). Increased expression or cleavage-processing to
mature form of ErbB family ligands has also been linked to increased EGFR stimulation
through autocrine (cell to self) and paracrine (cell to immediate surrounding cells) dosing
of growth-inducing ligands (124, 125). Finally, it has been suggested that EGFR
heterodimerization to other ErbB RTK family members could be a contextual contribution
to oncogenic signaling in tumors (122). Specifically, EGFR-ErbB3 heterodimerization has
been described in NSCLC as a possible source of EGFR targeted therapy resistance (39,
126). EGFR-ErbB3 dimers are imperative for EGFR regulation of PI3K/AKT. Specifically,
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the ErbB3 tyrosine kinase domain differs from EGFR which allows the docking of PI3K
directly to the kinase (127). EGFR-ErbB3 dimers are dissociated by EGFRIs, but the
resultant under-activation of AKT signaling leads to compensatory over-expression of
ErbB3. This shifts the receptor equilibrium, thereby reducing EGFRI response (127).
Inhibition of EGFR in Lung Cancer Therapy
There are currently two main classes of drugs targeting EGFR (EGFRI) in cancer:
1) small molecule inhibitors of the tyrosine kinase domain of EGFR (EGFR-TKIs) and 2)
monoclonal antibodies that bind the extracellular ligand binding domain preventing the
binding of EGF or other ErbB family ligands and activation of the receptor. Currently, only
the small molecule inhibitors of EGFR are used in lung cancers and a review of EGFRtargeting monoclonal antibodies in lung cancer and why they are not currently used is
provided below.
Small Molecule Inhibitors of EGFR
Preclinical work in the development of EGFR inhibitors demonstrated that point
mutations in the ATP binding pocket of EGFR could eliminate its tyrosine kinase activity
(128-130). This led to the development of two competitive, reversible, ATP binding pockettargeting small molecules as the first generation of EGFR-TKI inhibitors: gefitinib (Trade
name: Iressa) and erlotinib (Trade name: Tarceva) (130, 131). Early trials of the first
generation EGFR-TKIs revealed that patients with no smoking history, Asian ethnicity and
a tumor of adenocarcinoma histology were most likely to respond to treatment (132). It
was determined later that patients exhibiting these clinical characteristics most often
harbored the EGFR exon 19 deletion or exon 21 L858R activation mutations (3, 133). Due
to these observations, the prospective Phase 3 trial was performed specifically in patients
exhibiting these clinical characteristics in Asia (134). Mok et al. demonstrated that patients
with a confirmed EGFR mutation had a significantly higher overall response rate and
longer progression free survival when treated with gefitinib compared to the platinumbased chemotherapy arm (134). They also demonstrated the gefitinib treatment arm of
patients without an EGFR mutation had significantly lower overall response and a shorter
progression free survival (134). This study established EGFR mutation status as a
biomarker for EGFR-TKI patient selection (29, 135). Since then, a number of studies
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comparing the first generation EGFR-TKIs, gefitinib and erlotinib, as well as second
generation, afatinib, to platinum-doublet chemotherapies have consistently demonstrated
superior overall response rates, progression-free survival, and quality of life in the targeted
therapy arm (136-140). Retrospective analysis of some of these studies suggested that
afatinib treatment offered greater overall survival in exon 19 deletion tumors over L858R
tumors. However, the more recent LUX-Lung 7 trial designed to confirm prior study results
did not observe the same effect (141, 142). Erlotinib was FDA-approved in 2004 for the
treatment of NSCLC as a second or third line therapy. It was most recently redesignated
in October 2016 for the treatment of locally advanced or metastatic NSCLC harboring
EGFR exon 19 deletions or exon 21 L858R substitution mutations (143, 144). Notably,
gefitinib received conditional FDA approval following Phase II trials in 2003, but approval
was later withdrawn after negative Phase III results in unselected patients (145). In 2015,
gefitinib was FDA-approved a second time, but only as a first line therapy in patients with
metastatic, EGFR mutant NSCLC, and not in populations harboring other mutations (146).
Importantly, a majority of patients on first-line EGFR-TKIs do progress between 10-15
months following the start of treatment (29, 147).
The most common reason for progression is the development of secondary
resistance mutations in EGFR. For this reason, the second generation of EGFR-TKI
development has been largely centered around overcoming secondary mutations in
EGFR. Selecting the treatment following progression on EGFRI relies heavily on being
able to identify the source of resistance (147). Importantly, not all EGFR-TKI resistance
mechanisms arise due to mutations in EGFR. Bypass-signaling by other RTKs (e.g.,
HER2 and ALK), downstream mutations (e.g., BRAF and PIK3CA), and phenotypic
changes (e.g., EMT) are also sources of EGFR-TKI resistance (147, 148). As previously
stated, T790M mutations are the most common acquired EGFR-TKI resistance mutations
in NSCLC accounting for 50-60% of treatment-induced resistance (120). Because of this,
the second generation of EGFR-TKIs aimed to comprehensively target this acquired
resistance mutation (T790M) and other resistance sources (e.g., HER2, HER4) (145).
Second generation small molecule inhibitors, afatinib, dacomitinib, and neratinib, are each
irreversible inhibitors of the EGFR tyrosine kinase domain (147). Each targeted T790M
mutations, had some overlap in the EGFR sensitivity conferring mutations, and all include
some binding to the HER2/HER4 receptors which represent an additional source of
potential resistance (147). While the in vitro study of each of these three drugs appeared
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promising, clinical trials of the second-generation EGFR-TKIs in patients resistant to either
of the first generation EGFR-TKIs only demonstrated a response rate of around 10% (149151). Additionally, adverse side effects were observed at drug concentrations too low to
inhibit T790M mutated EGFR molecules in vivo (149-151). Currently, afatinib is the only
second generation, small-molecule EGFR-TKIs approved for the treatment of advanced
NSCLC harboring an exon 19 deletion mutation or an exon 21 L858R EGFR activation
mutation (152).
The third generation of small molecule EGFR-TKIs are being designed specifically
to target the T790M mutation more effectively than the second generation small
molecules. Rather than targeting both mutant and wild-type EGFR and other conserved
receptors (e.g., HER2 and HER4), these specifically target mutant EGFR (T790M, exon
19 deletion, and exon 21 L858R substitution) with minimal impacts on wild-type EGFR
(147). Importantly, this would theoretically limit adverse events, but minimal activity
against wild-type EGFR highlights that these inhibitors will not be utilizable in patients with
amplified/overexpressed EGFR. All third generation EGFR-TKI small molecule inhibitors
are irreversible inhibitors of EGFR (147). Of them, only one (osimertinib) has been
approved for the treatment of metastatic NSCLC with the EGFR T790M mutation (153).
The rocelitinib study has been paused in Phase II/III trials due to side effects, and olmutinib
is only approved in Asia. ASP8273 is in Phase III trials, and nazartinib, PF-06747775,
avitinib, and HS-10296 are all in Phase I/II trials (147). As with first and second generation
small molecule EGFR-TKIs, third generation inhibitors select tumor cells with novel or rare
point mutations (e.g., C797S in exon 20 or L798I/Q in cis with T790M) leading to
resistance (154-156). Most importantly, additional mechanisms of EGFR-independent
resistance to third generation EGFR-TKIs are being reported (147). Activating mutations
in NRAS (e.g., E63K) as well as amplification of wild-type NRAS and KRAS have been
reported in osimertinib resistance. These mutations were also observed in gefitinib and
afatinib resistance (157). It has been suggested that loss of the T790M population of cells
led to the over-growth of cell populations with HER2 amplifications, PIK3CA mutations or
BRAF V600E at the time of progression (158). Amplifications of HER2 and MET genes
have also been described as mechanisms for overcoming T790M-targeting EGFR-TKIs
(155). All of the resistance mechanisms described above in response to single-agent
EGFR-TKIs underscore the need to target other pathways concurrently or sequentially
with EGFRI-TKIs to minimize or eliminate resistance mechanisms. Very importantly, the
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third generation of EGFR-TKIs are much better tolerated than the first and second
generations and this observation has opened them to be explored as co-therapeutics with
new studies and clinical trials currently in the planning stages (147).
Targeting EGFR with Monoclonal Antibodies
Another therapeutic route for antagonizing EGFR signaling in NSCLC is the use of
EGFR-targeting monoclonal antibodies. Anti-EGFR monoclonal antibodies work by
targeting the ligand binding domain of EGFR and competitively block the interaction of
EGFR with any of its ligands (159). Complexes of EGFR and anti-EGFR monoclonal
antibodies are then internalized and degraded leading to a decrease in cell surface EGFR
(160). It has also been suggested that this action could lead to antibody-dependent cellular
cytotoxicity (161). EGFR-directed monoclonal antibodies currently being investigated are
cetuximab, matuzumab, panitumumab, and necitumumab, but others are in development
(160).
Cetuximab has been studied in Phase II and III trials in combination with first-line
chemotherapy in advanced NSCLC (162-164). Two Phase III trials, FLEX and BMS099,
were opened to compare the combination of chemotherapy with cetuximab. The FLEX
trial demonstrated improved overall survival with the combination treatment versus
chemotherapy alone whereas BMS099 did not demonstrate an improvement in
progression free survival (165, 166). Importantly, only the FLEX trial analyzed and
considered EGFR expression levels as a point of comparison in survival computations.
Patients expressing high EGFR levels that were treated with the combination of cetuximab
and chemotherapy had a median survival of 12 months compared to 9.8 months in
patients expressing low levels of EGFR, although this difference was not found to be
statistically significant (121, 167). Though demonstrated in colorectal cancers, KRAS
mutation status does not predict response rate, progression-free survival, or overall
survival in NSCLC (168, 169). Necitumumab was analyzed in two Phase III trials as well:
INSPIRE tested activity in advanced non-squamous cell NSCLC, and SQUIRE tested
efficacy in squamous NSCLC (170, 171). The INSPIRE trial was prematurely closed due
to an increased number of adverse events, grade 3 or higher, including fatal
thromboembolic events and sudden/unexplained death (170). The SQUIRE trial
demonstrated improved overall survival in the combination necitumumab arm compared
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to chemotherapy alone (171). Currently, only necitumumab in combination with
gemcitabine and cisplatin is FDA approved for use in lung cancer, specifically only in
squamous histological subtype NSCLC (172, 173).

C. TRANSFORMING

GROWTH
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As stated before, the Black laboratory’s efforts have been centered on identifying
predictive biomarkers for EGFR-TKI therapies. We also aim to leverage the genes
comprising the biomarkers to identify novel treatment options for overcoming both inherent
and acquired resistance to EGFR-TKIs in NSCLC. As will be described in more detail later,
one of our gene signatures indicated TGFβ as a putative source of EGFR-TKI resistance.
For this reason, I’ve included an in-depth look at TGFβ signaling and its role in cancer
below.
TGFβ is a ubiquitous cytokine that is active in a number of cell processes, and the
majority of cell types contain the ability to secrete the ligand as well as the receptors to
respond to it (174). TGFβ signaling is essential for development, cell differentiation,
homeostasis and wound healing in adult tissues (175). TGFβ belongs to the TGFβ
superfamily of receptors and transcription factors that has over thirty members. The TGFβ
superfamily can be subdivided into two distinct signaling families: 1) TGFβ, activin, nodal
and other factors and 2) growth and differentiation factors including the bone morphogenic
proteins (BMPs) and the anti-muellerian hormone (AMH/MIS) (176-178). Other members
of the TGFβ superfamily are responsible for embryonic stem cell differentiation,
organogenesis, body axis formation and symmetry establishment during development
(179). In the developed adult, TGFβ superfamily members are responsible for functions
like gonadal regulation, muscle development, and bone growth and repair (179). TGFβ
superfamily expression and signaling behavior is largely tissue-specific limiting their
signaling in adult tissues (176).
TGFβ Signaling
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The Receptors
TGFβ canonical signaling has three receptor types (TβR-I (type 1), TβR-II (type 2),
and TβR-III (type 3)), three ligands (TGF-β1, TGF-β2, and TGF-β3), and three
transcription factors (Smads 2, 3, and 4) (178, 180, 181). Importantly, TβR-III expression
is tissue-specific and lung tissues and tumors have very low levels of the type 3 receptor
expression (182). Outlined below are the activities of the TβR-I/II receptor complexes. The
TGF-β1 ligand isoform has been specifically shown to activate canonical Smad (2,3,4)
signaling via TβR-I and TβR-II interactions (183). TGF-β1 activates signaling by binding
the type 2 receptor (175). The active, ligand-bound type 2 receptor then binds a type 1
receptor forming a heterodimer where the type 2 receptor can transphosphorylate the type
1 receptor (175). The active heterodimer then binds to a second type 1 and type 2 receptor
resulting in a tetrameric complex of TGFβ receptors that can recruit, bind and activate
Smad transcription factors (180).
Canonical TGFβ Signaling
The term ‘Smad’ is derived from embryonic development work in Drosophila on
Mothers against decapentaplegic (MAD) and from SMA in C. elegans. In humans, the
conserved equivalent is called SMA and MAD related protein, hence the name Smad.
Smads 2 and 3, also known as the receptor Smads (R-Smads) due to their direct
interaction with the TGFβ receptor complex, are phosphorylated by the active type 1
receptor on the C-terminal SSXS motif contained within the MAD homology (MH) 2 domain
(181). Phosphorylation of Smads 2 and 3 results in a conformational change of the protein.
This reveals the MH1 domain containing the nuclear localization signal (NLS) and linker
region by which the R-Smads can complex with Smad 4 (181). Unbound Smad 4 traffics
between the cytoplasm and nucleus, and is the only Smad with a nuclear export signal
(NES) (181). Active Smad heterocomplexes accumulate in the nucleus, presumably due
to the masking of the NES on Smad 4 by the R-Smads (181, 183). Nuclear localization of
active Smad complexes enables them to interact with various co-activators and corepressors resulting in either the induction or repression of TGFβ signaling pathway
responsive genes respectively (183). Smad regulation of genes occurs specifically by their
binding to Smad Binding Elements (SBEs) contained in the promoters of TGFβ signaling
pathway responsive genes (181, 184).
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Figure 1.3: TGFβ Signaling Pathways.

28

CHAPTER 2
TGFβ signaling via the Smads is regulated by a variety of cellular mechanisms.
Smad 2 and 3 must dock with the receptor for activation by TβR-I and the process of
docking relies on several adaptor proteins including SARA, Hgs, and Dab2 (185-187).
Activation of Smads 2 and 3 can also be blocked by the inhibitory Smad (Smad7) that
impedes the phosphorylation of the R-Smads. Smad7 can do this with two mechanisms:
1) It can physically bind TβR-I blocking the binding of the R-Smads (188), and 2) it recruits
Smurf 1/2 (E3 ubiquitin ligase) to facilitate TGFβ receptor degradation (189). The RSmads also undergo linker region phosphorylation by other signaling effectors (e.g., ERK
1/2, JNK, p38, Casein Kinase 1, and CDKs) that results in stabilization of active Smad
signals (175, 190). Finally, Smad 2/3/4 complexes are disabled and disassembled by
PPM1A phosphatase, followed by Smurf 1/2 polyubiquination, and proteosomal
degradation (191, 192). The TGFβ receptor complex can also be regulated by proteins
that associate with it. One of these, TGFβ-receptor-interacting protein 1 (TRIP-1), interacts
with ligand bound TGFβ complexes and is phosphorylated by them (181). Increased levels
of TRIP-1 represses TGFβ signaling and mutants of TRIP-1 have been shown to enhance
TGFβ signaling (193).
Normal TGFβ canonical signaling is involved in the regulation of cytostasis and
autonomous growth suppression (175). TGFβ mediates cytostasis in the G1 Phase of the
cell cycle by specifically initiating the downregulation of c-Myc (180, 194). Myc
downregulation results from a complex of Smad 3, E2F4/5, and p107 bound to an SBE in
the Myc promoter (194, 195). Smad 3 also regulates ID1 via a complex of Smad 3 and
ATF3 bound to an ID1 promoter region SBE (196). In this context, this is a self-enabled
activity of Smad 3 as it is also responsible for the induction of ATF3 expression (196).
TGFβ also negatively influences cell proliferation by regulating the cyclin dependent
kinase inhibitors p15INK4b and p21CIP (180, 194). Specifically, Smad 3 downregulation of
Myc prevents the complex of Myc and Miz-1 from forming and thereby blocks p15
transcription that is reliant on the Myc/Miz-1 complex (197). Then Smad 3 complexes with
free Miz-1 and Sp1 to stimulate p15 transcription (197). TGFβ activation also results in the
formation of Smad 2:3/Sp1/FoxO complexes that are responsible for transactivating the
promoter of p21 (198).
Non-Canonical TGFβ Signaling
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Like many RTKs, the TGFβ receptor is able to modulate a network of signaling
pathways in addition to the canonical effectors. It is specifically able to activate the growth
and proliferation pathways MAPK-ERK, MAPK-p38, and MAPK-JNK (199, 200). The role
of TGFβ in MAPK-ERK signaling came to light after it was observed that Ras was rapidly
activated by TGFβ ligand treatment in epithelial cells (201). The TβR-I/II complex can
activate the MAPK-JNK and MAPK-p38 pathways via TGFβ-activated kinase 1 (TAK1).
TAK1 can also activate the growth and survival kinases PI3K/AKT/mTOR and AKT/PKB
as well as GTP binding effectors like RhoA, and Rac (202, 203). TGFβ signaling is known
to repress NFκβ signaling in non-cancerous cells (204). It has also been implicated in
mediating the activation of other kinases, including the focal adhesion kinase (FAK), Abl,
and Src, by either direct activation or transcriptional control (205-207).
Activated TGFβ receptors can also influence signaling in many of these pathways
via the Smads, which complicates our understanding of the TGFβ signaling network.
Smad-mediated activation of the MAPK-p38 signaling cascade has been shown to induce
Caspase-8 and Bid activation, resulting in apoptosis (208). TGFβ signaling can also
induce apoptosis through other members of the mitochondrial Bcl-2 family, as well as via
NFκβ, AKT, and MAPK-JNK intracellular moderators (209).
The Role of TGFβ in Lung Cancer
TGFβ Signaling Pathway Mutations in NSCLC
Mutations in the TGFβ signaling pathway members (e.g., Smads) do occur, but
most are not commonly observed in lung cancers. Loss of TβR-III expression is commonly
observed in lung cancers, which is not surprising as signaling via the TβR-III receptor has
been shown to block cell motility and invasiveness in NSCLC (210). Smad 2 mutations
are observed in 7% of lung cancers and are most commonly missense mutations
impacting the Smad-complex-forming region of the MH2 domain or the DNA binding
domain within the MH1 domain (211, 212).
The “TGFβ paradox”
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As previously stated, TGFβ signaling plays an imperative role in cellular
homeostasis and genomic stability by inducing cell cycle arrest, differentiation and
apoptosis of cells. In the early stages of tumor development, TGFβ signaling maintains
these roles, thus serving as a potent anti-cancer agent (213). In the later stages of tumor
development, TGFβ signaling activity switches to promote cell growth, invasive ability, and
ultimately metastasis. This dichotomous activity of TGFβ signaling has been rightly
dubbed the “TGFβ paradox” (175). While many theories exist on how this switch occurs
mechanistically, it is increasingly evident that the means by which the shift in TGFβ
signaling activity occurs likely happens on a case-by-case contextual basis adding further
complexity to this already enigmatic problem. Some of the mechanisms proposed to
explain the shift in TGFβ signaling include the changes in miRNA expression such as the
miR-106b-25 cluster (214, 215). Others have suggested that epigenetic changes altering
TGFβ signaling activity (e.g., TGFβ receptor methylation or promoter over-activation
depending on tissue-specific context) and target (e.g., ID1) expression result in the shift
from anti- to pro-tumorigenic TGFβ signaling (179, 216). As further described below, TGFβ
signaling results in the secretion of cytokine-stimuli into the tumor microenvironment and
is activated in response to stimuli in the tumor microenvironment as well. The positive
feedback loop between tumor cell TGFβ signaling and tumor-infiltrating immune cells that
amplify the stimuli have also been described as a possible mechanism for the signaling
switch to occur (217, 218). Finally, mutations in TGFβ signaling family members or
regulators (e.g., p15INK4b deletion eliminating TGFβ regulation) have been suggested as a
possible mechanism (213). What is evident is that there is neither a specific consensus
across tumor models or TGFβ-paradox arms as to how the paradox arises, nor a
methodology for accurately determining which arm is at play. This is incredibly important
because while pro-tumorigenic TGFβ seems to be an obvious and promising target,
unintentional targeting of anti-tumorigenic TGFβ signaling in unselected patient
populations may be detrimental (179, 219).
The Roles of TGFβ Driving the Hallmarks of Cancer
1) Growth Signal Autonomy: While there is no known mechanism underlying the
shift in TGFβ activity from growth suppressor to growth promoter, it has been
postulated that it may be coupled to TGFβ’s ability to induce the expression of
many cytokines, growth factors, and their receptors (175). TGFβ signaling
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promotes the production of EGFR and PDGFR receptors as well as cytokines
and ligands including: connective tissue growth factor (CTGF), bFGF, PDGF,
and TGFα (175). The phosphorylation of the Smad 2/3 linker region by
pERK1/2 is another source driving prolonged TGFβ signaling (175).
2) Genomic Instability: The role of TGFβ signaling in the accumulation of genomic
instability is more of an unintentional consequence than a direct action.
Specifically, tumors overcome the regulation of cell cycle progression via Smad
3 regulation of Myc, p15 and p21, which in turn impacts the DNA damage
recognition and repair pathways as well as the cell fate decision (197, 220).
TGFβ has also been shown to influence changes in the epigenome, which also
lead to accumulating genomic instability. Specifically, Smad 2 has also been
shown to complex with HDAC resulting in the silencing of targets such as p15
(221).
3) Evasion of Growth Suppressors: As stated earlier, normal TGFβ signaling
plays a role in negative cell cycle regulation. Neoplastic mechanisms for
overcoming cytostatic TGFβ activity include deregulated Myc expression,
methyltransferase inactivation of p21 transcription, and aberrant PI3K/AKT
signaling (197, 220, 222, 223). It has also been suggested that TβR-III and
TGF-β3 likely play a role in suppressing unregulated TGFβ signaling (210).
4) Tumor Promoting Inflammation: TGFβ ligands produced by cancer cells serve
as an attractant for tumor-infiltrating monocytes and macrophages (224).
These immuno-species are known for their ability to promote tumor invasion
and metastasis in response to TGFβ signals from the tumor cells. They do this
by stimulating angiogenesis and the breakdown of the extracellular matrix
(225).

They

also

secrete

additional

TGFβ

ligand

into

the

tumor

microenvironment further stimulating the tumor and in turn more immunospecies (225). Many other tumor microenvironment species also secrete and
respond to TGFβ ligands (e.g., myeloid-derived suppressor cells) amplifying
the TGFβ signal and driving TGFβ-metastasis (226).
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5) Evasion of Apoptosis: TGFβ signaling is specifically involved in the induction
of apoptosis in normal cells through both caspase-dependent and caspaseindependent means discussed above (209). Many of the aberrations
characteristic of in the “TGFβ paradox” shift to pro-tumorigenic activity (e.g.,
p15INK4b loss) specifically lead to a loss in growth suppression activity by TGFβ
(174).
6) Avoiding Immune Destruction: TGFβ activity has been shown to suppress
immunosurveillance by specifically inhibiting NK and cytotoxic T lymphocyte
differentiation resulting in a decrease in the cytotoxic effectors they secrete,
including: Fas ligand, perforin/granzyme, lymphotoxin-α, and interferon-γ (218,
227-229). Moreover, TGFβ further inhibits the tumor-targeting ability of these
two immune cell types by stimulating regulatory T cells in the tumor
microenvironment (230).
7) Unlimited Replication Potential: The shift of TGFβ signaling to pro-tumorigenic
activity results in cell cycle regulation loss and is important to the acquisition of
unlimited replication in cells (213). The shift also overcomes the ability of TGFβ
to induce apoptosis using a variety of means (209). While these hallmarks of
the “TGFβ paradox” shift do not truly result in unlimited replication potential (by
means like telomerase overexpression), they do contribute by deregulation of
the cell cycle and evasion of apoptosis.
8) Angiogenesis: TGFβ signaling enhances tumor vascularization in a number of
ways including the direct induction of key angiogenic factors including VEGF
and CTGF (231, 232). TGFβ also plays a role in the maturation of new blood
vessels. Smad 2/3 activation in response to TGFβ has been shown to correlate
with genes involved in blood vessel maturation, including plasminogen
activator inhibitor 1 (PAI-1) and fibronectin (233).
9) Deregulating Cellular Energetics: TGFβ signaling plays a role in deregulating
cellular energetics indirectly. TGFβ is specifically associated with the
development of rigid tumor microenvironments that allow for the enhancement
of cell selection and metastatic expansion (234). TGFβ signaling alters cellular
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energetics to meet the need of a growing and changing tumor by regulating the
expression of Lysyl oxidase (LOX) family members that are responsible for
cross-linking extracellular matrix building-block proteins like collagen and
elastin (175). In normal tissues, LOX family members play a role in embryonic
development and organogenesis. Importantly, their pro- or anti-tumorigenic
activity with respect to TGFβ signaling appears to correlate with the “TGFβ
paradox”.
10) Invasion and Metastasis: One of the best characterized role of TGFβ signaling
in cancer is its ability to induce EMT, one of the initiating steps of metastasis.
During EMT, cells lose their cellular polarity and adhesive properties and gain
enhanced migratory and invasive capabilities. It has been shown that the
induction of EMT by TGFβ relies on both Smad-dependent and Smadindependent signals (174). TGFβ-driven EMT is associated with the expression
of E-cadherin repressors Zeb1 and Zeb2 (235). Specifically, the Zeb proteins
associate with other corepressors, including Smad 3 to repress the
transcription of epithelial genes such as E-cadherin (E-cad) (236). Moreover,
many non-canonical pathways downstream of TGFβ activation contribute to
EMT induction in response to TGFβ signaling directly or pathway collaboration
with TGFβ signaling. The downstream signaling pathways shown to be
responsive to TGFβ or work in collaboration with TGFβ include MAPK-ERK,
PI3K/AKT, Rho/ROCK, Hedgehog, and WNT signaling pathways (190, 237).
Targeting TGFβ Signaling in Cancer: A Paradox Problem
Effectively targeting TGFβ signaling therapeutically in cancer without inducing side
effects has been the unachievable goal of the TGFβ community for decades. TGFβ clearly
plays a role in tumor progression by driving growth. However, more important when
considering therapeutic value are the roles of TGFβ in vascularization, reciprocal immunestimulatory activities within the tumor microenvironment, as well as invasion and
metastasis. As stated earlier, EMT is a process that not only complicates EGFRI
sensitivity, but also complicates cancer treatment across tumor types (1, 147). In lung
cancer alone, between 80-85% of patients present with a tumor that has already invaded
nearby tissues or distally metastasized. This high percentage of advanced tumors is the
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foremost reason why lung cancer treatments have such poor outcomes (6). For this
reason, it is understandable why the field would aim to target one of the premiere drivers
of tumor metastasis. Progress has been made in the last decade and a half towards
understanding the enigma of the “TGFβ paradox” and the role TGFβ plays in driving tumor
progression and metastasis will certainly keep it an attractive target moving forward (213).
Unfortunately, many attempts have been made to target TGFβ clinically, and while they
show promise in treating some tumors, they have devastating off-target effects in others
(219). This is likely attributable to the role of TGFβ in normal cells. As stated earlier, TGFβ
is specifically responsible for preventing cell growth, proliferation and survival in normal
tissues following appropriate completion of development processes (175). Delineating the
pro-tumorigenic activities of TGFβ from the anti-tumorigenic behaviors and determining
how to identify and target them clinically is paramount to the success of TGFβ inhibitors
(179).
Identifying which arm of the TGFβ-paradox is occurring continues to be enigmatic,
so we need to seek out means of targeting pro-tumorigenic TGFβ signaling activities
without targeting TGFβ directly. Recently, the activity of protein kinase CK2, also known
as Casein Kinase 2 (CK2), has been linked to TGFβ-induced EMT as well as the
development of acquired EGFRI resistance (238, 239). Initial clinical studies of its orallyavailable inhibitor, CX-4945, suggest that treatment is well tolerated by patients unlike
TGFβ inhibitors (240). For this reason, I explored it as an alternative avenue for
overcoming EGFRI resistance and have compiled an overview of it below.

D. CASEIN KINASE 2 (CK2) BIOLOGY

The Kinase
Casein Kinase 2 (CK2) is a protein kinase that is ubiquitously expressed in both
healthy and cancerous cells (241). CK2 consists of two catalytic subunits (α and α’; gene
IDs CSNK2A1 and CSNK2A2, respectively) and two regulatory subunits (both CK2β; gene
ID CSNK2B) (241). The complete protein kinase CK2 holoenzyme can be any tetrameric
arrangement of two α subunits and two β subunits (i.e. α2β2, αα’β2, α’2β2) (242). There is
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also mounting evidence that CK2α and CK2α’ subunits have kinase activity in their
monomeric forms, but the holoenzyme has a substantially higher affinity for substrates
(243, 244). Live-cell fluorescent imaging revealed that the majority of CK2 subunits are
not contained in holoenzyme, but are dispersed as single subunits throughout the cell
(245). Once the formed holoenzyme, subunits are predicted to remain associated as the
dissociation constant for the holoenzyme is incredibly low (246).
CK2α and CK2β subunits have been shown to be essential for viability using
murine knock-out studies. CK2α’ knock out mice are viable, but males of this genotype
are sterile (247). This suggests that while CK2α may be functionally distinct from CK2α’,
it is able to partially compensate for its loss (241). Loss of the CK2β subunit results in early
embryonic lethality in mice (248). CK2 has been shown to play a role in spermatogenesis
(247), organ development (248, 249), and it has been suggested that its function is
imperative during embryogenesis (250). In adult tissues, CK2 levels have also been
shown to increase during times of cell proliferation and return to basal expression levels
following proliferation events (242). While CK2 is constitutively expressed in nearly all
tissues, its basal levels are considered to be sparse compared to other kinases (251).
Importantly, unlike CK2, most kinases are regulated by expression levels and, more
specifically, by activation events like ligand binding. Since CK2 is constitutively active, low
expression levels are likely important to moderating CK2 activity.
What makes CK2 so unique is that unlike other proto-oncogenic kinases, CK2 is
constitutively active without the aid of a gain-of-function mutation in both normal and
cancer cells (252). Because CK2α subunits are constitutively phosphorylated, the source
of regulation must be something other than an upstream kinase. One of the known
mechanisms of CK2 regulation comes from the CK2β “regulatory” subunits, which have
been shown to act in a stimulatory fashion unlike the name suggests in most cases (253).
However, in very specific cases (e.g., calmodulin and MDM2), CK2β subunits have been
shown to be potent inhibitors of CK2α phosphorylation of the substrate protein and,
thereby, regulating the kinase activity of the α subunits (254, 255). The CK2 holoenzyme
has very high affinity for most of its substrates compared to free subunits and it has been
suggested that this ability to complex tightly with many of its substrates is bridged by the
CK2 dimer portion of the enzyme (256, 257). For this reason, decreases in CK2β
expression might lead to an imbalance of active substrates of CK2α monomeric activation
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Figure 1.4: CK2 Signaling Pathways.
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versus active substrates by the holoenzyme. CK2 is believed to be regulated by a
combination of its subcellular location as well as its binding to other proteins or non-protein
factors (255, 258). CK2 dynamically localizes to a variety of specific cellular compartments
and/or organelles based on a diverse set of cellular conditions (259-261). Specifically,
CK2 has been shown to shuttle between nuclear structures such as the chromatin and
nuclear matrix in response to changes in growth stimuli (262, 263). It is also known to be
dispersed throughout the cell during mitosis, which lends to the observation that its
aberrant signaling is occurring in cancer cells where the mitotic process is recurring far
more frequently than in normal cells (264). The protein degradation pathway has also been
implicated in regulating its action (265).
CK2 in Cancer
As stated earlier, CK2 expression levels are relatively stable and very small
changes in its protein expression heavily impact the regulation of cellular homeostasis
(242). Prior work has shown a link between CK2 subunit expression changes and the
transformation of cells (266-268). CK2 subunits are upregulated in all cancers that have
been profiled for its expression, including lung and bronchial, prostate, breast, colorectal,
ovarian and pancreatic cancers (269). Increased CK2 activity from overexpression of the
constitutively active kinase has been associated with aggressive tumor behavior (269,
270). Additionally, CK2 has no known gain-of-function mutations that would drive
neoplastic transformation (252). For this reason, the reigning opinion is that overexpression of CK2 subunits leads to malignant transformation of cells, and this mechanism
has been described as a “non-oncogene addiction” (271).
Perhaps most fascinating is that, across the literature, CK2 has been implicated
for playing a role in the genesis and maintenance of every one of the classic as well as
the emerging “hallmarks of cancer” (1):
1) The Role of CK2 in Growth Signal Autonomy
The global role of CK2 in cell signaling has been described as acting
“horizontally” across a number of “vertical” signaling pathways both in cancer and
in healthy cell signaling, thereby representing a means of pathway integration in
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cancer cells (271, 272). CK2 has been shown to regulate common developmental
signal transduction cascades known to be adulterated in tumorigenesis.
Specifically, PTEN is phosphorylated by CK2 altering its stability and limiting its
ability to regulate AKT signaling (273, 274). Similarly, CK2 drives AKT activation
by phosphorylating it at a specific serine residue, Ser129, leading to
hyperactivation of AKT signaling (275, 276). CK2 has also been shown to interact
with the kinase suppressor of RAS (KSR) molecular scaffold required for the
spatial regulation of MAPK-ERK signaling and its loss from that complex results in
impaired RAF, MEK, and ERK activation (277). CK2 also influences a number of
other signaling pathways responsible for aberrant growth and proliferation in
tumors including JAK/STAT (278), NFκβ (279), fibroblast growth factor (FGF) (280,
281), AKT/PKB signaling (275), Wnt signaling (279, 282), and Hedgehog signaling
(283). Importantly, CK2 has been shown to connect many of these pathways acting
as an intermediary effector in the network. Specifically, EGFR/ERK has been
shown to stimulate WNT/β-catenin through CK2α (284).
2) The Role of CK2 in Genomic Instability
CK2 has been well described for its role in regulating the response to DNA
damage. Perhaps the best described role of CK2 in the cell cycle is that it regulates
the tumor suppressor, p53. It does so by CK2-mediated phosphorylation at serine
392 in response to UV induced DNA damage (268, 285-287). Specifically, UVinduced DNA damage induces the assembly of the CK2-hSPT16-SSRP1 complex
(288). CK2 has also been shown to phosphorylate MDM2, which decreases its
binding affinity for pRB and reduces its ability to direct p53 degradation (285, 289).
Another important feature of CK2 activity that promotes the genomic instability
fueling oncogenic transformation is that it would appear to play a crucial role in
transcription and chromatin remodeling (290, 291). CK2 activity is also connected
to all three RNA polymerase functions, DNA topoisomerase II, as well as a number
of pre-mRNA transcription and splicing factors suggesting a further role in mRNA
translation (292-295). It is believed that phosphorylation of transcription and
splicing factors by CK2 likely changes their activity as well (296). CK2 has also
been shown to facilitate DNA repair through phosphorylation of the XRCC1
scaffolding protein required for single-strand break repair and base excision repair
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(297) and plays a role in many cellular mechanisms that recognize and repair DNA
damage and strand breaks (251).
3) The Role of CK2 in the Evasion of Growth Suppressors
CK2 also plays a role in the evasion of growth suppression by the negative
regulation of tumors suppressors like PTEN and PML. PML is a tumor suppressor
responsible for moderating the pathways involved in growth suppression,
apoptosis and senescence, and it is most frequently lost in tumors by posttranslational mechanisms (298). CK2 promotes ubiquitin-mediated degradation of
PML by phosphorylating it at Ser517 (298). CK2 has also been shown to
phosphorylate the tumor suppressor PTEN at its C-terminus tagging it for
proteasome-mediated degradation (274). Importantly, the CK2 phospho-site on
PTEN is not the only one influencing the fate of PTEN (299). CK2 has also been
recently identified for its ability to phosphorylate and inhibit the action of another
member of the p53 tumor suppressor family, the TAp73 variant, promoting a
cancer stem cell phenotype in head and neck cancers (300).
4) The Role of CK2 in Tumor Promoting Inflammation
CK2 has been shown to play a role in tumor-promoting inflammation
pathways. Specifically, it has been shown to respond to reactive oxygen species
(ROS) by interactions with p38, ultimately inducing NFκβ activation (301). Platelet
activating factor (PAF) and tumor necrosis factor α (TNFα) also drive the activation
of p38/CK2/NFκβ in response to ROS (301). CK2 has also been shown to
modulate IL-6 expression in breast cancer. It has been suggested that IL-6
stimulation induces CK2 to phosphorylate the EMT effector, TWIST, thereby
stabilizing it (302, 303). This is an example of how CK2 can influence and respond
to tumor microenvironment inflammation signals that promote tumor development.
It has also been shown that CK2 interaction with JAKs is necessary for the
induction of JAK/STAT signaling in response to inflammatory cytokines (278), and
inhibition of CK2 prevents constitutive STAT signaling (304). Interestingly, CK2
maintains epithelial characteristics in patients with chronic colitis preventing
inflammation-driven apoptosis (305).
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5) The Role of CK2 in the Evasion of Apoptosis
CK2 has been implicated for globally regulating apoptotic pathways
influencing Bid, Bad, Max, Faf1, Bcl-2 and Bcl-xL, caspase 2, caspase-inhibiting
protein ARC, and the inhibitor of apoptosis proteins (IAPs), which include survivin
(242, 263). Specifically, the activation of AKT/PKB signaling by CK2 has been
shown to upregulate survivin expression by β-catenin (306). It has also been
demonstrated that CK2 inhibition can sensitize breast tumor cells to TRAILinduced apoptosis mediated by the Apo2 ligand (307, 308). Moreover, targeting
overexpressed CK2 in glioblastoma results in the suppression of pro-survival
signaling pathways including PI3K/AKT, JAK/STAT, HSP90, Wnt, Hedgehog, and
NFκβ (309).
6) The Role of CK2 in Avoiding Immune Destruction
The role of CK2 in the ability of cancer cells to avoid immune response is
only coming to light very recently. Rather than a function in the cancer cells
themselves, CK2 activity in regulatory T-cells (Tregcells) has been implicated for its
role in helping tumor cells hide from immune responses. Specifically, it has been
shown that CK2β ablation in the Tregcells of mice results in the induction of a
cancer-killing inflammatory response called T helper type 2 (TH2) by dendrites
responding to the differentiated Tregcells (310). CK2 is overexpressed in Tregcells,
and its function specifically suppresses T-cell antigen receptor signaling in
Tregcells. Ultimately, this results in the induction of the TH2 inflammatory response
in the lungs (311). It has been suggested that global targeting of CK2 in cancer
treatment could possibly have the secondary impact of inducing the TH2 response
and eliciting an impactful anti-tumor immune response (311).
7) The Role of CK2 in Replicative Immortality
CK2 has been described as interacting with and/or phosphorylating many
of the proteins involved in the regulation of the G1/S cell cycle checkpoint as
described above. To date, CK2 interactions with p53 have not been shown to
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differentiate between normal and mutant p53 as well, so it is not surprising that its
action plays a role in replicative immortality in cancer cells expressing mutant p53
(312, 313). It has been demonstrated in glioblastoma cells that CK2 inhibition is
sufficient to induce p53-dependent cell cycle arrest and also results in sensitization
of cells to TNFα-driven apoptosis (314). CK2 inhibition also resulted in increased
telomerase activity and increased p53-dependent senescence, but importantly,
these functions by CK2 inhibition were only observed in p53 wild-type cells (314).
8) The Role of CK2 in Angiogenesis
CK2 has been well described for its role in promoting angiogenesis in
tumors. CK2 regulates hypoxia inducible factor-1α (HIF-1α), the main
angiogenesis inducing pathway, in a variety of ways (315). It has been shown that
inhibition of CK2 results in lower expression of HIF-1α during times of hypoxia
because of increased p53 levels (316, 317). CK2 has also been shown to
specifically phosphorylate Proline-Rich-Homeodomain protein (PRH) specifically
blocking its ability to bind DNA. This action prohibits PRH from repressing VEGF
and other components of VEGF signaling (318). FGF has also been implicated in
angiogenesis and it is also a known binding partner of CK2β. The complex of FGF2 and CK2 has also been shown to drive CK2 kinase to act on nucleolin which is
responsible for the synthesis and maturation of ribosomes (281). This relationship
suggests that CK2 activity is likely also important for the production of FGF and
VEGF signaling components (e.g., ligands, receptors). Finally, it has also been
shown that PDGF signaling, a common growth factor player in angiogenesis,
induced the expression of CK2α’ subunits.
9) The Role of CK2 in Deregulating Cellular Energetics
CK2 plays such an extensive role in the other hallmarks of cancer, so it is
no surprise that it also may play a role in the metabolic reprogramming of cells
required to compensate for the increased energy demands of developing tumors.
Specifically, CK2 kinase activity has been described as regulating the purinosome,
a multi-subunit complex responsible for purine synthesis in cells in response to
changes in available nucleotides (319). CK2 has also been directly linked to the
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hormonal regulation of carbohydrate metabolism as well as the regulation of other
enzymes involved in carbohydrate storage and metabolism (320). Finally, CK2
activity has been implicated in upregulating cytosolic levels of zinc, a secondary
messenger implicated in many growth and proliferation pathways including AKT
and ERK1/2 activation. CK2 phosphorylates the ZIP7 channel on the endoplasmic
reticulum simulating it to open, thereby releasing stored zinc levels into the cytosol
(321).
10) The Role of CK2 in Invasion and Metastasis
Recently, the greatest interest in CK2 as a tumor driver has been in its role
in invasion and metastasis. CK2 has been shown to be an intermediate effector
linking pERK activation by EGFR to the phosphorylation of α-catenin and the
subsequent transactivation of β-catenin leading to invasiveness of tumor cells
(284). CK2β down-regulation has been observed concurrently with dramatic
changes in cell migration and adhesive properties (322). A genome-wide
characterization of mRNA expression in CK2β-depleted breast cancer cells
highlighted the upregulation of the core mesenchymal genes (CDH2, VIM, SNAIL1,
TWIST1, ZEB1, ZEB2, etc.), and a down-regulation of the core epithelial genes
(CDH1, CDH3, MUC1, etc.) (322). CK2β-depleted breast cells also demonstrated
changes in a number of genes responsible for the necessary extracellular matrix
and cytoskeletal alterations required for EMT (e.g., ADAM19, ADAM23, FN1,
COL6A1) (322).
Therapeutic Targeting of CK2 in Cancer
The initial trepidation in targeting CK2 came from the revelations that it interacts
with a large fraction of the kinome, and when inhibited, might logically result in adverse
events in patients. It has also been shown that knockouts of two of the three subunit types
results in embryonic lethality (248, 249, 252). Despite this, the growing knowledge of the
role of CK2 in tumorigenesis of many types of cancer led to the development of the orallyavailable CK2 inhibitor, CX-4945 (Silmitatsertib), in 2010 (252). CX-4945 is in clinical
Phase 1/2 trials in cholangiocarcinoma (240) (323). However, CK2 inhibition is currently
not being investigated in lung cancers.
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CX-4945 treatment has been largely inconsequential as a single agent, likely
because the majority of its roles in cancer can be compensated for by other kinases (252).
Importantly, Franchin et al. demonstrated that CK2 null cells (α/α’(-/-)) still demonstrate
pAKT S129 levels despite the fact that the Serine 129 residue is a specifically known CK2
phosphosite (252, 324). This reinforces the notion that single-agent CK2 inhibition may
continue to have poor efficacy as an anti-tumor therapy because compensatory signaling
is readily activated. It also highlights that CK2 is a logical secondary signaling source that
may be responsible for drug-resistance to current targeted therapies. A Phase 1/2 trial in
cholangiocarcinoma is examining the combination of CX-4945 with gemcitabine and
cisplatin (323) and combinations of CX-4945 and other targeted agents are currently being
explored pre-clinically.

E. PROJECT OVERVIEW
The aim of our lab is to use pharmacogenomics to improve the clinical care of lung
cancer patients. Specifically, we have used high-density genomic data generated from
NSCLC cell lines with known sensitivities to EGFRI to do three things:
1) Develop predictors of EGFRI-response in order to accurately stratify NSCLC
patient response to EGFRI therapy. As stated earlier, clinically-utilized small
molecule inhibitors of EGFRI are specifically designated for the treatment of
tumors harboring specific EGFR mutations. Using single-gene mutation
statuses to identify patient response does not encompass all putative
responders, nor does it account for non-responders harboring the mutation of
interest. Developing more robust predictors is paramount to accurately
stratifying responders from non-responders. It can also identify the potential for
resistance development in patients.
2) Interrogate the deregulated genes and signaling pathways identified by gene
expression predictors to gain a greater understanding of the biology governing
response to EGFRI in NSCLC. Exploring the genes and pathways that indicate
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drug-sensitivity provide essential knowledge for identifying the mechanisms by
which resistance to therapy develops. We might also identify possible
secondary targets for the treatment of EGFRI-resistant NSCLC.
3) Leverage deregulated mRNA and miRNA genes to determine putative
interactions that might be exploited to identify novel drug targets and
methodologies for treating EGFRI-resistant NSCLC. We have developed a
methodology for expanding the network in a disciplined manner to identify
nodes connecting deregulated signaling pathways and cellular processes.
Using this multi-faceted approach to identify deregulated networks, we are able
to filter much of the “noise” generated by the heterogeneity among NSCLC
lines in the genomic studies. From a translational standpoint, this is a
particularly difficult hurdle in identifying novel drug targets and treatment
strategies for lung tumors that harbor immense amounts of somatic mutations
and expression level changes.
The history of targeting EGFR and managing EGFRI resistance has been built on
the philosophy of targeting “oncogene addictions” exclusively. While many NSCLC are
reliant on overactive EGFR signaling, almost all eventually develop resistance to EGFR
inhibitors because subpopulations of cells not requiring constitutively active EGFR
signaling or with mutant, drug-resistant EGFR arise (29, 147). The second and third
generations of EGFR inhibitors were built to overcome some of the resistance
mechanisms that are acquired, but have essentially continued to monotherapeutically
target EGFR (147). This strategy does not impact the development of other resistance
mechanisms through other kinases and oncogenes (e.g., MET, ALK and ROS1),
phenotypic changes (e.g., EMT), and alterations in downstream effectors (e.g., BRAF)
(147, 148). Moreover, consecutive generations of EGFRI have also allowed the selection
of novel resistance polymorphisms in well-characterized EGFRI antagonists (e.g., NRAS
E63K and EGFR L798I/Q) (147, 154-156). Mechanisms of drug-resistance across every
biological model from antibiotic-resistance in bacteria to anti-retroviral resistance among
HIV/AIDS patients highlight that drug-resistance results from the selection of
cells/organisms that have evolved means of bypassing drug efficacy. Complex eukaryotic
organisms like humans have cells that possess many more avenues of circumventing
specific nodes while achieving the same results in response to situations like genetic loss
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or damage. While this behavior of compensatory signaling is imperative for human growth,
development, and survival despite genetic defects, it is also exploited by tumor cells to
overcome both innate and pharmacological anti-cancer strategies. Continuing our current
method of simply modifying EGFR inhibitors with a focus on targeting only EGFR will likely
always be met with resistance mechanisms that will continually evolve to overcome the
newest anti-EGFRI.
Early EGFRI-TKI efficacy prediction relied on the presence of EGFR activation
mutations and KRAS activation status (3, 133, 143, 166, 169, 325, 326). This method of
identifying responders did not segregate responders completely. To address this, our lab
hypothesized that multivariate biomarkers could be used to better capture the EGFRIresistant and -sensitive phenotypes (327, 328). In line with our first aim to produce
biomarker signatures of drug efficacy, the lab produced two different polygenic biomarkers
predictive of EGFRI sensitivity, one of 180-mRNA and one of 13-miRNA genes (327, 328).
Importantly, both are the product of larger lists of deregulated genes that distinguish the
EGFRI-resistant and -sensitive phenotypes.
The second goal of our lab is to interrogate the list of deregulated genes that stratify
EGFRI-resistant and -sensitive cells. We do this to better understand the biology driving
each phenotype, thereby rationally seeking alternative methods for targeting EGFRIresistance. Of the mRNA that were found to be deregulated for the generation of the 180mRNA signature, MAPK-ERK and PI3K/AKT/mTOR signaling were prominently
represented (328). Because of this, our lab members have systematically interrogated the
value of MEK and EGFR combinatorial therapy (329), the regulation of downstream ERK
by deregulated dual-specificity phosphatases (DUSPs) (330), and the role of p110α
isoform compensation in PI3K inhibitor compensation (331).
The desire for a new perspective on the cellular deregulation stratifying EGFRIresistant and -sensitive cells led to the development of the second signature identifying
response to the EGFR-TKI, erlotinib. Comprised of 13- deregulated miRNA genes, the
additional signature was not only able to discriminate between EGFRI-resistant and sensitive cells, but was also able to distinguish clinical samples as primary or metastatic
lesions (327). Bioinformatic analysis of the 13-miRNA genes comprising the signature
revealed that they functionally converged on the TGFβ signaling pathway (327). As stated
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Figure 1.5: Cross talk amongst TGFβ, EGFR, and CK2 Signaling.
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earlier, phenotypic changes, like EMT, are sources of EGFRI resistance (148) and TGFβ
is a known driver of the EMT program (332, 333). Moreover, many of the signature miRNA
putatively control expression of EMT-related proteins (327). For this reason, the first
hypothesis I proposed and tested was that the miRNA comprising the signature of
response were transcriptionally regulated by canonical TGFβ signaling by Smad
activation/repression (Chapter 2). Canonical TGFβ signaling by Smad activity could be
responsible for controlling the expression of the miRNA that distinguish EGFRI-resistant
from –sensitive cells.
The second hypothesis I proposed and tested was that TGFβ signaling
impacted EGFRI-resistance differently between EGFRI-resistant and -sensitive
NSCLC (Chapter 3).
The third aim of our lab is to leverage the gene expression data generated over
time that is descriptive of the fundamental cellular differences between EGFRI-resistant
and -sensitive cells using novel mathematical and computational methods. The two
expression signatures were culled from larger lists of 1495 deregulated mRNA and 23
deregulated miRNA genes. We chose to bolster current studies by considering inversely
related miRNA:mRNA pairs. The third aim I proposed and tested was whether mRNA
and miRNA gene expression data interactions, whether physical or not, would
identify nodes of cell signaling. These interactions and their protein-protein
interacting partners may indicate new targets for novel treatment options (Chapter
4).
This work is a study of what we can learn about the biology of a tumor phenotype
(e.g., EGFRI resistance status) by interrogating gene expression differences. I will
demonstrate the value of cross-examining multiple levels of genomic data to identify
meaningful networks of deregulated signaling. I will also demonstrate that meaningful
therapeutic targets can be captured using basic mathematical characterization of
“significantly deregulated genes”. Finally, I will propose a method for the targeted
treatment of EGFRI-resistant lung tumors as identified by this new method of network
analysis.
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CHAPTER 2

A. OVERVIEW
Lung cancers are frequently diagnosed in later stages of disease progression with
few treatment options available for patients. In the last decade, a number of targeted
therapies have been developed against impactful oncogenic targets in lung cancer (e.g.,
EGFR, ALK, and ROS), but many tumors either lack an actionable oncogenic mutation or
harbor an inherent resistance mutation (e.g., KRAS). Therefore, most patients receive a
cytotoxic agent to which they may not respond (55, 83). Unfortunately, many patients with
a targetable mutation eventually develop resistance to targeted therapy enforcing the need
to couple or stage therapies to combat resistance.
Genome scale sequencing and gene expression technologies have provided
scientists and clinicians the tools to gather increasingly more specific insight on tumor
heterogeneity thereby allowing for tumor-specific therapeutic decisions to be made. While
the ability to characterize tumors at this level has revolutionized the concept of
personalized cancer care, the breadth of information presents the dilemma of how to
interpret molecular characteristics that are biologically relevant for treatment decisions.
Recently, The Cancer Genome Atlas (TCGA) conducted genomic, transcriptomic, and
proteomic profiling of 230 lung adenocarcinomas revealing that 73% of the tumors studied
showed activation of the Ras/Raf cascade downstream of a Receptor Tyrosine Kinase
(RTK) at the level of genomic alterations and gene expression, but only a subset of those
tumors showed aberrant activation of this cascade at the protein level (334). This
observation underscores the diversity within and between tumors reinforcing the need for
multivariate predictors of drug response to overcome the failings of single biomarker
methods of response prediction.
One of the more commonly targeted oncogenic RTKs in Non-Small Cell Lung
Cancers (NSCLC) is the Epidermal Growth Factor Receptor (EGFR). The EGFR inhibitor,
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erlotinib, is indicated for use in patients harboring an EGFR-activating mutation (10-15%
of patients) and is contraindicated for use in patients with mutated KRAS (25-30% of
patients) (335). Using only these two markers to assign erlotinib treatment in NSCLC has
yielded results that are modest at best (336). To augment the short-comings of KRAS and
EGFR mutation status as the sole predictive metric, the Black laboratory showed that
microRNA (miRNA) expression patterns in different cell lines could predict erlotinib
resistance, reporting that a 13-miRNA gene signature could be used for these purposes
(327). Our 13-miRNA gene signature of response is not only able to stratify NSCLC cells
and tumor samples into erlotinib-sensitive and -resistant groups, but was also able to
discriminate between primary and metastatic lesions. Understanding why the expression
of these small RNA molecules can distinguish response to anti-EGFR therapy and
discriminate metastatic lesions has implications for both prognostic and predictive clinical
applications.
MicroRNA are non-coding, small, RNA that regulate gene expression by pairing
with complementary mRNA resulting in translation inhibition or degradation of the mRNA
(337). miRNA play a role in a number of biological processes (e.g., growth, differentiation,
and proliferation), so it is not surprising that endogenous expression levels are
deregulated in cancer (338). Bioinformatic analysis of the 13-gene miRNA signature
showed that many of the proposed target genes functionally converge on the TGFβ
signaling pathway (327). For this study, we specifically focused on signature members
miR-140, miR-141, and miR-200c due to their opposing expression between erlotinibsensitive and -resistant cell lines. The miR-200 family, including miR-200c and miR-141,
is well-characterized for preventing EMT onset by targeting transcription factors (e.g.,
Zeb1 and 2) responsible for suppressing expression of epithelial characteristics, such as
the E-cadherin (E-cad) adhesion proteins (332, 339-341). High expression of these two
miRNA correlate with erlotinib-sensitivity in the 13-miRNA gene signature. Conversely,
miR-140 is highly expressed in erlotinib-resistant cells and is predicted to target the TGFβ
receptor and Smad 2 (327, 342). Importantly, these data demonstrate that opposing
expression profiles and activities are necessary for EMT.
The TGFβ signaling pathway is well documented for its role in the induction and
potentiation of the mesenchymal phenotype in tumor cells (343). TGFβ is a ubiquitous
cytokine that is active in a number of cell processes, and many of cell types secrete the
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ligand and express the receptors to bind it (174). Activation of TGFβ signaling is
accomplished by TGFβ ligands binding to the extracellular domain of TGFβII receptors.
This allows it to recruit the TGFβI receptor and then bind a second pair of activated
TGFβII/I receptors resulting in transautophosphorylation within the tetramer (179).
TGFβ canonical signaling is mediated by Smads 2, 3, and 4, which bind to Smad
Binding Elements (SBE) on DNA eliciting a transcriptional response (344). TGFβ
potentiates the Epithelial to Mesenchymal Transition (EMT) in some cancer cells by
signaling through a variety of other non-canonical pathways including PI3K/AKT and
MAPK/ERK (190). Interestingly, several groups have noted that erlotinib sensitivity tends
to correlate with the epithelial phenotype (345). Since TGFβ upregulates genes
responsible for the activation of the EMT program (346), and because the miRNA
signature is capable of stratifying between primary and metastatic lesions ex vivo (327),
we hypothesize that TGFβ supports differential expression of the signature miRNA
between erlotinib-resistant and -sensitive NSCLC.

B. METHODS

Cell Culture, Protein harvest, Immunofluorescence, and Western Blot
A549, PC9, H460, and H1650 cell lines (NSCLC) were purchased from ATCC.
They were cultured in RPMI 1640 supplemented with 10% FBS (USA Scientific) and
maintained in a humidified incubator at 37 °C at 5% CO2. Cells were seeded in 6-well
plates and were allowed to grow under maintenance media conditions for 48 hours prior
to treatments. Cells undergoing 24 hours of treatment were plated 4 x 104 cells/well, and
72- and 168-hour treated samples were plated at 1 x 104 cells. Cells were treated with
SB-431542 (3 µM) (Selleck Chem) and/or TGFβ (5 ng/ml) (Cell Signaling Technologies)
under minimal serum (1%) conditions for time frames specified. If treatment times
exceeded 72 hours, treatment media was replenished at the 72-hour time point. Wholecell extracts were collected using RIPA buffer (50 mM Tris-HCl, 1% NP-40, 150 mM NaCl,
1 mM EDTA, 0.25% DOC, 10% glycerol, in ddH2O) and protein content was quantified
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using a BCA kit (ThermoFisher) prior to western blotting. Proteins were separated using
SDS-PAGE and were transferred to a nitrocellulose membrane. Expression and/or
activation of specific proteins (pSmad 2, tSmad 2, pSmad 3, tSmad 3, tSmad 4, α-tubulin,
pERK1/2, tERK1/2, pAKT, tAKT, E-cad, Vimentin, N-cad, Zeb1) was assess by western
analysis

using

antibodies

purchased

from

Cell

Signaling

Technologies.

Immunofluorescence was performed using Alexa Fluor-conjugated antibodies of the
specific clone of E-cad and vimentin used for western blotting (Cell Signaling
Technologies). Immunofluorescence was measured using the AMG EVOS microscope
with built-in EVOS software (Thermo Fisher). Cell morphology images was recorded using
the Zeiss AxioObserver Microscope and processed using the AxioVision software.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were carried out with the Simple ChIP Plus Enzymatic Chromatin IP
Kit (Cell Signaling Technologies) to measure Smad 4 binding to two putative SBE sites in
the shared promoter of miRNA-141 and miR-200c at -1645/-1247 and - 1793/-1395 from
each transcriptional start site, respectively. Cells were plated at 5 x 105 cells per dish in
10 cm dishes for 48 hours prior to a media change to 1% FBS-containing RPMI +/- 5 ng/ml
TGFβ1 treatment for 24 hours. After treatment, cells were cross-linked, processed, and
digested as described in the Simple ChIP protocol (Cell Signaling Technologies). Samples
were divided following digestion and chromatin complexes were immunoprecipitated with
Smad 4 antibody (20 µl/ChIP) against a non-specific rabbit IgG (1 µl/ChIP) overnight and
then pulled down with magnetic ChIP-grade protein G beads for 2 hours (Cell Signaling
Technologies). Immunoprecipitated samples were washed, uncrosslinked, and DNA was
prepared as described in the Simple ChIP protocol (Cell Signaling Technologies). SYBR
Green qRT-PCRs (Applied Biosystems) were performed with negative-control α-Satellite
and positive-control ID1 Smad 4-specific control primers against the experimental region
containing the two putative SBEs in the shared promoter of miR-141/-200c (Forward:
GCATTACTCAGCAAATCCTTAC;

Reverse:

CCCGACAGGTGATTGCC.

Primers

designed in-house and produced by IDT). Data was analyzed using the Percent Input
method where signals from ChIP samples are represented as a percentage of the total
chromatin input. Each individual experiment was replicated in triplicate for each primer set
and processed using the 2% input method described in the Cell Signaling Technologies
protocol. Data represented is for three biological replicates (n = 3). P-values were
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generated using paired t-tests comparing each TGFβ treated sample to its respective
untreated sample.
Real-Time PCR Analysis of miRNA Expression
Total small RNA was harvested from the cells using the mirVANA™ miRNA
isolation kit (Life Technologies). cDNA was synthesized for U6, miR-140, miR-141, and
miR-200c using the TaqMan MicroRNA Reverse Transcription kit and corresponding
reverse transcription TaqMan primers for U6, miR-140, miR-141, and miR- 200c (Life
Technologies). cDNA was then subjected to quantitative Real Time PCR (qRT-PCR) using
TaqMan Mastermix II with no UNG, and corresponding TaqMan microRNA assay primers
(Life Technologies). qRT-PCR were performed by a 7900HT Fast Real-Time PCR system
(ABI) and all reactions were run in duplicate with corresponding positive and negative
controls. The data was analyzed using a 5-way ANOVA following internal normalization of
raw Ct values to the internal U6 as the normalization probe.
Propidium Iodide (PI) and Flow Cytometry
A549 and PC9 cells were subjected to the same treatments and time points as
previously described. Specifically, cells were rinsed in PBS at point of harvest, trypsinized,
and collected in a 15 ml conical tube. Cells are centrifuged at 1500 rpm and the
supernatant is removed. Cells are washed once with cold PBS, pelleted, and the
supernatant removed. Finally, the cell pellet was resuspended in 400 µl of cold PBS and
then 1 ml of cold, 100%, molecular biology grade ethanol was added to each sample
dropwise while gently vortexing and then samples were placed on ice for 30 minutes. Cells
were pelleted by centrifugation and the supernatant removed, and then washed in cold
PBS/1%BSA. The pellet was resuspended in 0.3 ml of PI solution (1X PBS/1% BSA/50
µg/ml PI/0.5 mg/ml RNase A). Samples were incubated in the PI solution for at least 30
minutes at 4 °C protected from light. Samples were assayed on the Attune Flow Cytometer
acoustic focusing cytometer, and 10,000 cells from each sample were profiled for PI
emission, and data was collected with the Attune-specific software provided (Applied
Biosystems/ThermoFisher). Percentage of total cells in each phase of the cell cycle was
determined using the cell cycle analysis platform in the FlowJo V10 software (FlowJo).
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Statistics
To analyze changes in endogenous gene expression data generated by qRT-PCR
described above, a five-way ANOVA was performed using the following variables:
treatment with TGFβ, treatment with SB-431542, time point, expression as internally
normalized Ct values, and cell line, along with all interaction terms. The overall F-test,
followed by partial F-tests were used to determine significant effects. Following the
ANOVA, post-hoc comparisons were made for significant terms in the ANOVA using twosample t-tests to compare subgroups of interest. Tests were determined to be significant
if p-values were less than 0.05. All analyses were performed in SAS Version 9.3 or above
(SAS Institute Inc., Cary, NC).

C. RESULTS

Most Signature miRNA Promoters Contain Smad Binding Elements
The promoter of each of the 13 signature miRNA was analyzed using
chipMAPPER (347, 348) for putative SBEs (344, 349). Predicted SBEs were retained if
they had conservative E-values (≤ 25) and a score greater than 3.0. SBEs matching these
criteria were found in the promoter regions of twelve of the thirteen signature miRNA
(Figure 2.7). The three signature miRNA genes we focused on in this study (miR-140,
miR-141, and miR-200c) have multiple predicted SBEs within -2000 base pairs of
transcriptional start site (Figure 2.1) (184, 344, 350).
The activity of complexes containing Smad 2 and Smad 3 along with the DNAbinding member, Smad 4, have been shown to have both positive and negative effects on
transcription (351, 352). Since the signature miRNAs are differentially expressed among
cell lines, the majority of their promoters contain putative SBEs, and the known dual
behavior of TGFβ activity on gene expression, we hypothesized that the canonical TGFβ
signaling pathway likely controls opposing expression levels of signature miRNA between
erlotinib-sensitive and -resistant NSCLC lines.
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TGFβ-mediated Smad Signaling has an Opposing Phenotype in Erlotinib Resistant
and -Sensitive Cell Lines
A549 and PC9 cell lines were selected as representative NSCLC cell lines due to
their opposing erlotinib responses and opposing expression levels of the 3 candidate
miRNA. A549 are inherently erlotinib-resistant because they harbor a KRAS activation
mutation, and PC9 are erlotinib-sensitive treatment because they contain an activating
exon 19 deletion in EGFR (328).
We first examined the expression and activation of the Smad molecules, Smad 2,
Smad 3, and Smad 4, after treatment with exogenous TGFβ ligand, an inhibitor of
TGFβRII, SB-431542, or the combination in these cell lines (Figure 2.2A) by western blot
to determine if these effectors could be responsible for signature miRNA regulation. In
both A549 and PC9 after 24 hours of treatment, pSmad 2 and pSmad 3 levels are elevated
in cells treated with TGFβ, and the effect was diminished in cells treated with SB-431542
or the combination of SB- 431542 and TGFβ. Total Smad 2, Smad 3 and Smad 4 levels
appear to be consistently expressed across treatments at 24 hours. There were no
obvious levels of pSmad 2 or pSmad 3 in either cell line or in any treatment condition at
the 72-hour treatment time point. Total Smad 2 and Smad 4 levels appear to be
consistently expressed in both cell lines across both treatments. However, in both cell
lines, tSmad 3 levels were diminished in cultures treated with TGFβ.
At 168 hours, pSmad 2 levels were seen only in A549 treated with TGFβ. PhosphoSmad 3 levels were not observed in either line at 168 hours. tSmad 2, tSmad 3, and Smad
4 appear diminished in PC9 treated with TGFβ alone, and this phenotype was not
observed in any other condition. A549 demonstrated similar expression of total Smad
molecules across all treatment conditions.
We observed the cyclical activation of Smad 2 in A549 while activation of Smad 3
was observed early following initial stimulation, but did not return. In PC9, a different
phenotype emerged with diminished levels of all Smad 2, Smad 3, and Smad 4 molecules
by 168 hours. Taken together, these data suggest that the TGFβ canonical signals are
managed differently in A549 and PC9.
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TGFβ Treatment Induces an EMT Protein Expression Switch in A549 but not in PC9
Like many, we observed that A549 cells treated with TGFβ undergo a
morphological change with treatment and appropriately activate R-Smad proteins - a
phenotype consistent with EMT. PC9 cells did not undergo these changes with TGFβ
treatment, but interestingly, PC9 cells treated with the TGFβ inhibitor displayed an EMT
intermediate phenotype known as “Metastable” (Figure 2.8) (353). For this reason, we
assessed a panel of EMT protein markers to determine if the morphological changes
observed were indicative of EMT progression and correlated with signature miRNA
endogenous expression changes.
A549 and PC9 were plated, treated, and harvested as described for protein
measured by BCA assay prior to western blotting. Lysates were assessed for
mesenchymal markers N-Cadherin (N-cad), Zeb1, and vimentin as well as the epithelial
marker, E-cadherin (E-cad) to confirm if the morphological changes were consistent with
EMT occurring (Figure 2.2B). As a comparison, we also profiled A549 and PC9 cells for
E-cad and vimentin expression by immunofluorescence at 24- and 168-hour (7 days) time
points (Figure 2.2C-F). mRNA levels of E-cadherin were examined in both cell lines at 24, 72- and 168-hour time points to fully capture the change in expression of this epithelial
marker across time points (Figure 2.9I).
In A549, TGFβ suppressed E-cad expression across each of the time points in the
experiment, as expected. Conversely, vimentin expression increased over the time course
of TGFβ treatment. N-cad and Zeb1 appear in the 72- and 168- hour time points,
respectively, in TGFβ-treated A549. The immunofluorescence profile of E-cad expression
at the 24 hour and 7 day –treated time points in A549 cells was consistent with the levels
observed by western analysis. Vimentin levels increased in A549 cells also mirrored the
western blot results (Figure 2.2C,D).
In PC9, neither TGFβ stimulation nor its inhibition decreased E-cad expression or
induced expression of the mesenchymal markers assessed. E-cad expression was
consistent between the western and immunofluorescent assays. Vimentin expression was
not observed by western or immunofluorescence assays (Figure 2.2E,F). Since PC9
responded unexpectedly to treatment, we sought to determine if TGFβ directly regulated
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the expression of two candidate miRNA genes in both A549 and PC9 by assessing if
Smad 4 directly binds a shared putative SBE.
TGFβ Induces Smad 4 Binding to Putative SBEs in the Promoter of mir-141/200c in
Erlotinib-Sensitive Cells
To test the impact of the observed deregulation of R-Smad activity in A549 and
PC9 on candidate miRNA expression, we asked whether Smad 4 was directly binding the
promoters of our miRNA genes. Smad 4 is the only member of the canonical-Smad family
with a nuclear localization signal, and others have shown that it is required for any active
Smad complex to translocate into the nucleus to regulate transcription. Direct regulation
of gene expression by TGFβ-activated Smad complexes is expected to occur within 24
hours of treatment (184). For these reasons, we only tested Smad 4 binding to the SBE
locus after 24 hours of treatment by Chromatin Immunoprecipitation (ChIP).
In A549 cells, TGFβ treatment induced a significant enrichment of the positive
control, the ID1 promoter SBE, bound to Smad 4 (p = 0.0171). The mir-141/-200c promoter
region was not significantly enriched in A549 cells in any treatment or antibody
combination (Figure 2.3A). In PC9 cells, TGFβ treatment enriched both the positive
control, ID1 (p = 0.0035), and the mir-141/-200c promoter containing the SBE locus (p =
0.0006), suggesting that Smad 4 is bound to the shared promoter region in PC9 cells and
not in A549 cells treated with TGFβ (Figure 2.3B). This observation led us to ask whether
the observed DNA interaction between the Smad 4- containing complex and the SBE
resulted in changes in endogenous levels of miR-141 or miR-200c.
Time, Not Treatment, Alters the Expression of the Candidate microRNAs
Activated Smad 2 and Smad 3 were present in both lines at 24h post-TGFβ
treatment and pSmad 2 returned at 168h after treatment in A549. We have also shown
that Smad 4 is expressed in all conditions and binds mir-141/200c promoter at 24 hours
post-TGFβ treatment in PC9. For these reasons, we anticipated that differential
expression of the signature miRNA genes would occur under these conditions as a result
of TGFβ treatment. To explore this, A549 and PC9 were cultured and harvested as
described and assessed for endogenous expression changes of three signature miRNA
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genes, miR-140, miR-141, and miR-200c by qRT-PCR. Importantly, these experiments
were performed in 1%-serum media to minimize the impact of exogenous cytokines. We
tested each of the three miRNA profiled in the conditions indicated here in both 1% serum
and 10% serum treatment conditions to confirm that the changes observed are not due to
serum levels. Importantly, miRNA expression does not significantly differ between the two
serum levels for any of these three miRNA (Figure 2.13).
The miRNA expression trends did not differ significantly among treatment
conditions, but differences across time points were observed (Figure 2.10). An initial 2way ANOVA comparing endogenous miRNA expression changes as internally-normalized
Ct values within each cell line indicated that the most impactful variable governing
endogenous expression change was the time of treatment. The 2-way ANOVA was not
able to compare whether the expression changes correlated with other miRNA tested or
the erlotinib- sensitivity status of a cell line. In order to capture this complexity, we used a
5-way ANOVA to identify significant interactions between five variables: 1) miRNA
expression (Ct values), 2) time point sample was taken, 3) TGFβ treatment addition, 4)
SB-431542 treatment addition, and 5) cell line. All combinations of factors were
simultaneously calculated (5-way ANOVA Input in Supplementary Table 1, Ct averages in
supplementary file 1, Appendix I). The 5-way ANOVA revealed that treatments and miRNA
expression levels are not related, and that the most influential experimental component
was the time of treatment (Figure 2.4A and Figure 2.11). Figure 2.11 shows that individual
miRNA expression follow the same trends across treatments over time. For simplicity,
since expression trends did not differ drastically between treatments, we chose to present
the overarching miRNA expression trends generated as averages of treatments in each
individual cell line at each time point (Figure 2.4A). The table highlights the significance of
endogenous expression changes among time points separated by miRNA gene in each
cell line (Figure 2.4B). Taken together, these data demonstrate that treatment was not
impactful in the changes in endogenous miRNA expression, but the time of treatment was.
Importantly, individual miRNA expression changes did not correlate with the erlotinib
sensitivity of each cell line. From these data, we hypothesized that the impact of the time
of treatment may be directly related to the cell cycle position of the cells.
Time, Not Treatment, Alters the Cell Cycle Position of A549 and PC9 Cells
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To assess whether observed changes in miRNA expression correlate with cell
cycle position, as a measure of time, A549 and PC9 cells were assessed for percentage
of cells in each cell cycle position at each of the time points. Cells were treated and
harvested as described for cell cycle analysis using propidium iodide staining and flow
cytometry. For each sample, 10,000 events were counted to ensure percentages were not
skewed by the differing number of cells present in each sample at the end of treatment.
Overall proliferation following respective treatment times is shown in Figures 2.12 and
2.13 as cell counts.
Irrespective of treatment, the percentage of A549 cells in the G0-G1 phase of the
cell cycle increased over time of treatment. PC9 cells behaved similarly (Figure 2.5).
However, PC9 cells treated with TGFβ failed to continue to proliferate after 72 hours while
the percentage of cells in G0-G1 changed. To understand the impact of time and treatment
on percentage of cells in the G0-G1 phase of the cell cycle, a 2-way ANOVA was performed
within each individual cell line to capture the most impactful factor influencing the trends.
The ANOVA confirmed that the most important factor governing the increasing number of
cells in of G0-G1 phase was cumulative time of treatment. In A549 cells, time of treatment
significantly explained cells in the G0-G1 phase of the cell cycle (p<0.0001). In PC9, both
treatment conditions (p<0.0001), time of treatment (p = 0.0002), and the interaction of the
two variables (p = 0.0168) had a significant impact on the percentage of cells in the G0-G1
phase of the cell cycle. Because cell cycle position interacted with time of treatment, we
wondered whether a specific non-canonical signal transduction cascade downstream of
TGFβ was activated that might impact cell cycle progression.
TGFβ Activation of Non-Canonical Effectors ERK1/2 and AKT Differs Between A549
and PC9
Since miRNA endogenous expression changes appeared to correlate with
changes in the cell cycle rather than TGFβ treatment, we endeavored to understand the
impact of TGFβ treatment on non-canonical effectors known to drive growth and
proliferation, Ras/MAPK and PI3K/AKT pathways. The same protein lysates profiled for
the R-Smad effectors and EMT marker proteins in Figure 2.2 were assessed for both
pERK1/2 and pAKT expression. Corresponding total protein expression of each across
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the same treatments and time points described above were measured by western blot
(Figure 2.6). In A549, pERK1/2 levels increase with TGFβ treatment across the time points
while total protein levels remained constant. pAKT levels in A549 increased at the 24-hour
time point, but then diminish across time points while total levels of the protein were
constant. In PC9, pERK1/2 and pAKT levels were elevated at the 24-hour time point, but
both diminish over time without a decrease in total protein levels in the cells treated with
SB-431542 with and without co-treatment with TGFβ. Densitometry performed on these
blots can be seen in Figure 2.14. These data suggest that the relationship between TGFβ
and non-canonical growth and proliferation pathways and may explain why the changes
in endogenous miRNA expression correlated with an increasing percentage of cells in the
G0-G1 phase of the cell cycle.

D. DISCUSSION
In early stages of tumor development, TGFβ acts as a tumor suppressor
preventing the proliferation, differentiation, and overall survival of the impacted cells. In
later stages of tumor development, TGFβ shifts from tumor suppressive functions to
promotion of tumorigenesis by driving the transcription of pro-EMT genes, which stimulate
tumor cells to invade and metastasize (354, 355). The role of TGFβ signaling in EMT is of
particular interest to our group because the 13-gene miRNA signature not only stratified
NSCLC into erlotinib-sensitive and erlotinib-resistant groups, but was also able to
discriminate between primary and metastatic tumors (327), and multiple members of the
miRNA signature have been shown to play either a promoting or repressing role in EMT
in NSCLC (332, 356, 357). For this reason, we endeavored to understand the role of TGFβ
signaling on the expression of microRNA genes dysregulated in erlotinib-sensitive
compared with erlotinib–resistant cell lines.
TGFβ drives EMT by using the canonical signaling pathway, mediated by the RSmads, which upregulate transcription responsible for the repression of epithelial
characteristics (190). Analysis of the TGFβ-driven R-Smad family members, showed a
differential response to TGFβ treatment between the erlotinib-resistant, A549 cells, and
erlotinib-sensitive, PC9 cells. Activated Smad 2 and Smad 3 expression was observed in
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both cell lines at similar levels at early time points of treatment. At the 168-hour time point,
activated Smad 2 levels return in A549 cells treated with TGFβ, compared to unchanging
total Smad 2, Smad 3 and Smad 4 levels across treatments. In PC9 cells after 168 hours
of TGFβ treatment, the total expression of all TGFβ effectors tested was reduced
suggesting the impact of some negative feedback mechanism. TGFβ is known for
promoting EMT in late stages of tumor development, but in the early stages, it functions
in an anti-EMT capacity (355). We believe this cyclical pattern of TGFβ activation and RSmad molecule repression to be indicative of TGFβ acting in an anti-EMT capacity in these
cells.
To delve further into whether TGFβ treatment acted by different mechanisms
between the two lines tested, we explored TGFβ-driven morphological changes and EMT
marker protein expression changes. It is known that TGFβ treatment induces a very long,
fibroblast-like phenotype in A549 cells (Figure 2.8) and western blot analysis of the EMT
markers E-cad, vimentin, N-cad, and Zeb1 shows that TGFβ treatment induced a protein
expression phenotype consistent with EMT (Figure 2.2B) (358). However, this study is the
first to demonstrate biological differences in “epithelial” NSCLC cell lines, like PC9 cells,
treated with TGFβ. In PC9 cells, the morphology after TGFβ treatment is unchanged.
Interestingly, PC9 cells treated with the TGFβ inhibitor, SB-431542, with and without costimulation with TGFβ develop a morphology consistent with an EMT-intermediate
phenotype known as “metastable” suggesting that the inhibition of TGFβ in PC9 cells may
play a role in the induction of EMT (Figure 2.8) (353, 359). This observation, as well as
that of the change in expression of the R-Smads in these cells, is consistent with the
TGFβ-paradox theory and also correlates with the signature’s ability to stratify primary and
metastatic lesions. To test whether TGFβ inhibition induced EMT initiation in PC9 cells,
we profiled EMT protein markers to determine if the morphological change was indeed
indicative of an EMT intermediate. While PC9 cells treated with the TGFβ inhibitor, SB431542, undergo a morphological change consistent with EMT initiation, the western blot
and immunofluorescence analyses revealed that the cadherin switch, that is essential for
full-EMT, did not occur in response to treatment (360). Taken together, these data suggest
that while TGFβ may act as a pro-tumorigenic, pro-EMT fashion in A549 cells, it may play
an anti-EMT and protective role in PC9 cells because the inhibition of TGFβ did not induce
a complete EMT transition in these cells.
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Since A549 and PC9 cells appeared to represent either side of the TGFβ paradox,
we sought to elucidate whether TGFβ directly regulated the expression of the candidate
signature miRNA genes to understand whether the differing impact of TGFβ observed by
R-Smad and EMT marker expression was also differentially regulating the expression of
some of the signature miRNA genes. We expected TGFβ to directly regulate the
expression of the signature miRNA and from there we expected to be able to triangulate
a relationship between erlotinib- sensitivity, TGFβ signaling, and the 13-miRNA gene
signature to determine therapeutically-relevant, secondary targets for overcoming
inherent or acquired erlotinib-resistance. To test if TGFβ was directly influencing the
expression of miR-200c and miR-141, we performed a ChIP assay to determine whether
TGFβ induced the binding of Smad 4 to an SBE site in the shared promoter of mir200c/mir-141. These two miRNA genes have very different baseline expression profiles
between the mesenchymal, A549, and epithelial, PC9, cell lines. We showed that TGFβ
treatment induced Smad 4 interaction with the shared mir-141/mir-200c promoter only in
PC9 cells. However, in PC9 cells endogenous miR-141 and miR-200c expression at 24
hours after treatment showed no impact of any treatment condition, suggesting that TGFβ
signaling may not be important in this context. Importantly, Smad 4 must be bound to
activated Smad 2 or Smad 3 to carry out transcriptional control, and we did not test
whether pSmad 2/3 was present with Smad 4.
While we did not observe a change in endogenous expression of any of the three
miRNA in response to treatment, we did observe that the change in expression of miR200c and miR-141 in response to changes in the time of treatment, and we believe that
time is reflective of cell cycle position. Importantly, miR-200c and miR-141 are thought to
be under coordinated transcriptional regulation because of an overlapping promoter
region (361). Our data suggests that, at least in these treatment conditions and cell lines
tested, miR-141 and miR-200c are not commonly regulated as is expected of genes that
share a promoter region. We also observed that the trends in expression changes did not
segregate the two erlotinib-resistant lines, A549 and H460 cells, from the two erlotinibsensitive lines, PC9 and H1650 cells, suggesting that changes in the expression of these
miRNA did not correlate with erlotinib-resistance or EMT status (Figure 2.4 and Figure
2.11).
Using a 5-way ANOVA, we discovered that that the most important factor
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governing the changes in endogenous miRNA expression was the time of treatment. Thus,
we investigated whether cell cycle stage could impact the expression of these genes. In
Figure 2.15, we interrogated the putative transcription factor binding sites of one cell cycle
regulated effector, ELK1, using the ChipMAPPER algorithm (347, 348). The analysis
revealed putative ELK1 sites in the promoters of 12 out of 13 of the miRNA genes profiled,
supporting our hypothesis that cell cycle progression may control the expression of the
candidate miRNA genes. Analysis of the cell cycle position of A549 and PC9 cells across
the same treatments and time points revealed that as time of treatment increased, the
percentage of cells in the G1-G0 phase of the cell cycle increased, except in TGFβ treated
cells at the final time point (Figure 2.5). Importantly, the impact of treatment alone on cell
cycle stage was only significant in PC9 cells (Figure 2.5). Figures 2.12 and 2.13 illustrate
cell counts, reflective of doublings, in both 1% and 10% serum across treatment
conditions. PC9 cells failed to continue to grow in the presence of TGFβ and 1% serum
which may explain the reduction of cells in G1-G0 phase of the cell cycle at 168 hours.
Further experimentation will be necessary to understand this modest but significant
decline.
Finally, because of the observation that cell cycle position may be important in
expression of the miRNA examined in this study, we interrogated the activation of TGFβ
non-canonical growth and proliferation pathways, Ras/MAPK and PI3K/AKT, to determine
if they may play a role in the relationship of cell cycle position and endogenous miRNA
expression. pERK activation increased across the time points in A549 cells, and its
activation may influence the re-emergence of pSmad 2 levels at 168 hours because pERK
is known to phosphorylate the linker region of Smad 2 to stabilize the signal (190). pERK
signaling is also required for TGFβ- driven EMT, consistent with the increase in pERK
signal in A549 cells undergoing TGFβ-induced EMT (353). PC9 cells harbor an EGFRactivating mutation resulting in the constant expression of pERK and pAKT. Perhaps most
interestingly, treatment with the TGFβ receptor inhibitor, SB-431542, resulted in the
reduction of both signals regardless of co-treatment with TGFβ ligand. SB-431542 is a
competitive ATP binding site kinase inhibitor and has been shown to disallow ERK, JNK,
or p38 pathway activation from other signals or their response to serum (362). These data
suggest that, at least in PC9 cells, the perpetual activation of ERK and AKT signals from
active EGFR signaling may rely on basal activation from TGFβRII in order to persist. We
anticipate testing this using a TGFβ-receptor knock-down to observe whether the same
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impact on ERK and AKT signals is observed.
Our future experiments will attempt to fill the gaps noted from this work. We will
determine whether the remaining erlotinib-sensitive cell lines used to generate gene
expression data have a similar response to long term TGFβ treatment even though we
know that erlotinib-sensitive tumors also have metastatic capability. We will also determine
if erlotinib response is altered by time in treatment as miRNA expression and cell cycle
position were. We will test whether the expression of ELK1 in cells is important for cell
cycle progression in this context because the shared promoter of mir-141 and mir-200c
contains an ELK1 binding site. We might also determine if E2F sites are present and active
because TGFβ-driven, DNA-binding Smad complexes have been shown to interact with
cell cycle regulating elements (363, 364). Therefore, it is possible that Smad 4 binding to
the SBE in PC9 cells does requires coordinate cell cycle regulation, through ELK1, to
regulate the expression of miR-141. The presence of known cell cycle responsive
elements in the promoters of most of the 13-signature miRNA suggests that the cell cycle
may play a role in governing the expression levels of these miRNA genes. Understanding
the mechanism of regulation of the signature miRNA genes might help us further
understand whether TGFβ signaling is a driver of EMT and metastasis or a passenger
alongside cell cycle-dependent regulation of these genes.

E. CONCLUSIONS
Our original hypothesis that TGFβ directly regulated the expression of the
microRNA gene signature and that it modulated gene expression differently in erlotinibresistant versus erlotinib-sensitive cells was founded on a bioinformatics analysis of these
genes with little regard for cellular context. We found that TGFβ is likely not directly
responsible for control of the expression of the microRNA genes we tested. However, we
still find it an attractive therapeutic target if we can understand the cellular or tumoral
context wherein targeting this cytokine impacts NSCLC patient survival.
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is descriptive of TGFβ behaviour in NSCLC. Scientific Reports. 2017
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Figure 2.1: Signature microRNA genes contain SBE elements. Promoter analysis was
conducted using the ChipMAPPER algorithm (347, 348). microRNA genes -140, -141,
and -200 contain putative SBE elements as represented by the triangle with conservative
E-values less than or equal to 25 and a score greater than 3.0.

66

CHAPTER 2
Figure 2.2: Total Smad expression, Smad activation and EMT program marker
expression varies with TGFβ or inhibitor treatment. Erlotinib-resistant, A549 cells,
and erlotinib-sensitive, PC9 cells were plated, treated and harvested as described.
Proteins were visualized by western blotting. All blots from the same samples; α-tubulin
levels are representative controls for each sample. (A) Profiling of Smad family
member expression and activation across time demonstrates changes in TGFβ
canonical signaling. (B) EMT protein markers demonstrate program initiation and
progression among treatment conditions. (C) A549 cells treated for 24 hours for Ecadherin and vimentin expression by immunofluorescence (D) A549 cells treated for 7
days for E-cadherin and vimentin expression by immunofluorescence (E) PC9 cells
treated for 24 hours for E-cadherin and vimentin expression by immunofluorescence
(F) PC9 cells treated for 7 days for E-cadherin and vimentin expression by
immunofluorescence.

A

B
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Figure 2.3: TGFβ induces Smad 4 binding to SBEs in the promoter of mir-200/141
in PC9 cells. Chromatin immunoprecipitation was performed to identify whether a
physical interaction between Smad 4 and a predicted SBE locus in the shared promoter
of mir-200c/-141 resulted from TGFβ treatment. Normal rabbit IgG served as

the

antibody negative control and α-Satellite primers as the negative PCR control. ID1 locus
immunoprecipitation was the positive control for Smad 4 binding. (A) In A549, positive
Smad 4-ID1 association is observed with TGFβ

treatment, but an Smad 4-SBE

interaction is not. (B) In PC9, both Smad 4-ID1 and Smad 4-SBE interaction is
observed. Significance was calculated using an unpaired t-test comparing TGFβtreated cells and -untreated samples with the same primer set. (n=3)
A
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Figure 2.3 (continued): TGFβ induces Smad 4 binding to SBEs in the promoter of
mir-200/141 in PC9 cells.

B
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Figure 2.4: Time of TGFβ treatment reflects changes in endogenous miRNA gene
expression. Changes in endogenous gene expression were analyzed using a fiveway ANOVA considering the variables: TGFβ treatment, SB-431542 treatment, time
point, expression as internally normalized Ct values, and cell line, along with all
interaction terms. (A) Data presented here is aggregated by averaging over treatments
in order to capture overarching trends in miRNA and cell line patterns at multiple time
points. Fine-scale trends were broken down by individual treatments as presented in
Figure 2.10. (B) Comparison of the significance of endogenous expression changes
between time point’s samples and by individual miRNA genes in each cell line.
A
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Figure 2.4 (Continued): Time of TGFβ treatment reflects changes in endogenous
miRNA gene expression.

B
Cell Line

Resistant

A549

H460

Sensitive

PC9

H1650

miRNA

24 vs 72 hours

24 vs 168 hours

miR-140

<0.0001****

0.0002***

miR-141

<0.0001****

<0.0001****

miR-200c

0.0471*

0.0675

miR-140

0.5221

0.0656

miR-141

0.2548

0.0605

miR-200c

0.9663

0.1077

miR-140

0.1875

0.5760

miR-141

<0.0001****

<0.0001****

miR-200c

0.0561

0.0500*

miR-140

0.7751

<0.0001****

miR-141

0.4358

<0.0001****

miR-200c

0.7586

0.0051***
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Figure 2.5: A549 and PC9 cells exit the cell cycle regardless of treatment with
TGFβ or SB-431542. The graph reflects the percentage of A) A549 or B) PC9 cell
populations in G0-G1 phase of the cell cycle at 24, 72, and 168 hours following
treatment. Significance was determined using an unpaired t-test comparing the 72- and
168-hour time points individually to the 24-hour time point of the same treatment. (C)
A two-way ANOVA was utilized to determine the significance of treatment and/or time
point reflective of the percentage of cells in the G0-G1 phase of the cell cycle.
A
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Figure 2.5 (Continued): A549 and PC9 cells exit the cell cycle regardless of
treatment with TGF or SB-431542.
B

C
Source

of

A549

PC9

Interaction

0.0583

0.0168*

Time

<0.0001****

<0.0001****

Treatment

0.1042

0.0002***

Variation
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Figure 2.6: TGFβ modulation differentially impacts ERK and AKT activation
between A549 and PC9. A549 and PC9 cells were plated, treated, and harvested as
described in the methods. α-tubulin levels are representative of an individual lysate pool.
Lysates profiled here are the same as in figure 2.2. ERK-MAPK and PI3K-AKT signaling
are non-canonical signaling effectors of the TGFβ signaling pathway. All blots from the
same samples; α-tubulin levels are representative of each sample.
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Figure 2.7: Signature microRNA genes contain SBE elements. Promoter analysis was
conducted using the ChipMAPPER algorithm (347, 348). Twelve out of thirteen of the
signature microRNA genes contain putative SBE elements as represented by the triangle
with conservative E-values less than or equal to 25 and a score greater than 3.0 (181,
184).
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Figure 2.8: TGFβ induces a mesenchymal phenotype in A549, but inhibition
generates an EMT-intermediate phenotype in erlotinib-sensitive, PC9 cells. A549
and PC9 cells were treated as described in the methods. Bright field images of cell
morphology were acquired using the microscope and software described in the methods.
(A) Shows full-sized bright-field images taken at 5X magnification, and (B) shows a closer
representation of the morphology changes. Time is in hours.

A

B
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Figure 2.9: E-cad expression in response to treatment. (A) E-cad mRNA levels
quantified by qRT-PCR in A549 (n=1). (B) E-cad mRNA levels quantified by qRT-PCR
in PC9 (n=1). mRNA levels are demonstrated as fold change relative to respective
untreated samples which are standardized to a fold change of 1.

A
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Figure 2.9 (continued): E-cad expression in response to treatment. (A) E-cad
mRNA levels quantified by qRT-PCR in A549 (n=1). (B) E-cad mRNA levels quantified
by qRT-PCR in PC9 (n=1). mRNA levels are demonstrated as fold change relative to
respective untreated samples which are standardized to a fold change of 1.

B
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Figure 2.10: Normalized Ct values demonstrate that time change, not individual
treatment, affects endogenous miRNA expression changes in A549 and PC9 cells.
(A-F) Raw miRNA expression levels using qRT-PCR experiments as described in Figure
4 and Supplemental Figure 5.

81

CHAPTER 2
Figure 2.11: Time of treatment has the most significant influence on miRNA
expression changes. Changes in endogenous gene expression were analyzed using a
five-way ANOVA considering the variables: TGFβ treatment, SB-431542 treatment, time
point, expression as internally normalized Ct values, and cell line, along with all interaction
terms.
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Figure 2.12: A549 cell counts following corresponding treatments and time points
comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml TGFβ (C)
+3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 x 104
cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted at
the appropriate harvest time using a hemocytometer. (n=2)

A
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

B
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

C
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

D
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Figure 2.13: PC9 cell counts following corresponding treatments and time points
comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml TGFβ (C)
+3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 x 104
cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted at
the appropriate harvest time using a hemocytometer. (n=2)

A
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Figure 2.13 (continued): PC9 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

B
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Figure 2.13 (continued): PC9 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

C
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Figure 2.13 (continued): PC9 cell counts following corresponding treatments and
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted
at the appropriate harvest time using a hemocytometer. (n=2)

D
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Figure 2.14: Densitometry of Figure 2.6 western blots. (A) pERK and tERK in A549
(B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT in PC9. Blots
were quantified using ImageJ and quantification was calculated using the area under the
curve measurements for each band using the same sized box sample for each to ensure
consistency (n=1).

A
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT
in PC9. Blots were quantified using ImageJ and quantification was calculated using the
area under the curve measurements for each band using the same sized box sample for
each to ensure consistency (n=1).

B
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT
in PC9. Blots were quantified using ImageJ and quantification was calculated using the
area under the curve measurements for each band using the same sized box sample for
each to ensure consistency (n=1).

C
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT
in PC9. Blots were quantified using ImageJ and quantification was calculated using the
area under the curve measurements for each band using the same sized box sample for
each to ensure consistency (n=1).

D
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Figure 2.15: Signature microRNA genes contain both putative SBE elements and
putative ELK1 binding sites. Promoter analysis was conducted using the ChipMAPPER
algorithm (348). Twelve out of 13 of the signature microRNA genes contain putative SBE
elements as represented by the grey triangle with conservative E-values less than or equal
to 25 and a score greater than 3.0. Twelve out of the thirteen signature miRNA also contain
putative ELK1 binding sites meting the same inclusion criteria as represented by the blue
triangles.

Copyright © Madeline Krentz Gober, 2017
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A. OVERVIEW
Erlotinib is a small molecule Epidermal Growth Factor Receptor (EGFR) inhibitor
that has been FDA approved for clinical use since 2004 (144). In October 2016, it was
specifically redesignated by the FDA for the treatment of locally advanced or metastatic
Non-Small Cell Lung Cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21
L858R substitution mutations (143). However, utilizing EGFR mutation statuses as the
sole determinant of erlotinib treatment remains limiting because EGFR somatic mutations
alone may not encompass all NSCLC that would respond to erlotinib. Further, the majority
of responders do eventually develop resistance to erlotinib therapy (365).
To encompass responders not captured by these EGFR mutations, prior work in
the Black laboratory showed that estimating response to EGFRI can likely be improved by
using multivariate gene expression patterns demonstrated in NSCLC cells and in a
retrospective analysis of tumors (327, 328). From this work, a 13-gene miRNA signature
predictive of response to the EGFRI, erlotinib, was identified (327). Bioinformatic analysis
of the 13-gene miRNA signature revealed a functional convergence on the TGFβ signaling
pathway, suggesting a relationship between the TGFβ and EGFR signaling pathways
(327). The 13-gene miRNA signature of response was able to stratify cells and tumor
samples into erlotinib-sensitive and -resistant groups and it discriminated primary tumors
from metastatic lesions (327). Others have shown that NSCLC patient tumors that have
undergone the Epithelial to Mesenchymal Transition (EMT) are largely erlotinib-resistant
when compared with the epithelial-phenotype tumors (366). TGFβ is an inducer of EMT
and it has also been shown to have paradoxical functions in tumorigenesis, as a tumor
suppressor in early stages of the disease and as an oncogenic, pro-metastatic player in
later stages (349, 350).
In a previous study comparing the effects of TGFβ treatment between
representative erlotinib-resistant and –sensitive NSCLC cell lines, I showed that erlotinibresistant, A549, and erlotinib-sensitive, PC9, cells show different activation and
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expression profiles of the canonical TGFβ effectors, Smads 2, 3, and 4, as well as
differential activation of non-canonical TGFβ signaling pathways (ERK-MAPK and PI3KAKT) after TGFβ treatment (367). As expected, TGFβ treatment induced a mesenchymal
phenotype in A549 cells as evidenced by morphological changes and expression of EMT
marker proteins (368). In PC9 cells, which maintain a baseline epithelial phenotype,
inhibiting TGFβ with the TGFβ inhibitor, SB-431542, induced an EMT-intermediate
morphological change even though EMT marker protein expression did not change (367).
These results suggest that there are relationships between the induction of EMT by TGFβ,
EMT and erlotinib resistance, and the expression of the 13 miRNA genes comprising the
signature.
For these reasons, we hypothesize that TGFβ induces EMT in erlotinib-resistant
NSCLC and that inhibiting TGFβ signaling may sensitize these NSCLC to erlotinib
treatment.

B. METHODS

Cell Culture
NSCLC cell lines are from ATCC (A549) or gifted from the Haura laboratory (Moffitt
Cancer Center, FL). All cells were cultured in RPMI 1640 (Life Technologies)
supplemented with 10% Fetal Bovine Serum (FBS/serum) (USA Scientific), HEPES,
glucose and pyruvate and maintained in a humidified incubator at 37 °C at 5% CO2 unless
otherwise specified. Cells were seeded in-6 well plates and were allowed to grow in 10%
serum-containing RPMI 1640 media conditions for 48 hours prior to treatments. Dishes
were seeded with 1 x 104 cells and were treated with SB-431542 (3 µM) (Selleck Chem),
LY-2109761 (3 µM) (Cayman Chem), and/or TGFβ (5 ng/ml) (Cell Signalling
Technologies) under minimal serum (1% FBS) conditions for time frames specified.
Treatment media was replenished at the 72-hour time point in 168-hour culture
experiments.
Transwell Migration Assay
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Cells were pre-treated for 7 days as described above prior to plating for the viability
assay. After pretreatment, cells were trypsinized and resuspended in serum-free RPMI
1640 media. The top of the 96-well HTS Transwell permeable plate (Corning) membranes
was coated with 600 µl of a collagen coating solution (750 µl 10X PBS, 14 µl culture-grade
collagen, 3.2 µl 0.1 M NaOH, 6.73 ml dH2O) and incubated for 1 hour in the culture
incubator at 37 °C. The collagen was aspirated, and the inserts were washed once with
1X PBS. Next, the bottoms of each Transwell were blocked with 600 µl of a serum-free
RPMI 1640 containing 0.1% BSA, and 100 µl of the blocking media was placed into each
Transwell insert. Blocking continued in the culture incubator at 37 °C for at least 1 hour up
to overnight. Following blocking, blocking medium is aspirated from the top and the bottom
wells. Cells (1 x 103) were seeded on top of each Transwell in serum free media and
allowed to migrate towards a bottom chamber containing RPMI 1640 and 1% serum for
16 hours. At this time, membranes were fixed in 100% methanol and stained with 0.5%
crystal violet in 100% methanol.
Wound Healing Assay
Cells were plated in 12-well plates at 5 x 105 cells/well to ensure confluence at time of
wounding. Cells were incubated in maintenance media (RPMI 1640 containing 10%
serum) for 24 hours following plating. After the initial 24-hour incubation, media was
changed to RPMI 1640 and 1% serum with respective treatments for 24 additional hours.
After 24 hours in treatments, cell monolayers were wounded using a 200 µl pipette tip and
media was changed to fresh RPMI 1640 and 1% serum with corresponding treatment.
Plates were marked to ensure the same point in the wound was analyzed each day.
Wound healing was measured over 72 hours and imaged using the Zeiss AxioObserver
Microscope and processed using the AxioVision software. Wounds were imaged at 24
hour intervals for 72 hours total. Wound healing measurements are averaged from 3
independent linear measurements across the field imaged per sample, per recording time.
Cell Viability Assay
Cells underwent pretreatment in 1% serum-containing RPMI 1640 with drug and/or
cytokine for 7 days as described above to ensure that all EMT-like events occurring in
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response to TGFβ treatment were fully realized prior to assessment of erlotinib response.
After treatment, cells were trypsinized, counted, and plated at 3x103 cells/well in a 96-well
plate in fresh treatments matching those from the 7-day period. After 36 hours adherence
time, erlotinib was added in indicated concentrations. Drug treatment persisted for 72
hours. After 72 hours, resazurin was added (100 µM final concentration) to each well, the
plates were gently rocked for 1 minute and then incubated for 3 hours prior to reading.
The plate was read for fluorescence at excitation, 560 nm, and emission, 590 nm,
wavelengths using a Spectramax M5 and corresponding Spectramax X5 software
(Spectramax).
Data Processing and Statistics
All graphical representations of data were made and analyzed using Prism Version
7.00 (GraphPad). Significance points in viability assay data compare the points specified
in each figure legend and in the results section. Significance was determined using
unpaired t-tests. Values measured between biological replicates from all viability assays
and wound healing assays were subjected to a Dixon’s Q test to eliminate outlier values.
For the Transwell migration assay, ‘cells migrated’ values are the number of cells
counted in five non-overlapping views per well, averaged from triplicate technical
replicates per individual experiment by three separate viewers. Values determined by
each individual were subjected to a Dixon’s Q-test outlier analysis prior to acceptance.
For the wound healing assay, ‘percent wound remaining’ was determined relative
to respective 0 hour wound width. Four independent biological replicates were performed,
and the four replicates were assessed for outliers using a Dixon’s Q-test.
For the viability assay, response to each treatment is normalized to cells from each
corresponding treatment that were not subjected to erlotinib. Readings were also
normalized to empty wells on each plate containing only media and resazurin. Data is the
result of four biological replicate experiments (n=4).

C. RESULTS
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TGFβ Treatment Has Opposing Effects on Migration in Erlotinib-Sensitive versus
Erlotinib-Resistant NSCLC Cells
We first wanted to understand the long-term functional changes in erlotinibresistant, A549 cells, and erlotinib-sensitive, PC9 cells, subjected to long-term TGFβ
treatment, and we assessed their migration ability using a Transwell Assay. TGFβ pretreatment induced a significant increase in A549 cells that migrated compared to untreated
cells (Figure 3.1). PC9 cells, pre-treated with TGFβ, demonstrated reduced migratory
ability, but this effect was not found to be significant (Figure 3.1). Since TGFβ treatment
induced migration in A549 cells, we next asked how TGFβ influenced wound healing ability
of cells.
TGFβ Inhibition Significantly Impairs Wound Healing Ability in PC9 Cells
Another measurable characteristic of migratory ability is wound healing and we
used this assay to determine the cellular response of A549 and PC9 cells to short-term
TGFβ treatment. For this experiment, we also used the TGFβ receptor inhibitor, LY2109761, that targets both type I and II TGFβ receptors, unlike SB-431542, to determine
whether differences observed could be attributed to partial TGFβ receptor inhibition. TGFβ
treatment did not significantly change the wound healing ability of either cell line.
Treatment with LY-2109761 significantly impaired the ability of A549 cells to migrate at
the 48-hour time point (Figure 3.2A). PC9 cells treated with LY-2109761, with and without
co-treatment with TGFβ, were significantly impaired in wound healing at the 48- and 72hour time points (Figure 3.2B).

TGFβ Influences Erlotinib Resistance Differently between A549 and PC9 Cells
We found that TGFβ induced an EMT-phenotype and increased chemotactic ability
in A549 cells, but not in PC9 cells. Next, we aimed to determine if TGFβ treatment had an
impact on erlotinib-sensitivity in each cell line. A549 cells pre-treated with TGFβ showed
significantly increased erlotinib resistance at lower erlotinib concentrations, but at 10 µM
and 30 µM erlotinib levels, TGFβ pre-treated A549 cells were significantly more sensitive
to erlotinib than untreated A549 cells (Figure 3.3A). No significant impact was observed in
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any combination of either TGFβ inhibitor with or without TGFβ ligand in A549 cells when
compared to untreated A549 cells (Figure 3.3A). Most notably, PC9 cells that had
undergone pre-treatment with TGFβ showed significant increased sensitivity to erlotinib
(Figure 3.3B). Moreover, pre-treatment with either TGFβ inhibitor with or without TGFβ
ligand significantly reversed the phenotype in PC9 cells (Figure 3.3B).

D. DISCUSSION
Bioinformatic analysis of a previously published 13-gene miRNA signature led us
to explore the contribution of TGFβ with respect to EMT-progression and its relationship
to erlotinib-sensitivity (327). Our previous work showed that TGFβ likely has opposing
roles in relation to EMT-induction and erlotinib-resistance between erlotinib-resistant and
-sensitive NSCLC cells. We observed that TGFβ treatment induced mesenchymal
morphologies between 5-6 days of treatment (367), so we chose to pre-treat cells for 7
days prior to the Transwell assay. We found that TGFβ pre-treatment in A549 cells
significantly increased cell migration by Transwell assay. TGFβ pre-treatment in PC9 cells
modestly decreased mobility, but this effect was not found to be significant. Changes in
PC9 cell migration after SB-431542 pre-treatment were not observed (Figure 3.1). We
also examined treatment with the TGFβ receptor type 1/2 inhibitor, LY-2109761, as a
comparison to SB-431542 by wound healing (369). We found that LY-2109761 pretreatment also induces a morphological change in PC9 cells consistent with the EMTintermediate phenotype known as metastable (353) (Data not shown). However, we
observed that LY-2109761 treatment, both alone and in conjunction with TGFβ, resulted
in a significantly suppressed wound healing capability in PC9 cells which is inconsistent
with an induction of EMT in PC9.
It has been noted by many groups that NSCLC cells sensitive to erlotinib usually
to have an epithelial phenotype and NSCLC cells resistant to erlotinib often have a
mesenchymal phenotype (366). We have shown that TGFβ treatment induces EMTprogression in erlotinib-resistant A549 cells and does not in erlotinib-sensitive PC9 cells
(367). For this reason, we endeavored to understand whether modulating TGFβ activity
contributed to changes in erlotinib sensitivity in the two cell lines. Most interestingly, PC9
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cells pre-treated with SB-431542 or LY-2109761, with and without TGFβ treatment,
showed significantly decreased erlotinib sensitivity. While these cells did not undergo an
EMT-reprogramming as defined by EMT marker-protein expression, increased wound
healing and increased migratory capabilities, our observation that the metastable
morphology corresponds with significantly decreased erlotinib-sensitivity in PC9 cells is
consistent with the observation that stable EMT intermediate phenotypes tend to be more
drug resistant (353, 370). Importantly, we did not examine whether the phenotypes
induced by TGFβ inhibitors correlated with changes in expression of EGFR or the rate of
EGFR receptor turnover. We have demonstrated that extended treatment did result in a
decrease of constitutively active ERK1/2 and AKT signaling (Figure 3.6). However,
Supplementary Figure I-7 (Appendix I) demonstrates that the decreases in ERK and AKT
signals in PC9 cells do not correlate with a cytostatic response by PC9 cells to TGFβinhibition.
Here, I have shown that TGFβ treatment influences erlotinib resistance in A549
cells but TGFβ inhibitors in combination with erlotinib do not sensitize A549 cells to
treatment. The novel observation of this work is that TGFβ-inhibition significantly
decreased erlotinib-sensitivity in PC9 cells, whereas TGFβ ligand induced more cell death
in conjunction with erlotinib than erlotinib did alone in PC9 cells. This indicates that TGFβ
likely plays a role in the maintenance of erlotinib-sensitivity in PC9 cells. Importantly, this
mirrors the observations of unsuccessful TGFβ inhibitor drug trials that cite side effects
that are likely due to pro- and anti-tumorigenic activities of TGFβ signaling (179, 219).
Accurately pinpointing which half of the TGFβ paradox is occurring and where is an
ongoing effort that has not been well established at this point in time (352, 371). This work
should be expanded into other NSCLC cell lines across the erlotinib-sensitivity spectrum
to reveal if these observations are specific to erlotinib-sensitivity status or linked to other
factors (e.g., KRAS mutation status).

E. CONCLUSIONS
While the relationship between the TGFβ and EGFR signaling networks suggests
that TGFβ represents a logical secondary target for the prevention of EMT and subsequent
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EMT-driven EGFRI resistance, the limitation of targeting TGFβ in unselected tumor
populations is evidenced by the PC9 cell model. Until a diagnostic test capable of
dissecting the TGFβ paradox exists, targeting TGFβ will remain an enigmatic and
implausible target in NSCLC and other tumor types. Further study to dissect the
mechanism of how TGFβ-inhibition significantly increases erlotinib resistance in PC9 cells
could have important implications for elucidating and diagnosing the arms of the TGFβ
paradox as well as the future of targeting TGFβ in lung cancers.

Copyright © Madeline Krentz Gober, 2017
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Figure 3.1: TGFβ treatment influences the migratory ability of A549 and PC9 cells.
Cells were plated as described in cell culture methods with the treatments specified over
a course of 7 days. Values graphed are the total number of migrated cells counted
between five independent views of each well by three independent readers. Outliers
between biological replicates, technical replicates, and individual readers were identified
and excluded using a Dixon’s Q-test. Significance was determined by an unpaired t-test
comparing each experimental treatment to its respective untreated values (n = 3). *

Average of Cells Migrated

indicates p-value is 0.05 ≥ p.

104

CHAPTER 3
Figure 3.2: LY-2109761 alters wound healing capabilities of A549 and PC9 cells. (A)
A549 and (B) PC9 cells were plated and treated as described in the methods. Percent
wound remaining is calculated for each biological replicate compared to the respective 0
hour wound size. Biological replicates were assessed for outliers using a Dixon’s Q-test
(n=4). * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is ≤ 0.0001.

Percent Wound Remaining

A
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Figure 3.2 (continued): LY-2109761 alters wound healing capabilities of A549 and
PC9 cells. (A) A549 and (B) PC9 cells were plated and treated as described in the
methods. Percent wound remaining is calculated for each biological replicate compared
to the respective 0 hour wound size. Biological replicates were assessed for outliers using
a Dixon’s Q-test (n=4). * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is
≤ 0.0001.

Percent Wound Remaining

B
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Figure 3.3: TGFβ treatment alters erlotinib response in A549 and PC9 cells. (A) A549
and (B) PC9 cells were treated for 7 days prior to initiation of the proliferation assay and
treated as described. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is
≤ 0.0001. (n=3)

A
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Figure 3.3 (Continued): TGFβ treatment alters erlotinib response in A549 and PC9
cells. (A) A549 and (B) PC9 cells were treated for 7 days prior to initiation of the
proliferation assay and treated as described. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ
indicates that p-value is ≤ 0.0001. (n=3)

B
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A. OVERVIEW
Inhibitors of the epidermal growth factor receptor (EGFR) were introduced as a
targeted therapy because some non-small cell lung cancers (NSCLC) are dependent on
the EGFR oncogene for growth and proliferation (3). Further, it was observed that cells
and tumors with KRAS activating mutations were inherently resistant to treatment with
these inhibitors (EGFRI) (67). KRAS activation mutations are the most common mutation
in lung adenocarcinomas and are observed in 25-40% of cases (19, 22). Methods for
targeting KRAS that have been investigated include farnesyl transferase inhibitors that
target the necessary association of KRAS with the cell membrane, but resistance
mechanisms involving other transferases occur (372, 373). Antisense oligonucleotides,
including engineered miRNA, have also been explored as a method for targeting mutant
KRAS without disrupting the expression of non-mutant KRAS and some have been
successful in pre-clinical testing (374, 375). The high prevalence of patients with this
inherent EGFRI resistance mechanism has made targeting mutant KRAS a priority, but so
far, significant clinical benefits have not been observed (375). To overcome the limitation
of our inability to successfully target mutant KRAS directly at this time is to target the
multiple pathways that KRAS influences downstream (376).
In early EGFRI research on gefitinib and erlotinib, several groups found that many
patients who were initially sensitive to first-generation EGFRI became resistant because
tumor cells emerge after therapy with secondary mutations in the EGFR gene (e.g.,
T790M) and mutations in other molecules (e.g., MET) from compensating signaling
cascades (377). Regardless, inherent and acquired resistance leaves many patients
without treatment options (23). Second- and third-generation EGFRI have been developed
to subvert some resistance mechanisms that can provide new therapeutic options for
some patients, but next generation inhibitors have already been met with new resistance
mechanisms (147). We believe that bioinformatics interrogation of existing gene
expression data may reveal alternative therapeutic strategies to overcome both inherent
(e.g., KRAS) and acquired EGFRI resistance (e.g., EGFR T790M) (378).
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This laboratory previously developed two gene expression signatures of response
to the EGFRI, erlotinib, with the hypothesis that patients without EGFR activating
mutations may also respond to EGFRI, and those patients might be identified by particular
gene expression phenotypes (327). Genes from the second EGFRI response signature,
comprised of miRNA genes, not only predicted response to erlotinib but also intersected
the TGFβ signaling cascade (327). These data suggested that response to EGFRI may
be influenced by activation of TGFβ receptors, and inhibition of this signaling pathway
could sensitize EGFRI-resistant tumor cells to erlotinib (327). However, other groups have
tested this hypothesis in clinical practice and have been largely unsuccessful in targeting
TGFβ, likely due to the competing pro- and anti- tumorigenic activities of the TGFβ axis
(179, 219). Despite these shortcomings, efforts to target aberrant TGFβ signaling are
ongoing (379).
Further inspection of the interactions between the mRNA and miRNA signatures
of erlotinib response revealed enzymatic activities that integrated both the EGFR and
TGFβ signaling cascades. Casein kinase 2 (CK2) emerged as a potential target. CK2 is a
multi-subunit kinase that can contribute to tumorigenesis when subunit expression is
altered. CK2 exists mainly as a tetrameric holoenzyme consisting of any combination of
two α or α’ subunits and two β subunits, but it has been suggested that the α and α’
subunits have monomeric kinase activity as well (243, 244). Interestingly, no oncogenic
mutations have been found in CK2 kinase subunits, but deregulation of subunit expression
levels might contribute to the oncogenic process (252). Moreover, it has been shown to
be an upstream regulator of AKT/PI3K/mTOR, NFκβ, and JAK/STAT signaling cascades
irrespective of the receptor tyrosine kinases shown to activate them (380). As stated
earlier, EGFRI resistance is known to be caused by alterations in parallel signaling
pathways, including the PI3K/AKT/mTOR and JAK/STAT (145). Therefore, we postulated
that inhibition of CK2 might represent an alternative target for the treatment of NSCLC that
are resistant to EGFRI. This strategy may provide some NSCLC patients an additional
opportunity for therapeutic intervention.

B. METHODS

Cell Culture and Western Blotting
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A549, H460, and H1650 (NSCLC) cell lines were purchased from ATCC. PC9 cells
were a gift from the Haura lab (Moffitt Cancer Center, FL) Cells were cultured in RPMI
1640 (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (USA
Scientific), HEPES, glucose and pyruvate and maintained in a humidified incubator at
37°C at 5% CO2 unless otherwise specified. For western experiments, 1 x 104 cells were
plated into a 12-well dish and allowed to adhere in RPMI 1640 containing 10% FBS for 48
hours. Following the adherence period, cells were treated with the drug concentrations of
CX-4945 (Cayman Chem) or AZD6244 (Astra Zeneca) in RPMI 1640 containing 1% FBS
for the treatment durations indicated. Both adherent and non-adherent cells from each
sample were harvested for total protein. Equal volumes of cell total cell extracts were
loaded. Cleaved PARP and α-tubulin antibodies were purchased from Cell Signaling
Technologies.
Generation of miRNA and mRNA Expression Datasets
mRNA and miRNA expression levels were measured in growing non-small cell
lung cancer (NSCLC) cell lines using Affymetrix U133 2.0 microarrays (GSE31625) and
Taqman cards from Applied Biosystems (ABI) (previously published data) (327, 328). We
evaluated interactions among the 1495 mRNA genes and 23 miRNA that are significantly
deregulated in erlotinib-sensitive compared with erlotinib-resistant NSCLC cells (327,
328).
Feasible Solutions (FS) Statistical Methodology with Work Flow and Protein-Protein
Interaction Network Analysis
The following analysis was performed by Dr. Arnold Stromberg and Josh Lambert
(Department of Statistics, University of Kentucky):
Feasible Solutions (FS) was used to identify mathematical interactions in the
expression data. We included mRNA that demonstrated higher expression (~800
probeIDs) in the erlotinib-resistant cell lines, and we enumerated the possible solutions,
or interacting miRNA, that resulted, regardless of direction of expression relative to the
mRNA. The algorithm works as follows:
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Consider fixing p+ explanatory variables in a preliminary model. Denote these
variables Xp+. Let m(Y;Xp+) be an objective function that can be a measure of model
quality i.e., R2; AIC; BIC; etc. We wish to find the k additional variables denoted Xk to add
to the model that optimizes the objective function m(Y;Xp+;Xk). The FS algorithm attempts
to solve this problem in the following way:
1. Choose Xk randomly and compute the objective function m.
2. Consider exchanging one of the k selected variables from the current model.
3. Make the exchange that improves the objective function m the most.
4. Keep making exchanges until the objective function does not improve. These
variables Xp+;Xk are called a feasible solution.
5. Return to (1) to find another feasible solution.
We chose the 100 probeIDs with the lowest Prob>F (Supplementary Table II-1,
Appendix II) for further biological evaluation by STRING analysis that was performed by
Dr. Robert Flight (Markey Cancer Center, University of Kentucky).
Using the miRNA:mRNA interactions described by FS modeling, the Affymetrix
probesets were converted to Ensembl IDs. STRING database v 10.0 (FS) (381) files
specific for human proteins were downloaded for further processing. The Bioconductor
v3.0 package (382) for Affymetrix(R) HGU133-plus2 chips (hgu133plus2.db v3.0.0) was
used to translate Affymetrix (R) probeset identifiers to gene identifiers (symbols, gene
names, Entrez IDs and ENSEMBL Proteins) in R v3.3.2 (2016). From ENSEMBL protein
IDs, the species ID 9606 was added to provide STRING protein IDs. The full set of
STRING protein-protein interactions (PPI) were filtered to those with a combined score
greater than 400, as well as individual scores greater than 400 in any one of the
"experimental", "database", and "co-expression" evidences. From this subset of PPIs, the
interactions with the original set of genes and their interactors (those genes within one
edge or interaction) were extracted from the PPI database (Full list of initial genes
extracted in Supplementary Table II-2, Appendix II). We were interested in interactions
G1-X-G2, where G1 and G2 are from our list of proteins, X can be any protein that
connects G1 to G2 (Full list of genes comprising the expanded network in Supplementary
Table II-3, Appendix II). For each PPI, only a record that there was an interaction between
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the two proteins was kept with no information on the number of evidences or the score of
the interaction. STRING protein IDs were translated to gene IDs using the human
database (org.Hs.eg.db v3.0.0) with Ensembl Protein (ENSEMBLPROT) as the query key
(STRING protein identifiers are a combination of species ID and Ensembl protein ID).
Cytoscape (383) and BioFabric (384) networks were constructed from these data.
Within the induced network, communities of genes with shared and related
functions

(Supplementary Table

II-7,

Appendix II)

were

identified

using the

cluster_walktrap function in igraph 1.0.1 (385, 386).
Cell Viability Assay
Cells were plated at 3x103 cells/well in a 96-well plate in fresh treatments and
allowed to adhere in RPMI 1640 containing 10% FBS for 36 hours. After 36 hours, CX4945 (Apex Bio) and AZD6244 (Astra Zeneca) was added in the final concentrations
indicated in RPMI 1640 containing 1% FBS. Drug treatment persisted for 72 hours. After
72 hours, resazurin was added (100 µM final concentration) to each well, the plates were
gently rocked for 1 minute and then incubated for 3 hours prior to reading. Each plate was
read for fluorescence at excitation, 560 nm, and emission, 590 nm, wavelengths using a
Spectramax M5 and corresponding Spectramax X5 software (Spectramax). Response to
each treatment is normalized to untreated cells from each corresponding treatment and
normalized to empty wells on each plate containing only media and resazurin. Three
biological replicates were performed and were assessed for outliers using a Dixon’s Qtest. Data were analyzed using Prism Version 7.00 (GraphPad).
Availability of Data
All code for network generation and enrichment analysis and Supplemental files are
available for download from figshare at: https://figshare.com/s/7e50e9ab2a66b5041451.

C. RESULTS
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CK2 Connects the miRNA and mRNA Signatures of EGFRI Sensitivity
We hypothesized that mRNA and microRNA gene expression data from NSCLC
cell lines could be used to identify novel targets for therapy in lung cancer patients resistant
to EGFRI. The Black laboratory previously identified two independent gene expression
signatures of response to EGFRI using a panel of NSCLC cell lines demonstrating
differential response to EGFR inhibition as measured by a cell death assay (327). The
signatures were culled from a larger set of differentially-expressed mRNA and miRNA.
Using the larger lists of genes (1495 mRNA and 23 miRNA), we sought to identify new
protein targets for therapy using statistically significant interacting pairs of mRNA and
miRNA discovered by the feasible solutions algorithm (FS) (Supplementary Table II-1,
Appendix II). FS modeling first evaluates expression levels of a random combination of
mRNA and miRNA pairs then considers swap-pairings of other miRNA to improve model
fit and arrive at significant pairings. Each pairing then becomes a feasible solution. In this
case, the model sought mRNA-miRNA pairs that have the property of high mRNA
expression in the erlotinib-resistant cell lines (~800 probe IDs) in order to find targets that
may have therapeutic value in erlotinib-resistant tumors. Given this outcome, we
hypothesized that identifying new druggable targets for erlotinib-resistant NSCLC may
depend on interactions with the EGFR signaling network. To investigate this hypothesis,
we chose to use our FS gene list to find other proteins that physically interact with the
candidate(s) and EGFR.
The 100 probes with the lowest probability (low Prob>F, Supplementary Table II1, Appendix II) were identified by FS. These 100 probes translated into 85 Ensembl IDs
that had matches in the STRING v10 network (387). We also included EGFR as a node
to triangulate the network specifically around EGFRI resistance. We carried out the
network expansion analysis considering the scenario G1-X-G2 wherein G1 and G2 were
proteins from the original list of 85 Ensembl IDs while X could be anything. Only 81 of the
85 proteins remained in this “induced network” (Supplementary Table II-3, Appendix II).
However, another 304 nodes were found (for a total of 385 proteins in the network) that fit
in the G1-X-G2 network (Supplementary Table II-3, Appendix II).
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From these induced nodes, CK2 was chosen for further study for three reasons:
1) It has been shown to regulate many of the signaling pathways represented in the
network, 2) it has been shown to be within 2 edges of 366 out of 385 of the identified nodes
in the network (Supplementary Table II-5, Appendix II), and 3) it has enzymatic activity
with an available pharmacological inhibitor (Table 4.1). The aim of this study was to
understand whether CK2 inhibition reduced cell viability in EGFRI resistant NSCLC cells.
We chose to examine the impact of CK2 inhibition on EGFRI resistant NSCLC cells with
a variety of driver mutations (Figure 4.2B).

CK2 Inhibition Induces Greatest Cell Death in KRAS Active NSCLC
To determine if CK2 activity is a novel target in EGFRI-resistant NSCLC with
KRAS-activation mutations, we performed a viability assay to determine whether
treatment with the CK2 small molecule inhibitor, CX-4945, decreased viability of KRASactive NSCLC cells. In A549 and H460 cells, we observed a ~50% decrease in cell viability
in CX-4945 treated cells compared to untreated cells (Figure 4.2). Considering CK2
inhibition alone was not sufficient to decrease cell viability completely, we next aimed to
identify and test a secondary target within or related to the expanded network.

CK2 and the Members of the EGFR-MAPK-ERK Signaling Cascade Appear to
Function Exclusively of one Another
Of the 366 members of the induced network shown to be within two edges of CK2α
and CK2α‘ (CSNK2A1/CSNK2A2), we isolated the network members that are within one
edge of CK2α/CK2α’ (Supplementary Table II-4, Appendix II). Unexpectedly,
Supplementary Table II-4 (Appendix II) specifically demonstrates that CK2α and CK2α’ do
not directly interact with any of the members of the EGFR-RAS-RAF-MEK-ERK signaling
cascade. All of the members of that signaling cascade identified by FS (HRAS, KRAS,
NRAS, MAPK1, RAF1) were found to be at least two edges away from CK2α/CK2α’
(Supplementary Table II-5, Appendix II). Because CK2 inhibition alone did not reduce cell
viability completely in any cell line, we next explored whether downstream members of the

115

CHAPTER 4
MAPK-ERK pathway could be logically co-targeted with CK2 in EGFRI resistant NSCLC
cells.

Combinatorial Targeting of CK2 and MEK Induces Apoptosis in KRAS Active
NSCLC Cells
We focused our selection of a secondary target on the goal of inhibiting the EGFRMAPK-ERK pathway without targeting the EGFR receptor. CX-4945 resistance has been
demonstrated in head and neck cancers and was shown to be overcome by MEK inhibition
(388). Importantly, MEK was not a member of the induced network and none of the other
EGFR-MAPK-ERK pathway members identified exist within one edge of CK2α/CK2α’
(Supplementary Tables II-3 and II-4, Appendix II). Moreover, CK2α/CK2α’ were
determined to be members of community #19 whereas EGFR was identified in community
#4 and other ERBB receptor family members and KRAS were identified in community #2
(Supplementary Table II-7, Appendix II). This suggests that while connected in the overall
network, the MAPK-ERK cascade and CK2 likely function independently of one another.
To examine the impact of CK2 inhibition (CX-4945) in combination with MEK
inhibition (AZD6244), we observed the induction of apoptosis in NSCLC cells by western
blot (Figure 4.3). Both of the KRAS active cell lines examined demonstrated elevated
levels of cleaved PARP at the higher concentrations of CX-4945. Levels of cleaved PARP
also appear to increase between the 24- and 48-hour time points in both cell lines.
We screened A549 and H460 cells to determine if the responses to the
combination of CX-4945 and AZD6244 represented a synergistic, additive, or antagonistic
using a resazurin-based viability assay as was used for the single agent CX-4945 viability
assays (Figure 4.4). The strongest synergism between the CX-4945 inhibitor and the
AZD6244 inhibitor occurred when AZD6244 was present at 10μM and 3μM and
concentrations of CX-4945 were between 0.1-30μM in both KRAS active cell lines (Figure
4.4).
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D. DISCUSSION
There is an urgent need to develop strategies for treating lung tumors harboring
KRAS activation or other EGFRI-resistance mutations. Not only are inherent EGFRIresistance mutations common, but secondary mutations that cause EGFRI-resistance to
develop are also prevalent and novel drug targets and treatment strategies are paramount
for all lung cancer patients. Our goal was to use a combination of statistical and
computational methods that integrated existing gene expression signatures linked by
disease and drug response phenotypes. From this, we aimed to use interacting pairs of
mRNA:miRNA to identify a network of relevant protein-protein interactions (389). In
collaboration with Dr. Flight and the Stromberg group, we used the FS algorithm to identify
interacting pairs of mRNA and miRNA because of prior work that indicated that pairing
these RNA species may lead to an improved understanding of the disease (390). To return
pharmacologically actionable targets, we focused on evaluating the protein-coding genes
as drug targets, rather than the microRNA partner of the pair. The FS data was empirically
reduced to the top 100 statistically-significant pairs of which the mRNA partner had highest
expression in erlotinib-resistant cell lines (Supplementary Table II-1, Appendix II). Using
KEGG GENES and Gene Ontology databases, each mRNA gene was paired with a
molecular function, and STRING was utilized to determine protein-protein interactions
(PPI). Each of these filters was intended to be an in silico screen to identify candidate
protein-coding genes that are involved in or linked to EGFR signaling in EGFRI-resistant
NSCLC. Because of our efforts to focus the network identification around EGFR and
EGFRI resistance, the nodes identified thereby represent putative drug targets for the
treatment of EGFRI-resistant NSCLC.
The limitation of our initial method of identifying alternative drug targets is that not
all pharmacologically actionable proteins influencing EGFRI resistance are captured when
considering only those deregulated genes directly connected to EGFR. For this reason,
we chose to expand the network of deregulation in search of plausible nodes controlling
EGFRI resistance. We specifically chose to look for a node linking at least two oncogenic
signaling pathways (391).
To identify actionable nodes linking the members of our list of significantly
deregulated proteins, we chose to expand our network by only identifying and adding
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proteins known to link two members of the original list. We did this by identifying proteins
that met the criteria: G1-X-G2, where G1 and G2 are members of the original list of
deregulated genes including EGFR while X is any protein linking the two. What we
determined is that by adding this additional level of selection, we identified nearly every
EGFRI resistance mechanism described in NSCLC thus far (Communities #2 and #4,
Supplementary Table II-7, Appendix II) among a number of novel putative targets
(Supplementary Table II-7, Appendix II). Of the expanded network, we selected CSNK2A1
and CSNK2A2, which encode the kinase subunits of CK2. We determined that they are
within two edges of 366 out of 385 members of the expanded network indicating their
value as a well-connected target (Supplementary Table II-3, Appendix II). Not only was
CK2 predicted by our in silico model to interact with many sources of EGFRI resistance,
but it has been also described as influencing many other members of the network of
deregulated genes between EGFRI resistant and sensitive NSCLC, notably including NFκβ and PI3K/AKT (392). The network specifically includes nearly every source of inherent
or acquired EGFRI resistance described to date (19, 145) and they were largely contained
to two communities of common action, neither of which included CK2 (Supplementary
Table II-7). Considering the global potential influence of CK2 in the network of
dysregulation of EGFRI resistance, and that a kinase inhibitor of CK2 has been tested in
Phase II trials (323), we next aimed to determine if CK2 inhibition was impactful against
NSCLC cells that are resistant to EGFRI.
EGFRI-resistant, KRAS active NSCLC cells were found to be sensitive to CK2
inhibition, but the maximal response observed was only around 50% cell viability
compared to untreated cells (Figure 4.2A). We compared the effect of CX-4945 in KRAS
active NSCLC to other cell lines harboring EGFR mutations. We found that PC9 cells, that
harbor only an EGFR exon 19 deletion mutation, were resistant to CX-4945. However,
H1650 cells that harbor both an exon 19 deletion as well as a PTEN null mutation
demonstrated a response curve similar to KRAS active A549 and H460 (Figure 4.2A).
Specifically, H1650 cells only have intermediate sensitivity to EGFRI despite the EGFR
activation mutation because loss of the PTEN tumor suppressor allowing these cells to
compensate for EGFRI action through deregulated PI3K/AKT signaling. Importantly, CK2
was identified as a possible target for overcoming PTEN null mutations via a
chemogenomic study in 2015 (393). It is also interesting to note that both PC9 and H1650
harbor a p53 mutation, and from these data, it would appear that mutant p53 likely does
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not influence CX-4945 efficacy. Interestingly, H460 cells have a PIK3CA E545K mutation
resulting in less efficient activation of the p110α isoform of the PI3K catalytic domain but
were still sensitive to upstream CK2 inhibition. We have previously demonstrated that
PI3K p110 isoforms are capable of compensation. H460 express high levels of the p110β
isoform as well as high levels of PTEN protein expression suggesting that the regulation
of this pathway by CK2 is still possible despite the PIK3CA mutation (331). To examine
whether these observations were related to expression of CK2 subunits, we profiled each
of the NSCLC cell lines tested above for CSNK2A1, CSNK2A2 and CSNK2B mRNA
expression (Supplementary Figure II-1, Appendix II). Of the NSCLC cell lines we profiled,
KRAS active cells demonstrated the lowest expression of CSNK2B compared to normal
cells. This suggests that constitutively active KRAS signaling may play a role in repressing
CK2β expression.
We next aimed to identify a second expanded network member or member of a
network pathway as a plausible secondary target to be paired with CK2 inhibition because
none of the cell lines tested were exquisitely sensitive to CK2 inhibition. Importantly, the
KRAS active NSCLC tested were the most sensitive to CK2 inhibition. The KRAS
activation mutation drives MAPK-ERK signaling regardless of EGFR activation or
inhibition, and we observed in the expanded network that not all of the MAPK-ERK
signaling cascade were represented and none were directly connected to CK2. For this
reason, we hypothesized that CK2 and MEK inhibition would be sufficient to overcome
compensatory signaling by the induced network identified in KRAS active NSCLC. This
hypothesis was also founded with the knowledge that MEK inhibition has been used to
overcome CX-4945 resistance in head and neck cancers (388). Our lab and others have
similarly demonstrated that inhibition of MEK concurrently with EGFRI sensitizes NSCLC
with EGFR T790M mutations to treatment (329, 394). Initial exploration of AZD6244 and
CX-4945 co-treatment on NSCLC cells revealed that the apoptotic marker, cleaved PARP,
was expressed in KRAS active NSCLC cells. Moreover, increased cleaved PARP relative
to α-tubulin were observed at 48 hours when compared with 24 hours. We screened KRAS
active A549 and H460 for synergistic drug interactions between CX-4945 and AZD6244
and found that the strongest synergism between the two drugs occurred when AZD6244
was present at 10μM and 3μM and concentrations of CX-4945 were between 0.1-30μM in
both KRAS active cell lines (Figure 4.4). These data demonstrate that this combination of
CK2 and MEK inhibition may represent a novel approach for the treatment of EGFRI119
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resistant, KRAS-active NSCLC. We plan to expand on this observation by performing a
battery of viability assays against a range of NSCLC cells to determine if these
observations reign true for other cell lines with varying responses to EGFRI therapies.
A combination of MEK and CK2 inhibition encompasses many of the signaling
pathways by which non-EGFR-receptor EGFRI resistance develops and should continue
to be explored as an avenue for the treatment of inherently resistant NSCLC (e.g., KRAS).
It should also be explored as an avenue for overcoming acquired EGFRI-resistance (e.g.,
EGFR T790M) as well. This strategy of bypassing EGFR and KRAS as therapeutic targets
may represent a novel therapeutic approach for treating a variety of NSCLC tumors.

E. CONCLUSIONS
Many cancers are quickly becoming chronic diseases and will require new therapies
for patient care and management of emerging resistant diseases. We have demonstrated
that gene expression signatures descriptive of a specific tumor phenotype can be used to
identify potential targets for new therapeutics or co-therapeutic methodologies. Using the
FS algorithm and STRING, we unveiled a network of proteins found to be deregulated
between EGFRI resistant and sensitive NSCLC. From this network, we identified and
tested CK2α/CK2α’ as a therapeutic target for the treatment of EGFRI resistant NSCLC,
but CK2 inhibition alone did not substantially decrease cell viability. The expanded network
suggests that EGFR-MAPK-ERK signaling and CK2 activity exist somewhat exclusively
which prompted us to examine the impact of combinatorial CK2 and MEK inhibition. Initial
CK2+MEK inhibition experiments revealed that the combination of the two drugs is lethal
in KRAS active NSCLC cells and was synergistic when AZD6244 was present at 10μM
and 3μM with all concentrations of CX-4945 in both KRAS active cell lines. We believe
that the combination of MEK and CK2 inhibition has important implications for the
treatment of KRAS active NSCLC and has potential as an alternative to those who acquire
EGFRI-resistance during treatment. We also seek to improve this novel pipeline for drug
discovery by automating a process that utilizes gene expression signature as inputs and
objectively leverages bioinformatics filtering of prospective targets to minimize wet lab
validation. We must also consider multiple computational and statistical methods to
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identify gene-gene interactions and associated validation schemes that appropriately
manage high-density data from comparatively few biological observations.
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Figure 4.1: The G1-X-G2 expanded network links nearly every EGFRI resistance
described to date. The network of protein protein interactions was simplified to a
collection of “communities” with collective activities using the cluster_walktrap function in
igraph. Putative community activities were determined by manual data mining and
literature search. (A) Complete network of communities. (B) Magnification of central
communities with putative actions and known EGFRI resistance mechanisms highlighted.
A
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Figure 4.1 (continued): The G1-X-G2 expanded network links nearly every EGFRI
resistance described to date. The network of protein protein interactions was simplified
to a collection of “communities” with collective activities using the cluster_walktrap function
in igraph. Putative community activities were determined by manual data mining and
literature search. (A) Complete network of communities. (B) Magnification of central
communities with putative actions and known EGFRI resistance mechanisms highlighted.
B
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Table 4.1: G1-X-G2 Analysis-Induced EGFRI Resistance Network Members that
interact with CK2α or CK2α’ within one edge and are pharmacologically actionable.
Table members are from the complete network of 385 proteins that interact with CK2α or
CK2α’ within one edge (Supplementary Table II-4, Appendix II). Abridged table members
below represent those for which both pharmacological inhibitors exist and have at least
entered Phase I clinical trials.

SYMBOL

GENE NAME

TYPE

AKT1

v-akt murine thymoma viral oncogene homolog 1

Induced

CDK1

cyclin-dependent kinase 1

Induced

CSNK2A1

casein kinase 2, alpha 1 polypeptide

Induced

CSNK2A2

casein kinase 2, alpha prime polypeptide

Induced

CTNNB1

catenin (cadherin-associated protein), beta 1, 88kDa

Induced

histone deacetylase 1

Induced

HDAC1

heat shock protein 90kDa alpha (cytosolic), class A
member 1
heat shock protein 90kDa alpha (cytosolic), class B
HSP90AB1
member 1
HSP90AA1

HSP90B1

Induced
Induced

heat shock protein 90kDa beta (Grp94), member 1

Induced

PSMA3

proteasome subunit alpha 3

Induced

PSMA4

proteasome subunit alpha 4

Induced

PTEN

phosphatase and tensin homolog

SIRT1

sirtuin 1

Induced

SRC proto-oncogene, non-receptor tyrosine kinase

Induced

SRC
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Figure 4.2: NSCLC cells resistant to EGFRI are most sensitive to CK2 inhibition. (A)
Viability assays were performed on KRAS active, EGFRI resistant NSCLC (A549 and
H460 cells) treated with CX-4945. Shown in comparison with intermediate-EGFRI
sensitivity, H1650 cells (EGFR exon 19 deletion and PTEN null), and EGFRI-sensitive,
PC9 cells (EGFR exon 19 deletion). Values are log-transformed. (n=3) (B) A table
demonstrating the EGFRI resistance, mutational statuses, and response to 10μM CX4945 for each of the NSCLC analyzed.

A
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Figure 4.2 (continued): NSCLC cells resistant to EGFRI are most sensitive to CK2
inhibition. (A) Viability assays were performed on KRAS active, EGFRI resistant NSCLC
(A549 and H460 cells) treated with CX-4945. Shown in comparison with intermediateEGFRI sensitivity, H1650 cells (EGFR exon 19 deletion and PTEN null), and EGFRIsensitive, PC9 cells (EGFR exon 19 deletion). Values are log-transformed. (n=3) (B) A
table demonstrating the EGFRI resistance, mutational statuses, and response to 10μM
CX-4945 for each of the NSCLC analyzed.

B

EGFRI

EGFR

KRAS

PI3K/AKT

Resistance

Mutation

Mutation

Mutations

Status

Status

Status

Status

A549

Resistant

WT

H460

Resistant

WT

CELL
LINE

G12S
(Active)
Q61H

PIK3CA

(Active)

E545K (Null)

Exon 19
H1650

Intermediate

Deletion

WT

WT

(Activating)

PTEN Null
(Activating)

Percent
Viability at
10μM CX4945
53.2405
57.2708

53.4981

Exon 19
PC9

Sensitive

Deletion

WT

(Activating)
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Figure 4.3: Co-treatment with CX-4945 and MEK inhibitor, AZD6244, induces cell
death in KRAS active NSCLC. Cells handled and treated as described in the methods.
Both adherent and non-adherent components of each well were harvested for total protein.
Each well represents 1/3 of the total volume of protein harvested from each sample
assessed for cleaved PARP and α-tubulin. Response to drug combinations were observed
by western blot using the apoptotic marker, cleaved PARP at 24 and 48 hours. (A) A549
cells (B) H460 cells.

A

B
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Figure 4.4: Screening for synergistic interactions between the CK2 inhibitor, CX4945, and the MEK inhibitor, AZD6244. Cells were assessed by resazurin viability assay
to identify possible synergistic, additive or antagonistic responses of CX-4945 in
combination with AZD6244 using combination index (CI) values. CI values were then used
to generate the heat map for each cell line. (A) A549 cells (B) H460 cells.

CI Values
≤0.5
0.51-0.99
1-1.49
1.5-1.99
≥2.0

Synergism
Slight Synergism
Additive
Slight Antagonism
Antagonism

A

CX-4945 (μM)

30
10
3
1
0.3
0.1

10
0.71992
0.55608
0.42711
0.67159
0.71075
0.85743

CX-4945 (μM)

AZD6244 (μM)
30
1.02049
0.95206
0.79595
1.14371
1.258
1.51505

30
0.23853
30
10 0.6804
3 1.79495
1 5.32872
0.3 10.7842
0.1 0.67055

10
0.15484
0.78631
0.59703
0.68241
0.57414
0.56424

3
0.59235
0.5078
0.72412
0.89036
0.65023
0.72815

1
0.55049
0.98279
1.63317
2.10645
1.00434
0.59457

0.3
0.61981
0.98735
6.43996
15.3454
12.1634
115.893

0.1
0.73616
0.73973
3.39567
1.78956
0.36242
0.29457

B

AZD6244 (μM)
3
0.24985
0.59991
0.41602
0.52064
0.45335
0.26205

1
0.3
0.1
0.35815 0.1522 0.23068
2.73233 0.7952 0.74581
1.09675 4.1732 0.44567
1.04351 0.78227 0.97133
10.8271 7.33228 0.40307
25.8473 37.7681 0.13553
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A. OVERVIEW
EGFR is not the only driver mutations found in NSCLC which is why not all tumors
are responsive to EGFRI treatments (19). Moreover, many patients that receive EGFRI
therapies eventually develop resistance which underscores the need for alternative
therapeutic options to overcome these limitations of EGFRI. Our 13-gene miRNA
signature of EGFRI response initially indicated that the TGFβ signaling cascade may be
a putative secondary target for the treatment of drug-resistant NSCLC (327). In Chapter
3, we demonstrated that TGFβ inhibitors had value in impeding cell mobility as well as
increased erlotinib resistance in A549 cells. However, we also determined that the
inhibition of TGFβ induced a significant increase in erlotinib resistance in PC9 cells that
are otherwise exquisitely sensitive to erlotinib treatment. Our work examining the value of
TGFβ as a target confirmed observations that targeting TGFβ may be detrimental in
unselected tumor populations (Chapter 3) (179, 213).
Further analysis of our gene expression data using Feasible Solutions
mathematical model to find putative mRNA-miRNA gene interactions (Chapter 4) identified
CK2 as an alternative target for the treatment of EGFRI-resistant NSCLC. Initial
examination of CK2 as a therapeutic target demonstrated that it may have value as a
treatment option for NSCLC harboring KRAS activation mutations or PTEN null mutations
(Chapter 4). Maximal cell viability decreases were only observed at approximately 50%
cell viability suggesting that CK2 inhibition would likely be most successful as part of a
combination therapy. Interestingly, the inhibition of CK2 has been shown to impede the
induction of EMT by TGFβ (239). CK2 inhibition showed promise in treating A549 cells,
but had no effect in PC9 cells (Chapter 4). Given these results combined with the observed
relationship between the induction of EMT by TGFβ and CK2, we hypothesize that
inhibition of CK2 can block TGFβ-induction of EMT and reduce erlotinib resistance in A549
cells. In this context, CK2 inhibition could augment EGFRI by blocking the induction of
EMT and EGFRI-resistance thereby eliminating the need for TGFβ inhibition all together.
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B. METHODS

Cell Culture
The NSCLC cell lines used were A549, purchased from ATCC, and PC9, gifted
from the Haura lab (Moffitt Cancer Center, FL). All cells were cultured in RPMI 1640 (Life
Technologies) supplemented with 10% FBS (USA Scientific), HEPES, glucose and
pyruvate and maintained in a humidified incubator at 37 °C at 5% CO2 unless otherwise
specified. Cells were seeded in 6-well plates and were allowed to grow under RPMI 1640
containing 10% serum media conditions for 48 hours prior to treatments. Cells were plated
at 1 x 104 cells and were treated with SB-431542 (3 µM) (Selleck Chem), LY-2109761 (3
µM) (Cayman Chem), CX-4945 (1 µM) (Apex Bio) and/or TGFβ (5 ng/ml) (Cell Signalling)
under minimal serum (1%) conditions for time frames specified. Treatment media was
replenished at the 72-hour time point in 168-hour culture experiments.
Cell Viability Assay
Cells underwent pretreatment in 1% serum-containing RPMI 1640 with drug and/or
cytokine for 7 days following the plating and treatment conditions described above. After
treatment, cells were trypsinized, counted, and plated at 3x103 cells/well in a 96-well plate
in fresh treatments matching those from the 7-day period. After 36 hours adherence time,
erlotinib was added in indicated concentrations. Drug treatment persisted for 72 hours.
After 72 hours, resazurin was added (100 µM final concentration) to each well, the plates
were gently rocked for 1 minute and then incubated for 3 hours prior to reading. The plate
was read for fluorescence at excitation, 560 nm, and emission, 590 nm, wavelengths using
a Spectramax M5 and corresponding Spectramax X5 software (Spectramax).
Data Processing and Statistics
Values measured between biological replicates from all viability assays and wound
healing assays were subjected to a Dixon’s Q test to eliminate outlier values. For viability
assays, response to each treatment is normalized to cells from each corresponding
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treatment that were not subjected to erlotinib. Readings were also normalized to empty
wells on each plate containing only media and resazurin. Individual experiments were
done in triplicate and were assessed for outliers using a Dixon’s Q-test (n=4). All graphical
representations of data were made and analyzed using Prism Version 7.00 (GraphPad).
Significance points in viability assay data compare the points specified in each figure
legend and in the results section. Significance was determined using unpaired t-tests.

C. RESULTS

CX-4945 increases erlotinib-sensitivity in PC9 but not in A549 cells
In Chapter 3, we demonstrated that while TGFβ ligand treatment increases
erlotinib sensitivity in PC9 cells, it significantly decreased A549 erlotinib-sensitivity in a
dose-dependent manner (Figure 3.3). Also, TGFβ receptor inhibition (with SB-431542 or
LY-2109761) reversed the erlotinib phenotype in TGFβ ligand-treated A549 cells, and the
presence of either TGFβ receptor inhibitor significantly decreased erlotinib sensitivity in
PC9 cells (Figure 3.3). For this reason, we endeavored to determine whether co-inhibition
of another linked target, CK2, could sensitize erlotinib-resistant A549 cells to treatment.
CK2 and TGFβ activate common growth, proliferation and survival pathways. For these
reasons, we sought to elucidate whether CK2 inhibition could prevent the changes on
erlotinib-sensitivity in A549 and PC9 cells induced by TGFβ ligand or TGFβ inhibitors
respectively.
Pre-treatment of A549 cells with a combination of CX-4945 and TGFβ ligand
(Figure 5.1A) prevented the increased erlotinib-resistance phenotype observed in A549
cells that had been pre-treated with TGFβ ligand

alone (Chapter 3, Figure 3.3A).

Conversely, SB-431542 pre-treatment in combination with CX-4945 decreased erlotinibresistance in A549 cells at lower erlotinib concentrations (0.1-3 µM) compared with cells
pre-treated with CX-4945 alone (Figure 5.1A).
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In PC9 cells, pre-treatment with CX-4945 alone and in combination with TGFβ
ligand increased erlotinib sensitivity when compared to the matched CX-4945 naïve cells
in Chapter 3, Figure 3.3B (Figure 5.1B). Importantly, this experiment showed that the pretreatment of PC9 cells with CX-4945 did not eliminate the decrease in erlotinib-sensitivity
resulting from exposure to either of the TGFβ inhibitors (SB-431542 or LY-2109761) with
or without TGFβ ligand (Figure 5.1B).

D. DISCUSSION
In Chapter 3, we showed that TGFβ ligand can contribute to erlotinib resistance in
A549 cells because TGFβ inhibitors reversed this phenotype. Conversely, TGFβ-inhibition
significantly reduced erlotinib sensitivity in PC9 cells, whereas TGFβ ligand induced more
cell death in conjunction with erlotinib than erlotinib did alone (Figure 3.3B, Chapter 3).
Identifying which arm of the TGFβ paradox signaling is active remains elusive, but CK2
inhibition has been shown to reverse TGFβ-driven EMT offering a possible alternative
(239). For this reason, we endeavored to determine if CK2 inhibition using CX-4945
(Silmitasertib) could similarly prevent the increase in erlotinib resistance.
We found that CX-4945 impedes the increase in erlotinib resistance induced by
TGFβ ligand in A549 cells (Figure 3.3A), but it does not sensitize A549 cells to erlotinib.
This suggests that the combination of EGFRI and CK2 inhibition is not a sufficient
treatment option for KRAS active NSCLC like A549. Importantly, the significant decrease
in erlotinib-sensitivity induced by TGFβ-inhibition in PC9 cells was not blocked by coinhibition with CX-4945. CX-4945 treatment did increase erlotinib sensitivity significantly
in PC9 cells both treated and untreated with TGFβ ligand when compared to matched PC9
(Supplemental Figure III-1, Appendix III).

E. CONCLUSIONS
EGFRI and CX-4945 efficacy appear to be linked by a co-dependent relationship
between PI3K/AKT and MAPK-ERK signaling (238, 395, 396). The decrease in erlotinib
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sensitivity in PC9 cells induced by TGFβ inhibitors was not prevented by co-incubation
with the CK2 inhibitor, CX-4945. This reinforces that TGFβ-inhibitors continue to have
limited to no value in this context since the off-target effects of TGFβ-inhibition are still
evident in PC9 cells. While the interactions among signaling networks certainly impacts
the influence of TGFβ on EGFRI resistance, the limitation of targeting TGFβ in unselected
tumor populations is not mitigated by the inclusion of CK2 inhibitors.
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Figure 5.1: TGFβ treatment in combination with CX-4945 alters erlotinib response
in A549 and PC9 cells. (A) A549 and (B) PC9 cells. Cells were treated with TGFβ in
combination with CX-4945 with or without SB-431542 or LY-2109761 at the same time as
the samples used in figure 3.3. Values are normalized to corresponding cells untreated by
erlotinib. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is ≤ 0.0001. (n
= 3)

A
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Figure 5.1 (Continued): TGFβ treatment in combination with CX-4945 alters erlotinib
response in A549 and PC9 cells. (A) A549 and (B) PC9 cells. Cells were treated with
TGFβ in combination with CX-4945 with or without SB-431542 or LY-2109761 at the same
time as the samples used in figure 3.3. Values are normalized to corresponding cells
untreated by erlotinib. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is
≤ 0.0001. (n = 3)

B
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A. SUMMARY OF RESULTS
My goal for this body of work was to utilize genomic data to identify and test
putative targets for the treatment of drug-resistant lung cancers. Using the previous data
generated by the lab to produce two gene signatures of EGFRI response, I hypothesized
that:
1) The 13 miRNA genes comprising the second expression signature of response
to EGFRI are transcriptionally regulated by TGFβ signaling.
2) TGFβ drives EMT and enforces EGFRI resistance in EGFRI-resistant NSCLC.
3) The cell line RNA expression data used to generate the miRNA and mRNA
signatures can be analyzed using novel mathematical and computational
models to uncover interactions among these RNA. These nodes of cellular
regulation, captured by utilizing both lists of deregulated genes, may identify
novel targets to combat EGFRI-resistance in NSCLC.
In Chapter 2, I explored my first hypothesis that the miRNA comprising the
signature of response were being transcriptionally regulated by canonical TGFβ
signaling via the Smads. It has been demonstrated that TGFβ has the ability to promote
or repress the expression of genes in a contextually-specific manner (351, 352). More
importantly, twelve out of the thirteen miRNA genes contained putative Smad binding
elements (SBEs) in their promoter regions (Figure 2.7) (347, 348). Considering that
miRNA frequently act upon the pathways that regulate their expression, I aimed to
determine if the differences in signature miRNA expression between EGFRI-resistant and
EGFRI-sensitive NSCLC cells were regulated by TGFβ (327, 397). I demonstrated that
over a 7-day course of TGFβ treatment, activation of the canonical TGFβ signaling
pathway via the R-smads, Smad 2, Smad 3 and Smad 4, occurs differently between the
model EGFRI-resistant and EGFRI-sensitive cell lines. Moreover, extended TGFβ
treatment induced downregulation of total Smad 2, Smad 3, and Smad 4 by long-term
TGFβ treatment in the EGFRI-sensitive cell line. TGFβ induced morphological and protein
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expression changes in the EGFRI-resistance model consistent with EMT, but this effect
was not observed in the EGFRI-sensitive model. In the EGFRI-sensitivity model, the
inhibition of TGFβ induced a morphology consistent with an EMT intermediate phenotype
known as metastable (353). These data confirm that TGFβ possesses differential activity
that may be responsible for the expression of the miRNA differentiating EGFRI-resistant
from EGFRI-sensitive cells. Because of this, I next explored the direct contribution of TGFβ
on the expression of three candidate miRNA from opposing sides of the response
signature, miR-140, miR-141, and miR-200c.
Using chromatin immunoprecipitation, I determined that Smad 4 bound to the
shared promoter of miR-141 and miR-200c in EGFRI-sensitive cell lines in response to
TGFβ stimulation. Because there was no binding to the promoter of miR-140, I suspected
that differential regulation was occurring in line with the initial hypothesis. Because of this,
I next aimed to observe if TGFβ induced differential endogenous expression changes of
the three candidate miRNA. Using a 5-way ANOVA and two models of EGFRI-resistant
cells and two EGFRI-sensitive cell lines, I aimed to elucidate the source of the endogenous
expression changes considering five factors: 1) miRNA expression, 2) time of treatment,
3) TGFβ treatment, 4) SB-431542 treatment, 5) cell line. I considered the additional H460
and H1650 cell lines as a metric of determining if the changes observed correlated with
EGFRI-sensitivity status of cells or if miRNA expression changes were a cell line specific
phenomena. I determined that the most impactful variable governing the expression of the
signature miRNA levels was the time of treatment. I interpreted this to be a response to
the loss of cell cycle progression and aimed to elucidate whether the percentage of cells
in the G0G1 phase of the cell cycle correlated with the changes in miRNA endogenous
expression levels. I determined that regardless of treatment conditions, all cell lines
accumulated in the G0G1 phase of the cell cycle as a function of time in culture.
Analysis of the qRT-PCR data and the cell cycle experiment led us to explore
whether the signature miRNA promoters contained putative cell-cycle responsive
elements. I determined that twelve of thirteen signature miRNA contained promoter
elements that may be cell-cycle responsive (Supplementary Figure I-9, Appendix I). I then
asked whether TGFβ stimulation activated growth and proliferation pathways, MAPK-ERK
and PI3K/AKT, and correlated with endogenous miRNA expression level changes. I
determined that TGFβ activation of these pathways was different between the cell models
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but did not correlate with the endogenous miRNA expression changes observed. I
concluded that the signature miRNA are likely responsive to elements associated with cell
cycle progression. I also concluded that while the activity of TGFβ in the EGFRI-resistance
model is consistent with the ability of TGFβ to drive EMT, an opposing phenotype was
found in the EGFRI-sensitive cell line.
Future directions of this work will explore the influence of the cell cycle on the
expression of the signature miRNA. To start, we will use the ChIP method for determining
transcription factor association with a promoter to determine if ELK1 is bound to the sites
in each of the promoters. We will triangulate this back to the changes in miRNA expression
at each time point as well as the percentage of cells exiting the cell cycle at this time point.
If ELK1 is not found to be bound to the promoters of the signature miRNA, other cell cycle
responsive transcription factors will also be examined by western blot at each time point
in order to isolate another cell cycle responsive candidate to interrogate.
In Chapter 3, I tested my second hypothesis that TGFβ signaling enforces
EGFRI-resistance correlating with its ability to activate EMT. I explored the
contribution of the differential TGFβ activity observed to cellular migration, wound healing
and response to a candidate EGFRI, erlotinib. I determined that TGFβ induced migration
in the EGFRI-resistance model and the phenotype was reversed with the TGFβ inhibitor.
I also determined by wound healing assay that TGFβ inhibition prevented wound healing
in both the EGFRI-resistance and EGFRI-sensitive models. This demonstrated that the
TGFβ-induced, EMT phenotype in the EGFRI-resistant cells was prevented by TGFβinhibition. It also demonstrated that the EMT-like intermediate observed in the EGFRIsensitive model did not correlate with the induction of other EMT-characteristics such as
migratory ability. Finally, to determine if TGFβ represented a clinically-relevant secondary
target in relation to resistance to EGFRI, I determined whether extended TGFβ treatments
altered sensitivity to EGFRI. In the EGFRI-resistance cell model, I determined that longterm TGFβ treatment significantly increased cell viability in response to erlotinib. This
increase in erlotinib resistance by TGFβ in EGFRI-resistant cells was not observed in cells
co-treated with a TGFβ inhibitor. This suggests that while TGFβ inhibitors may reduce
TGFβ-driven EMT events and erlotinib resistance, it is not a secondary target that will
sensitize EGFRI-resistant cells to EGFRI treatment.
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I also examined the role of TGFβ signaling on EGFRI-sensitivity in known EGFRIsensitive cell line model. Interestingly, extended TGFβ pre-treatment in the EGFRIsensitive model cell significantly decreased erlotinib sensitivity in these cells. This effect
may be due to the ability of TGFβ to impair cell proliferation in this cell line model (179,
371). Because these were cells treated with TGFβ in minimal serum (1% FBS) media
conditions, the reduced proliferation may be due to a cross talk between TGFβ and EGFR
signaling in response to nutrient availability. These observations are consistent with the
anti-tumorigenic-arm of the “TGFβ paradox” theory (371). Most importantly, all instances
of TGFβ-inhibition in the EGFRI-sensitive cell model resulted in a significant increase in
erlotinib resistance. However, I confirmed by measuring the migration and wound healing
capabilities indicative of EMT induction that TGFβ-inhibition was not inducing EMT in the
EGFRI-sensitive cell line. Remarkably, the change in erlotinib-sensitivity aligns with the
observations from Figure 2.6 where TGFβ inhibition resulted in a reduction of pERK1/2
and pAKT signaling in these cells. I did not examine whether the phenotype was related
to an increase in internalization and ubiquitination of active EGFR or the result of
downstream signal ablation (e.g., RAS downregulation). From the data herein, I cannot
confirm a mechanism for how TGFβ inhibition reduces erlotinib sensitivity in cells that are
otherwise exquisitely sensitive to EGFRI treatment. To determine a mechanism, I would
propose measuring the impact of TGFβ modulation on the expression of EGFR mRNA
and protein levels. A study on the internalization and degradation rates of EGFR would
also be informative in determining the source of the decreasing pERK1/2 and pAKT levels
in response to TGFβ inhibition. Nevertheless, this observation reinforces that anti-TGFβ
therapies will likely continue to be unsuccessful clinically in unselected patient populations,
as has been observed (179, 219).
Future directions of this work will be to identify alternative targets besides TGFβ
for the treatment of drug-resistant NSCLC. To identify targets for the treatment of drugresistant NSCLC, I employed mathematical and protein-protein interaction modeling
algorithms. This effort to identify alternative targets for EGFRI-resistant NSCLC is
described in Chapter 4.
In Chapter 4, I tested my hypothesis that combining the mRNA and miRNA
data would identify nodes of cellular deregulation captured by both lists of
deregulated genes. This may identify alternative targets for combatting EGFRI
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resistance in NSCLC. I sought to identify other, pharmacologically actionable signaling
nodes that may be targeted to overcome EGFRI resistance in NSCLC. We used the
Feasible Solutions (FS) algorithm to systematically test for possible direct interactions
between the 1495 mRNA and 23 miRNA found to be deregulated in EGFRI resistant
NSCLC cells. We took the mRNA member of each of the 100 most statistically-significant
interacting mRNA:miRNA pairs as determined by FS and annotated them to 85 separate
Ensembl IDs that had protein matches in STRING v10 (387). The 85 proteins were
inducted in the STRING network to search for interactions with EGFR. We found that 81
proteins were within two edges of EGFR in the initial STRING network. Of the 81 proteins,
many have been studied and/or implicated in EGFRI resistance. We chose to expand the
network of genes considering the scenario “G1-X-G2” where G1 and G2 are any member
of the original 85 Ensembl IDs imported into STRING and X is any induced node that
connects them. From this, the network grew to 304 induced nodes, for a total of 385 nodes
in the expanded deregulated network.
The resulting network identified nearly every EGFRI resistance or compensatory
signaling mechanism currently known, including: AKT/PI3K/mTOR (398), ataxia
telangiectasia mutated (ATM) kinase (399), Aurora kinase (400), other ErbB family
receptors (Her2, ErbB3 and ErbB4)(401), all three RAS isoforms (HRAS, KRAS and
NRAS) (402), insulin-like growth factor receptor (IGFR) (403), MET receptor tyrosine
kinase (39), and members of NFκβ, Notch, and TNFα signaling (109, 404, 405). The list
also includes a number of cellular functions related to EGFR signaling regulation
mechanisms including internalization (e.g., calmodulin1/2), ubiquitination (e.g., E3 protein
ligases), and proteosomal degradation (e.g., proteasome subunits). Moreover, when
divided into “communities” of node cellular functionality (Supplementary Table II-5,
Appendix II), nearly every of the hallmarks of cancer were represented in the deregulated
network suggesting that this network encompasses many of the mechanisms employed
by EGFRI resistant NSCLC cells to maintain proliferation.
Of the list of proteins comprising the network of deregulation we, I selected
CK2α/CK2α’ (the catalytic subunits of CK2 encoded by genes CSNK2A1 and CSNK2A2)
to further pursue for three reasons: 1) the complete holoenzyme has been shown to
interact with/regulate many of the members and pathways represented in the network, 2)
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it was shown to be within two edges of most of the induced nodes in the network, and 3)
it possesses enzymatic activity that can be inhibited by a pharmacological agent.
I assessed pharmacological inhibition of CK2 using the CK2 inhibitor, CX-4945, on
NSCLC cells that are resistant to EGFRI. I determined that NSCLC harboring KRAS
activation and PTEN null mutations, both inherently resistant to EGFRI, were most
sensitive to CK2 inhibition. However, the maximal response observed in these cells was
approximately 50% cell viability, suggesting that CX-4945 may be most successful as a
combination therapy. Further, cells harboring EGFR activation mutations were resistant to
CX-4945 treatment suggesting that a coupling of EGFRI and CX-4945 would likely have
no added therapeutic value.
My goal was to identify an alternate target or a combination of targets to overcome
EGFRI resistance in NSCLC. Considering that the majority of EGFRI resistance occurs as
either mutations to EGFR (e.g., EGFR T790M) or downstream (e.g., KRAS), I aimed to
identify a secondary drug target downstream of these resistance mechanisms. When we
reduced the network to include only proteins within one edge of CK2α/CK2α’, no member
of the EGFR-RAS-RAF-MEK-ERK signaling cascade was represented. This suggests that
while EGFR-MAPK-ERK and CK2 signaling may interact, they do not do so directly (Table
4.2). Because of this, I chose to evaluate the value of coupling CK2 and MEK inhibition.
Initial experiments examining the impact of co-treatment of CX-4945 and the MEK
inhibitor, AZD6244, revealed that the drug combination resulted in increasing levels of the
apoptotic marker, cleaved PARP, across increasing drug concentrations and across time
points (Figure 4.3). Future experiments will determine if this effect is also observed in cell
viability assays, and if so, whether the effect is additive or synergistic.
Finally, I explored whether CK2 inhibition could act as a surrogate for inhibition of
TGFβ in KRAS active NSCLC. I previously demonstrated that TGFβ inhibition prevented
increased EGFRI resistance in A549 cells and TGFβ inhibition induced EGFRI resistance
in PC9 cells. This illustrates that in unselected populations, TGFβ inhibition is not clinically
meaningful. I found that the combination of treatments did not increase cell death overall
in A549 cells. I observed that CK2 inhibition can act as a surrogate for TGFβ inhibition
blocking the increased erlotinib resistance brought on by TGFβ. Unfortunately, CK2
inhibition did not prevent the induction of EGFRI resistance by TGFβ inhibitors in PC9.
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These results suggest that TGFβ inhibition will still be a clinically-irrelevant treatment
option until we have a methodology for selecting patients considering the status of TGFβ
with regards to the “TGFβ paradox”.
Intriguingly, I observed that the combination of CX-4945 and EGFRI decreased
cell viability in PC9 cells at low doses of EGFRI although this effect was not found to be
significant. These data suggest that the combination of therapies may be ideal in EGFRIsensitive tumors to prevent acquired mutations. CX-4945 treatment has already been
shown specifically to prevent the development of EGFR T790M acquired-EGFRIresistance mutations in PC9 (238).

B. EXPERIMENTAL LIMITATIONS
The work described herein is the result of a combination of pharmacogenomic,
systems biology, and pharmacologic methods to identify treatment alternatives for drugresistant NSCLC using gene expression data. This combinatorial analysis allows us to test
broad inferences about the biology that underpins the phenotype of EGFRI resistance in
NSCLC. From the data analyzed, I formed hypotheses regarding the role of the
deregulated proteins identified in EGFRI sensitivity and/or resistance. Finally, I tested my
hypotheses using cell line models of NSCLC with pharmacological agents that interrupt
the pathways of interest. While this method allows us to gain a valuable understanding of
the biology of EGFRI resistance and streamline the putative target discovery pipeline, it
does have a number of limitations.
Genomic Modeling of the Deregulation of EGFRI-Resistant NSCLC
The strength in this methodology is that the in silico models can identify large
networks of deregulated genes and proteins. Bioinformatic tools can also identify the
nodes that connect them. The difficulty in developing and employing these methodologies
is that many data points are generated and must be annotated in order to find meaningful
putative targets. In revisiting Supplementary Table II-2 (Appendix II), one will find that
there are many known oncogenic kinases and deregulated signaling pathways known to
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drive tumorigenesis. There are also many network members that are less characterized
that must be sorted through. The expanded network of 385 proteins also includes
members known to be pharmacologically non-targetable to date (e.g., KRAS).
Another limitation to the specific genomic analyses that we performed is that we
specifically used expression data derived from NSCLC cells with known EGFRI sensitivity
and known mutational statuses influencing EGFRI sensitivity in each of the lines. For the
first of these profiling endeavors (the deregulated mRNA), the favorable alternative would
have been to use human tumors with known EGFRI clinical outcomes. Unfortunately,
samples with known EGFRI outcomes were not available at the time of the mRNA
signature development (328). By the time we profiled the miRNA genes in the same cells,
clinical samples were growing increasingly available. However, the ideal choice was to
profile for miRNA expression in the same cell lines profiled for mRNA deregulation so the
data sets could be compared. Specifically, this also allowed us to revisit the miRNA data
and mRNA together with the goal of identifying nodes of deregulation shared between the
two probesets as we’ve done here. This allowed us to identify a network of putative drug
targets with more evidence than the original two analyses because it encompasses two
“omic” levels of deregulation between EGFRI-resistant and –sensitive NSCLC.
Biological and Pharmacological Testing of the Hypotheses Identified in silico
A prominent limitation of the work herein is the use of only cell line models for
examining in silico generated hypotheses for the sake of determining novel avenues for
the clinical treatment of lung tumors. The value of cell culture models lies in their ability to
be a method for testing hypotheses in a well-controlled environment, but this is also the
downside of the model. Cell line testing is an important stage in the development of an in
silico hypothesis to a clinical treatment model because it allows us to rapidly test the value
of novel targets both alone and in combinatorial analyses in a model that is significantly
less expensive than in vivo models.

C. CONTRIBUTION TO THE FIELD
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Bioinformatic analysis of the 13-miRNA gene signature that predicts erlotinib
sensitivity in NSCLC cells and tumor samples identified TGFβ signaling as a pathway of
convergence of the miRNA genes. For this reason, I asked whether TGFβ played a role
in the expression regulation of three of the candidate miRNA. We determined that TGFβ
did not directly impact the expression of the miRNA, but cell cycle position may be
important. Further study to characterize the remaining miRNA and to directly test the
promoter elements for the transcriptional regulation of the signature miRNA is necessary
to validate this hypothesis. However, a deeper understanding of if and how the cell cycle
contributes to the expression of the signature miRNA could be useful for retraining the 13miRNA gene signature to not only indicate putative erlotinib response, but to indicate
reliance on rapid cell cycle passage for viability. This additional piece of information could
have value in determining which tumors are likely to respond to cell cycle targeting agents.
This study was the first to characterize that TGFβ inhibition in PC9 cells leads to a
significant loss of erlotinib sensitivity. TGFβ also decreased proliferation in these cells in
low serum conditions indicating that it may play a role in attenuating mutant EGFR
signaling. TGFβ inhibitors have entered clinical trials numerous times and are chronically
unsuccessful due to side effects on TGFβ signaling in normal cells (179, 219).
This is a combinatorial analysis of two “omic”-level studies of deregulated mRNA
and miRNA species adds value to the targets identified as they are represented in both
the mRNA and miRNA transcriptomes. This methodology for identifying networks of
deregulation between phenotypes is valuable for dissecting the differences between many
cellular phenotypes. We believe this paired analysis of functionally-related “omic”-level
data (such as miRNA that act on mRNA) is ideal for identifying the network of genes most
pertinent to a chosed phenotype (e.g., EGFRI-resistance). This study is also proof-ofconcept that mining existing gene expression data has merit for identifying and addressing
new hypotheses surrounding specific phenotypes (e.g., EGFRI-resistance versus sensitivity).
This study is the first to specifically identify the network of deregulated signaling
surrounding CK2 as it relates to EGFRI-resistance. CK2 is both a member of this network
and is connected to most of its members. A relationship between EGFR and CK2 signaling
activity has been described in the sense of co-targetability and common influence.
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Figure 6.1: The Impact of Co-Targeting MEK and CK2 on Cancer Signaling
Pathways.
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However, our analysis is the first to model that they likely act independently of one another
with common downstream signaling nodes in pathways other than MAPK-ERK. I showed
that EGFRI resistant cells harboring a KRAS activation mutation were most sensitive to
CK2 inhibition suggesting that it could be a viable option for KRAS active lung tumors that
comprise approximately 20% of the lung cancer population (168). I demonstrated that CK2
inhibition in conjunction with EGFRI was not sufficient to sensitize KRAS active cells to
EGFRI. This indicates that inhibition downstream of active KRAS is likely necessary to
attenuate signaling. My initial examination of the CK2 and MEK co-inhibition is the first
study to demonstrate that this combination likely has value in treating EGFRI resistant
NSCLC harboring a KRAS activation mutation.

D. CONCLUSIONS
I conclude that an analysis considering multiple gene expression species that
physically interact and regulate one another (e.g., mRNA and miRNA) are ideal for
identifying a concise network of proteins that define a phenotype of choice. The network
identified using this methodology performed best for us using the G1-X-G2 scheme to
capture other the contributing members of a network. This novel approach for identifying
possible therapeutic targets requires further validation in cell culture as well as in another
data set to determine the sensitivity and specificity of the approach. I identified CK2 as a
putative target due to its expansive relationships with the other network members,
specifically those known to contribute mechanistically to the generation of EGFRIresistance. Examination of its activity suggests that CK2 inhibition shows promise for
treating EGFRI-resistant NSCLC, specifically those harboring KRAS active mutations. We
also conclude that inhibition of CK2 concurrently with MEK inhibition has the potential to
maximize targeted therapy benefit for the treatment of KRAS active, EGFRI-resistant
NSCLC tumors.

Copyright © Madeline Krentz Gober, 2017
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APPENDIX I: SUPPLEMENTARY FIGURES FOR CHAPTER 2

Supplementary Table I-1: Output of 5-way ANOVA analysis. (Data pairs with
Supplementary figures I-4 and I-5) (A) Variable names used in analysis. (B) Five-way
ANOVA Overall F-test of the endogenous miRNA data. (C) Tests of the effects within the
five-way ANOVA.

A
Class Level Information
Class

Levels Values

Time

3

168 Hour 24 Hour 72
Hour

Expr

3

miR-140 miR-141 miR200

status 4

A549 H1650 H460 PC9

TGF

2

NY

SB

2

NY

B
Sum of
Source

DF

Squares

Mean Square

Model

143 8088.984432

56.566325

Error

288 283.797472

0.985408

Corrected Total

431 8372.781904
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F Value
57.40

Pr > F
<.0001
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Supplementary Table I-1 (Continued): Output of 5-way ANOVA analysis. (Data pairs
with Supplementary figures I-4 and I-5)

C

Source

DF Type III SS

Mean Square

F Value

Pr > F

Time

2

79.952136

39.976068

40.57

<.0001

Expr

2

1885.221769

942.610885

956.57

<.0001

Time*expr

4

54.519027

13.629757

13.83

<.0001

TGF

1

10.424204

10.424204

10.58

0.0013

Time*TGF

2

1.076126

0.538063

0.55

0.5798

expr*TGF

2

1.079149

0.539574

0.55

0.5790

Time*expr*TGF

4

0.646410

0.161602

0.16

0.9565

SB

1

1.546384

1.546384

1.57

0.2113

Time*SB

2

0.471393

0.235697

0.24

0.7874

expr*SB

2

1.520563

0.760281

0.77

0.4633

Time*expr*SB

4

0.324106

0.081027

0.08

0.9878

TGF*SB

1

0.134397

0.134397

0.14

0.7122

Time*TGF*SB

2

0.541967

0.270983

0.27

0.7598

expr*TGF*SB

2

1.295853

0.647926

0.66

0.5189

Time*expr*TGF*SB

4

0.965323

0.241331

0.24

0.9126

Status

3

3240.479541

1096.16

<.0001

Time*status

6

364.036762

60.672794

61.57

<.0001

expr*status

6

2266.034942

377.672490

383.27

<.0001

127.856402

10.654700

10.81

<.0001

Time*expr*status

12
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Supplementary Table I-1 (Continued): Output of 5-way ANOVA analysis. (Data pairs
with Supplementary figures I-4 and I-5)

Source

DF Type III SS

Mean Square

F Value

Pr > F

status*TGF

3

2.810260

0.936753

0.95

0.4165

Time*status*TGF

6

4.252351

0.708725

0.72

0.6344

expr*status*TGF

6

2.875868

0.479311

0.49

0.8183

Time*expr*status*TGF

12

2.785062

0.232089

0.24

0.9964

status*SB

3

12.852156

4.284052

4.35

0.0051

Time*status*SB

6

0.954675

0.159113

0.16

0.9866

expr*status*SB

6

6.327867

1.054644

1.07

0.3804

Time*expr*status*SB

12

3.120940

0.260078

0.26

0.9939

status*TGF*SB

3

6.390615

2.130205

2.16

0.0927

Time*status*TGF*SB

6

2.107473

0.351246

0.36

0.9058

expr*status*TGF*SB

6

4.105405

0.684234

0.69

0.6544

Tim*expr*stat*TGF*SB

12

2.275306

0.189609

0.19

0.9987
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Supplementary File I-1: Experimental Ct Averages. (A)A549, (B) H460, (C) H1650,
(D) PC9.
(A) A549
+TGFβ

miR-200c

miR-141

miR-140

Untreated
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour

12.33757

11.43739

11.60239

12.39578

12.97549

12.15190

9.787602

10.08148

10.61999

9.900755

10.42333

11.50879

9.758026

10.54176

11.49169

10.53289

11.00631

11.92199

17.06016

15.32151

19.90596

17.07662

17.98000

20.07600

15.54128

13.97606

14.51325

15.44358

15.80907

16.95060

14.27188

12.21063

11.12456

15.88630

13.84227

15.35418

14.10283

14.30923

14.84075

14.54479

14.74094

15.67361

13.32989

12.92316

14.99424

13.60149

13.89697

15.47936

12.67405

13.07983

14.84481

13.63927

14.52270

16.56609

+TGFβ + SB-431542

miR-200c

miR-141

miR-140

+SB-431542
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour

11.89172

12.01508

11.48558

12.45281

11.61382

12.25275

9.535458

10.08252

10.83031

9.738522

10.67040

11.51334

8.811357

9.751716

10.45633

10.03573

10.56819

11.34701

12.00429

16.11283

19.87011

14.06351

15.08848

19.66269

14.33568

16.13022

13.74338

14.67358

11.94453

12.31492

13.87545

11.08248

12.75059

14.71158

10.58473

13.92210

14.04283

14.31766

14.49006

14.54913

14.46255

15.62704

13.09006

12.68363

15.03674

12.67218

12.74576

15.55015

12.99181

13.09153

14.56104

12.99181

12.78577

15.02792
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460,
(C) H1650, (D) PC9.

miR-200c

miR-141

miR-140

miR-200c

miR-141

miR-140

(B) H460
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour

17.05264

+TGFβ
17.90481

17.99017

17.46496

17.12854

16.66626

18.02826

17.54043

16.98263

16.64818

17.56977

17.08109

17.08539

17.28380

17.33617

17.18618

17.62590

17.00420

16.61845

17.04087

15.97914

17.28608

16.24639

16.81126

16.26302

16.34669

15.99137

16.66824

17.00029

16.70879

10.67178

11.04102

11.36006

10.62387

11.23187

11.26765

10.96402

11.11371

10.36812

11.05747

10.45827

11.33282

10.77904

13.99327

10.41068

11.04071

11.77847

11.16143

17.39966

+SB-431542
18.23286

18.15083

+TGFβ + SB-431542
17.61480
18.01347
18.38200

16.91612

18.07499

17.15804

17.68611

18.51481

18.12220

16.93595

17.08220

16.81208

16.85756

17.29420

17.47745

17.10256

17.40165

17.29394

17.65773

17.38723

16.82007

16.67177

17.03223

16.15025

17.48135

17.73611

16.58182

16.83432

16.60688

16.06160

16.52186

16.67512

16.34198

10.75649

11.10807

11.17131

10.87258

11.09417

11.12668

10.32638

11.28246

10.31851

11.51607

12.77857

11.01471

13.58082

10.98377

10.31083

11.05021

11.20028

13.88309

17.14272

Untreated
17.91426

18.13599

17.21708

17.84024

16.66319
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460,
(C) H1650, (D) PC9.

miR-200c

miR-141

miR-140

miR-200c

miR-141

miR-140

(C) H1650
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour

12.28511

+TGFβ
12.96206

12.49449

12.64218

12.49287

13.47596

13.12842

17.23288

17.92211

17.46275

17.47145

17.98014

7.839454

7.535492

7.558471

8.04034

7.626134

6.945391

7.115704

6.608805

7.225541

7.719368

7.437265

7.523124

11.69064

11.75101

11.83241

11.88982

11.90958

11.97695

4.654358

4.169437

5.087824

4.834063

5.230578

4.853105

4.231399

4.793982

4.516056

4.626641

5.374649

5.112733

5.979657

6.024038

6.170614

5.993081

6.253736

6.156914

12.02541

+SB-431542
13.26263

12.93686

+TGFβ + SB-431542
12.56955
13.30433
12.94468

12.13073

13.18402

12.97675

12.74410

13.90631

11.57144

17.24517

17.57818

17.67087

17.44893

17.80485

17.78832

7.658577

8.035284

7.288847

7.757186

8.216744

6.859854

7.295649

7.448415

7.114004

7.415254

8.310852

6.352814

11.48486

11.61927

11.82947

11.41379

11.91031

11.76493

4.553339

5.694854

5.120974

5.110865

5.906208

4.517555

4.311621

4.661685

4.998656

4.919242

7.163925

3.526715

5.897517

6.226531

6.095646

6.014628

6.505982

6.126934

12.24568

Untreated
12.01147

12.93231

12.17126

12.94157

17.22546
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460,
(C) H1650, (D) PC9.

miR-200c

miR-141

miR-140

miR-200c

miR-141

miR-140

(D) PC9
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour
24
Hour
72
Hour
168
Hour

14.57736

+TGFβ
11.73476

13.76189

13.88492

12.71534

13.55068

14.44901

13.77642

14.75037

13.84855

14.09694

14.88830

7.121312

10.00169

9.931498

7.876611

8.188897

10.06823

6.306454

3.402984

3.121106

6.319069

4.80151

5.335824

5.817623

3.519702

5.124096

5.819985

4.690588

5.166902

5.756327

6.305108

6.344949

5.612942

5.945666

6.384396

4.948423

4.166431

6.540284

4.255959

3.853093

7.538871

4.483598

4.663599

6.590467

4.483084

4.430461

6.680311

14.78079

+SB-431542
13.46474

13.18096

+TGFβ + SB-431542
14.64627
13.47323
13.75304

12.70899

13.05903

13.79732

12.37238

13.11935

13.77495

13.05962

14.00124

14.74730

13.65988

13.76325

14.75263

8.433583

10.00693

8.825805

8.76599

10.44693

10.97337

6.583571

3.124386

2.23386

6.249595

4.266571

6.207948

6.500151

1.581450

5.662973

6.34292

3.582123

6.186862

6.06497

5.257848

5.868316

5.77605

6.038063

5.926589

4.760397

3.741873

6.390911

4.907626

4.191823

6.659156

4.517351

4.478639

6.310415

4.340795

4.377823

6.354835

14.94061

Untreated
13.26866

14.54584

12.83986

13.43117

13.50625
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APPENDIX II: SUPPLEMENTARY FIGURES FOR CHAPTER 4

Supplementary Table II-1: Interacting mRNA:miRNA genes (100) from the Feasible
Solutions (FS) analysis. The 100 probe IDs with the lowest probability (low Prob>F) as
determined by the FS analysis. To identify targets that may have value in EGFRI resistant
tumors, the model sought mRNA with high expression in EGFRI-resistant NSCLC cells.
Probe ID
213302_at
204497_at
201002_s_at
210139_s_at
214830_at
208241_at
218467_at
218970_s_at
211505_s_at
203482_at
212764_at
58780_s_at
208919_s_at
201379_s_at
213262_at
210910_s_at
201778_s_at
37117_at
219002_at
219020_at
204115_at
213058_at
219395_at
213798_s_at

Interacting
miRNA
hsa.miR.135b
hsa.miR.210
hsa.miR.135b
hsa.miR.197.
hsa.miR.410
hsa.miR.135b
hsa.miR.200b
hsa.miR.200b
hsa.miR.200b
hsa.miR.200b
hsa.miR.518b
hsa.miR.873
hsa.miR.30c
hsa.miR.141
hsa.miR.873
hsa.miR.205
hsa.miR.873
hsa.miR.197
hsa.miR.873.43
95467
hsa.miR.758.43
95180
hsa.miR.873.43
95467
hsa.miR.873.43
95467
hsa.miR.125a.5
p.4395309
hsa.miR.636.43
95199

hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.628.5p.4395544
hsa.miR.616.4395525
hsa.miR.628.5p.4395544
hsa.miR.616.4395525
hsa.miR.125a.3p.4395310
hsa.miR.628.5p.4395544
hsa.miR.616.4395525
hsa.miR.616.4395525
hsa.miR.636.4395199
hsa.miR.873.4395467
hsa.miR.616.4395525
hsa.miR.518f.4395499

Prob > F
2.14712E-05
2.49071E-05
3.56988E-05
5.82491E-05
8.11249E-05
8.31544E-05
0.000132681
0.000168687
0.000169371
0.000169684
0.000211397
0.000233999
0.000251931
0.000320846
0.000364971
0.000398141
0.000410072
0.000434778

hsa.miR.636.4395199

0.000449861

hsa.miR.616.4395525

0.000511882

hsa.miR.636.4395199

0.000574862

hsa.miR.30c.4373060

0.000638761

hsa.miR.616.4395525

0.000662677

hsa.miR.628.5p.4395544

0.000670364
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from
the Feasible Solutions (FS) analysis.

Probe ID
219388_at
201565_s_at
209222_s_at
204243_at
219785_s_at
217744_s_at
209225_x_at
219547_at
221704_s_at
205807_s_at
203551_s_at
201380_at
218264_at
207320_x_at
218720_x_at
207000_s_at
201608_s_at
201566_x_at
201589_at

Interacting
miRNA
hsa.miR.200c.4
395411
hsa.miR.200c.4
395411
hsa.miR.200c.4
395411
hsa.miR.200b.4
395362
hsa.miR.135b.4
395372
hsa.miR.125a.5
p.4395309
hsa.miR.363.43
78090
hsa.miR.200b.4
395362
hsa.miR.135b.4
395372
hsa.miR.224.43
95210
hsa.miR.135b.4
395372
hsa.miR.873.43
95467
hsa.miR.628.5p
.4395544
hsa.miR.410.43
78093
hsa.miR.200b.4
395362
hsa.miR.200b.4
395362
hsa.miR.873.43
95467
hsa.miR.200b.4
395362
hsa.miR.125a.5
p.4395309

Prob > F
hsa.miR.363.4378090

0.000675789

hsa.miR.363.4378090

0.000684861

hsa.miR.363.4378090

0.000752997

hsa.miR.410.4378093

0.000754944

hsa.miR.616.4395525

0.000762204

hsa.miR.616.4395525

0.000856678

hsa.miR.628.5p.4395544

0.000926545

hsa.miR.224.4395210

0.000932786

hsa.miR.873.4395467

0.001141837

hsa.miR.628.5p.4395544

0.001186811

hsa.miR.616.4395525

0.001191469

hsa.miR.616.4395525

0.001287701

hsa.miR.616.4395525

0.001328277

hsa.miR.628.5p.4395544

0.001400914

hsa.miR.197.4373102

0.001477025

hsa.miR.616.4395525

0.001484342

hsa.miR.628.5p.4395544

0.001502097

hsa.miR.616.4395525

0.001534329

hsa.miR.363.4378090

0.001595775
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from
the Feasible Solutions (FS) analysis.

Probe ID
55065_at
200929_at
218365_s_at
213434_at
210662_at
201594_s_at
208747_s_at
211240_x_at
203650_at
210114_at
205847_at
215146_s_at
219121_s_at
216095_x_at
219733_s_at
200640_at
203884_s_at
201426_s_at
218451_at

Interacting
miRNA
hsa.miR.518f.4
395499
hsa.miR.636.43
95199
hsa.miR.197.43
73102
hsa.miR.628.5p
.4395544
hsa.miR.873.43
95467
hsa.miR.205.43
73093
hsa.miR.210.43
73089
hsa.miR.363.43
78090
hsa.miR.873.43
95467
hsa.miR.873.43
95467
hsa.miR.125a.5
p.4395309
hsa.miR.873.43
95467
hsa.miR.363.43
78090
hsa.miR.30c.43
73060
hsa.miR.221.43
73077
hsa.miR.205.43
73093
hsa.miR.200b.4
395362
hsa.miR.125a.5
p.4395309
hsa.miR.141.43
73137

Prob > F
hsa.miR.616.4395525

0.001647671

hsa.miR.628.5p.4395544

0.001668389

hsa.miR.518b.4373246

0.001691602

hsa.miR.758.4395180

0.001763671

hsa.miR.616.4395525

0.001784274

hsa.miR.363.4378090

0.001825064

hsa.miR.363.4378090

0.001914552

hsa.miR.616.4395525

0.002018453

hsa.miR.636.4395199

0.002040117

hsa.miR.616.4395525

0.0020832

hsa.miR.616.4395525

0.002085028

hsa.miR.636.4395199

0.002090153

hsa.miR.616.4395525

0.002093259

hsa.miR.628.5p.4395544

0.002122563

hsa.miR.616.4395525

0.002188182

hsa.miR.628.5p.4395544

0.002204398

hsa.miR.636.4395199

0.002214892

hsa.miR.616.4395525

0.00231613

hsa.miR.139.5p.4395400

0.00236974
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from
the Feasible Solutions (FS) analysis.

Probe ID
205980_s_at
201839_s_at
203287_at
216641_s_at
213220_at
217388_s_at
208862_s_at
208634_s_at
221646_s_at
218526_s_at
214136_at
206343_s_at
202286_s_at
208319_s_at
205667_at
203883_s_at
206907_at
207011_s_at
214876_s_at

Interacting
miRNA
hsa.miR.197.43
73102
hsa.miR.200b.4
395362
hsa.miR.205.43
73093
hsa.miR.200c.4
395411
hsa.miR.200c.4
395411
hsa.miR.200c.4
395411
hsa.miR.873.43
95467
hsa.miR.200c.4
395411
hsa.miR.197.43
73102
hsa.miR.224.43
95210
hsa.miR.873.43
95467
hsa.miR.200b.4
395362
hsa.miR.224.43
95210
hsa.miR.873.43
95467
hsa.miR.873.43
95467
hsa.miR.200b.4
395362
hsa.miR.200c.4
395411
hsa.miR.200b.4
395362
hsa.miR.200c.4
395411

Prob > F
hsa.miR.410.4378093

0.002425474

hsa.miR.628.5p.4395544

0.002481076

hsa.miR.758.4395180

0.002584299

hsa.miR.363.4378090

0.002615599

hsa.miR.200b.4395362

0.002645648

hsa.miR.628.5p.4395544

0.002692429

hsa.miR.616.4395525

0.002761436

hsa.miR.363.4378090

0.002775792

hsa.miR.616.4395525

0.002913831

hsa.miR.616.4395525

0.0029388

hsa.miR.636.4395199

0.002991045

hsa.miR.197.4373102

0.002996291

hsa.miR.628.5p.4395544

0.003004819

hsa.miR.636.4395199

0.003172694

hsa.miR.616.4395525

0.003211669

hsa.miR.30c.4373060

0.003239375

hsa.miR.616.4395525

0.003303832

hsa.miR.628.5p.4395544

0.003310737

hsa.miR.616.4395525

0.003649619
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from
the Feasible Solutions (FS) analysis.
Probe ID
209110_s_at
208009_s_at
200982_s_at
202087_s_at
204416_x_at
221825_at
206015_s_at
209666_s_at
55872_at
217717_s_at
219157_at
218823_s_at
205263_at
209188_x_at
219338_s_at
201131_s_at
214724_at
203011_at
204148_s_at

Interacting
miRNA
hsa.miR.873.43
95467
hsa.miR.139.5p
.4395400
hsa.miR.873.43
95467
hsa.miR.200b.4
395362
hsa.miR.410.43
78093
hsa.miR.135b.4
395372
hsa.miR.200c.4
395411
hsa.miR.197.43
73102
hsa.miR.135b.4
395372
hsa.miR.205.43
73093
hsa.miR.363.43
78090
hsa.miR.200b.4
395362
hsa.miR.200b.4
395362
hsa.miR.210.43
73089
hsa.miR.141.43
73137
hsa.miR.221.43
73077
hsa.miR.125a.3
p.4395310
hsa.miR.125a.3
p.4395310
hsa.miR.197.43
73102

Prob > F
hsa.miR.616.4395525

0.003676755

hsa.miR.758.4395180

0.003697195

hsa.miR.636.4395199

0.003710188

hsa.miR.758.4395180

0.003774459

hsa.miR.628.5p.4395544

0.003811245

hsa.miR.139.5p.4395400

0.003949163

hsa.miR.363.4378090

0.00401435

hsa.miR.518b.4373246

0.004126397

hsa.miR.628.5p.4395544

0.004136091

hsa.miR.224.4395210

0.004187272

hsa.miR.616.4395525

0.004209738

hsa.miR.410.4378093

0.004274431

hsa.miR.335.4373045

0.004329786

hsa.miR.363.4378090

0.004396567

hsa.miR.224.4395210

0.004645033

hsa.miR.616.4395525

0.004743977

hsa.miR.518f.4395499

0.004792734

hsa.miR.518f.4395499

0.004849912

hsa.miR.616.4395525

0.004863654
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Supplementary Table II-2: Initial FS candidates that interact with EGFR. Table
members represent the 85 independent Ensembl IDs identified by the FS analysis.

SOURCE

GENE NAME

ARHGEF9

Cdc42 guanine nucleotide exchange factor (406) 9

DHRS4:DH
RS4L2:DHR
S4L1

dehydrogenase/reductase (SDR family) member 4,
dehydrogenase/reductase (SDR family) member 4 like 2,
dehydrogenase/reductase (SDR family) member 4 like 1

FANCF

Fanconi anemia, complementation group F

FBXO31

F-box protein 31

GNG11

guanine nucleotide binding protein (G protein), gamma 11

NRG1

neuregulin 1

NUBP2

nucleotide binding protein 2

PMP22

peripheral myelin protein 22

RAB11FIP2

RAB11 family interacting protein 2 (class I)

RNMTL1

RNA methyltransferase like 1

S100A3

S100 calcium binding protein A3

TFE3

transcription factor binding to IGHM enhancer 3

TNFSF9

tumor necrosis factor (ligand) superfamily, member 9

ACTA2

actin, alpha 2, smooth muscle, aorta

ADCY9

adenylate cyclase 9

ALDH1B1

aldehyde dehydrogenase 1 family, member B1

ANGEL2

angel homolog 2 (Drosophila)

ANXA6
ARHGEF40
ATP5G1

annexin A6
Rho guanine nucleotide exchange factor (406) 40
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1
(subunit 9)

BCCIP

BRCA2 and CDKN1A interacting protein

BRCC3

BRCA1/BRCA2-containing complex, subunit 3

C1QBP

complement component 1, q subcomponent binding protein

CAMK1

calcium/calmodulin-dependent protein kinase I
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Supplementary Table II-2 (continued): Initial FS candidates that interact with EGFR.
Table members represent the 85 independent Ensembl IDs identified by the FS analysis.

SOURCE

GENE NAME

COX15

cytochrome c oxidase assembly homolog 15 (yeast)

CRTAP

cartilage associated protein

CTSL

cathepsin L

CUTC

cutC copper transporter

DARS2

aspartyl-tRNA synthetase 2, mitochondrial

DIP2C

disco-interacting protein 2 homolog C

DIXDC1

DIX domain containing 1

DOCK10

dedicator of cytokinesis 10

DPYSL3

dihydropyrimidinase-like 3

EGFR

epidermal growth factor receptor

EIF3A

eukaryotic translation initiation factor 3, subunit A

FASTKD1 FAST kinase domains 1
FBXL15
GLRX
HS1BP3

F-box and leucine-rich repeat protein 15
glutaredoxin (thioltransferase)
HCLS1 binding protein 3

HSPA12A heat shock 70kDa protein 12A
ID2
IMPA1
INVS

inhibitor of DNA binding 2, dominant negative helix-loop-helix
protein
inositol(myo)-1(or 4)-monophosphatase 1
Inversin

KCTD9

potassium channel tetramerization domain containing 9

KYNU

Kynureninase

LIG3

ligase III, DNA, ATP-dependent

MID1IP1

MID1 interacting protein 1

MTMR9

myotubularin related protein 9
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Supplementary Table II-2 (continued): Initial FS candidates that interact with EGFR.
Table members represent the 85 independent Ensembl IDs identified by the FS analysis.

SOURCE
PFAS

GENE NAME
phosphoribosylformylglycinamidine synthase

POMZP3

POM121 and ZP3 fusion

PPP3CC

protein phosphatase 3, catalytic subunit, gamma isozyme

PROCR

protein C receptor, endothelial

PWP1

PWP1 homolog, endonuclein

RANGRF

RAN guanine nucleotide release factor

RBM3

RNA binding motif (RNP1, RRM) protein 3

SACS

sacsin molecular chaperone

SMC1A
STX2

structural maintenance of chromosomes 1A
syntaxin 2

TNPO1

transportin 1

TTC28

tetratricopeptide repeat domain 28

TUBGCP2 tubulin, gamma complex associated protein 2
UIMC1

ubiquitin interaction motif containing 1

USP9X

ubiquitin specific peptidase 9, X-linked

VIM
VPS33B
WRN

Vimentin
vacuolar protein sorting 33 homolog B (yeast)
Werner syndrome, RecQ helicase-like

ZC3H14

zinc finger CCCH-type containing 14

ZEB1

zinc finger E-box binding homeobox 1

CHUK

conserved helix-loop-helix ubiquitous kinase

PBK
PTEN

PDZ binding kinase
phosphatase and tensin homolog
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Supplementary Table II-3: G1-X-G2 Analysis-Induced EGFRI Resistance Network
Members. Table members were generated using the 85 independent Ensembl IDs
identified by the FS analysis. Table members generated by the STRING analysis
considering the scenario G1-X-G2 where G1 and G2 are from the original list of 85
Ensembl IDs of mRNA found to be upregulated in EGFRI resistant NSCLC cells and X is
any other node that connects them.

SYMBOL

GENE NAME

TYPE

ACACB

acetyl-CoA carboxylase beta

Induced

ACTA1

actin, alpha 1, skeletal muscle

Induced

ACTA2

actin, alpha 2, smooth muscle, aorta

Input

ADCY9

adenylate cyclase 9

Input

ADSS

adenylosuccinate synthase

Induced

AKT1

v-akt murine thymoma viral oncogene homolog 1

Induced

AKT2

v-akt murine thymoma viral oncogene homolog 2

Induced

ALDH1B1

aldehyde dehydrogenase 1 family, member B1

Input

ANGEL2

angel homolog 2 (Drosophila)

Input

ANXA6

annexin A6

Input

AP2A1

adaptor-related protein complex 2, alpha 1 subunit

Induced

adenomatous polyposis coli

Induced

androgen receptor

Induced

APC
AR
ARHGEF
40
ARHGEF
9
ARRB2
ATM
ATP5C1
ATP5G1
AURKA
BABAM1

Rho guanine nucleotide exchange factor (406) 40

Input

Cdc42 guanine nucleotide exchange factor (406) 9

Input

arrestin, beta 2

Induced

ATM serine/threonine kinase

Induced

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1
ATP synthase, H+ transporting, mitochondrial Fo
complex, subunit C1 (subunit 9)

Induced
Input

aurora kinase A

Induced

BRISC and BRCA1 A complex member 1

Induced
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

BARD1

BRCA1 associated RING domain 1

BCCIP

BRCA2 and CDKN1A interacting protein

BCL2

B-cell CLL/lymphoma 2

Induced

BIRC2

baculoviral IAP repeat containing 2

Induced

BIRC3

baculoviral IAP repeat containing 3

Induced

Bloom syndrome, RecQ helicase-like

Induced

BRCA1

breast cancer 1, early onset

Induced

BRCC3

BRCA1/BRCA2-containing complex, subunit 3

BLM

Induced
Input

Input

CALM1
CALM2

brain and reproductive organ-expressed (TNFRSF1A
modulator)
beta-transducin repeat containing E3 ubiquitin protein
ligase
complement component 1, q subcomponent binding
protein
carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase
calmodulin 1 (phosphorylase kinase, delta), calmodulin 2
(phosphorylase kinase, delta)

CALM2

calmodulin 2 (phosphorylase kinase, delta)

CAMK1

calcium/calmodulin-dependent protein kinase I

CAPZA1

capping protein (actin filament) muscle Z-line, alpha 1

Induced

CAPZB

capping protein (actin filament) muscle Z-line, beta

Induced

CASP8

caspase 8, apoptosis-related cysteine peptidase

Induced

caveolin 1, caveolae protein, 22kDa

Induced

Cbl proto-oncogene, E3 ubiquitin protein ligase

Induced

cyclin D1

Induced

chaperonin containing TCP1, subunit 4 (delta)

Induced

CD2-associated protein

Induced

BRE
BTRC
C1QBP
CAD

CAV1
CBL
CCND1
CCT4
CD2AP
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Induced
Induced
Input
Induced
Induced
Induced
Input

APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

CDC37

cell division cycle 37

Induced

CDH1

cadherin 1, type 1

Induced

CDK1

cyclin-dependent kinase 1

Induced

CDK2

cyclin-dependent kinase 2

Induced

CDKN1A

cyclin-dependent kinase inhibitor 1A (p21, Cip1)

Induced

CDKN1B

cyclin-dependent kinase inhibitor 1B (p27, Kip1)

Induced

cofilin 1 (non-muscle)

Induced

CHAF1A

chromatin assembly factor 1, subunit A (p150)

Induced

CHORDC
1

cysteine and histidine-rich domain (CHORD)
containing 1

Induced

CHUK

conserved helix-loop-helix ubiquitous kinase

Input

CKAP5

cytoskeleton associated protein 5

Induced

CNOT4

CCR4-NOT transcription complex, subunit 4

Induced

COPS5

COP9 signalosome subunit 5

Induced

COX15

cytochrome c oxidase assembly homolog 15 (yeast)

CFL1

CREBBP

CREB binding protein

Input
Induced

CRTAP

cartilage associated protein

CSE1L

CSE1 chromosome segregation 1-like (yeast)

Induced

CSNK2A1

casein kinase 2, alpha 1 polypeptide

Induced

CSNK2A2

casein kinase 2, alpha prime polypeptide

Induced

CTNNB1

catenin (cadherin-associated protein), beta 1, 88kDa

Induced

CTSL

cathepsin L

CUL1

cullin 1

Input

Input
Induced
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

CUTC

cutC copper transporter

Input

DARS2

aspartyl-tRNA synthetase 2, mitochondrial

Input

DAZAP1

DAZ associated protein 1

Induced

decapping mRNA 2

Induced

DCP2
DHRS4
DHRS4L2
DHRS4L1
DIP2C
DIXDC1

dehydrogenase/reductase (SDR family) member 4,
dehydrogenase/reductase (SDR family) member 4 like
2, dehydrogenase/reductase (SDR family) member 4
like 1

Input

disco-interacting protein 2 homolog C

Input

DIX domain containing 1

Input

DKC1

dyskeratosis congenita 1, dyskerin

Induced

DLG1

discs, large homolog 1 (Drosophila)

Induced

DOCK10

dedicator of cytokinesis 10

Input

DPYSL3

dihydropyrimidinase-like 3

Input

DVL2
EEF1A1
EGF
EGFR
EIF2AK2

dishevelled segment polarity protein 2

Induced

eukaryotic translation elongation factor 1 alpha 1

Induced

epidermal growth factor

Induced

epidermal growth factor receptor
eukaryotic translation initiation factor 2-alpha kinase 2

Input
Induced

EIF3A

eukaryotic translation initiation factor 3, subunit A

EIF4A3

eukaryotic translation initiation factor 4A3

Induced

ELAVL1

ELAV like RNA binding protein 1

Induced

EP300

E1A binding protein p300

Induced

EPN1

epsin 1

Induced

EPS15

epidermal growth factor receptor pathway substrate 15

Induced
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

ERBB2

erb-b2 receptor tyrosine kinase 2

Induced

ERBB3

erb-b2 receptor tyrosine kinase 3

Induced

ERBB4

erb-b2 receptor tyrosine kinase 4

Induced

ERP44

endoplasmic reticulum protein 44

Induced

ESR1

estrogen receptor 1

Induced

EXOSC10

exosome component 10

Induced

FAM175A

family with sequence similarity 175, member A

Induced

FAM175B

family with sequence similarity 175, member B

Induced

FANCA

Fanconi anemia, complementation group A

Induced

FANCF

Fanconi anemia, complementation group F

Input

FANCG

Fanconi anemia, complementation group G

Induced

FANCM

Fanconi anemia, complementation group M

Induced

FASTKD1

FAST kinase domains 1

Input

FBXL15

F-box and leucine-rich repeat protein 15

Input

FBXO31

F-box protein 31

Input

FBXW7

F-box and WD repeat domain containing 7, E3
ubiquitin protein ligase

Induced

GRB2-associated binding protein 1

Induced

glyceraldehyde-3-phosphate dehydrogenase

Induced

GDA

guanine deaminase

Induced

GLRX

glutaredoxin (thioltransferase)

Input

guanine nucleotide binding protein (G protein), gamma
11

Input

GAB1
GAPDH

GNG11
GNS

glucosamine (N-acetyl)-6-sulfatase
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Induced

APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

GPHN

Gephyrin

Induced

GRSF1

G-rich RNA sequence binding factor 1

Induced

H2AFV

H2A histone family, member V

Induced

H2AFX

H2A histone family, member X

Induced

HDAC1

histone deacetylase 1

Induced

HECW2

HECT, C2 and WW domain containing E3 ubiquitin
protein ligase 2

Induced

HES1

hes family bHLH transcription factor 1

Induced

HGS

hepatocyte growth factor-regulated tyrosine kinase
substrate

Induced

HIST3H3

histone cluster 3, H3

Induced

HNRNPA
1

heterogeneous nuclear ribonucleoprotein A1

Induced

HNRNPF

heterogeneous nuclear ribonucleoprotein F

Induced

HRAS

Harvey rat sarcoma viral oncogene homolog

Induced

HS1BP3

HCLS1 binding protein 3

HSP90A
A1
HSP90A
B1
HSP90B
1
HSPA12
A

heat shock protein 90kDa alpha (cytosolic), class A
member 1
heat shock protein 90kDa alpha (cytosolic), class B
member 1

HSPA4

heat shock 70kDa protein 4

Induced

HSPA5

heat shock 70kDa protein 5 (glucose-regulated protein,
78kDa)

Induced

HSPA9

heat shock 70kDa protein 9 (mortalin)

Induced

HSPB1

heat shock 27kDa protein 1

Induced

Huntingtin

Induced

HTT

Input

heat shock protein 90kDa beta (Grp94), member 1
heat shock 70kDa protein 12A
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Induced
Induced
Induced
Input

APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL
HUWE1
ID2

GENE NAME

TYPE

HECT, UBA and WWE domain containing 1, E3
ubiquitin protein ligase
inhibitor of DNA binding 2, dominant negative helixloop-helix protein

Induced
Input

IGBP1

immunoglobulin (CD79A) binding protein 1

Induced

IGF1R

insulin-like growth factor 1 receptor

Induced

IGFBP3

insulin-like growth factor binding protein 3

Induced

IKBKAP

inhibitor of kappa light polypeptide gene enhancer in Bcells, kinase complex-associated protein

Induced

IMPA1
INVS
IQGAP1

inositol(myo)-1(or 4)-monophosphatase 1

Input

Inversin

Input

IQ motif containing GTPase activating protein 1

Induced

IRS1

insulin receptor substrate 1

Induced

IRS2

insulin receptor substrate 2

Induced

IRS4

insulin receptor substrate 4

Induced

ITCH

itchy E3 ubiquitin protein ligase

Induced

KCTD9

potassium channel tetramerization domain containing 9

KEAP1

kelch-like ECH-associated protein 1

Induced

KNG1

kininogen 1

Induced

KRAS

Kirsten rat sarcoma viral oncogene homolog

Induced

KYNU

Kynureninase

LAMTOR
3

Input

Input

late endosomal/lysosomal adaptor, MAPK and MTOR
activator 3

Induced

lactate dehydrogenase A

Induced

LDHAL6
B

lactate dehydrogenase A-like 6B

Induced

LIG3

ligase III, DNA, ATP-dependent

Input

LDHA
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

LIN7C

lin-7 homolog C (C. elegans)

Induced

LRRK2

leucine-rich repeat kinase 2

Induced

MAD2L1

MAD2 mitotic arrest deficient-like 1 (yeast)

Induced

MAGOH

mago homolog, exon junction complex core
component

Induced

microtubule-associated protein 1 light chain 3 alpha

Induced

MAP1LC3
A
MAP3K3

mitogen-activated protein kinase kinase kinase 1, E3
ubiquitin protein ligase
mitogen-activated protein kinase kinase kinase 3

MAP3K5

mitogen-activated protein kinase kinase kinase 5

Induced

MAP4K4

mitogen-activated protein kinase kinase kinase kinase
4
mitogen-activated protein kinase 1

Induced

microtubule-associated protein tau

Induced

MAP/microtubule affinity-regulating kinase 2

Induced

MAVS

mitochondrial antiviral signaling protein

Induced

MDC1

mediator of DNA-damage checkpoint 1

Induced

MET proto-oncogene, receptor tyrosine kinase

Induced

MAP3K1

MAPK1
MAPT
MARK2

MET

Induced
Induced

Induced

MID1IP1

MID1 interacting protein 1

MINOS1

mitochondrial inner membrane organizing system 1

Induced

mutL homolog 3

Induced

mitochondrial ribosomal protein S7

Induced

MSH2

mutS homolog 2

Induced

MSI1

musashi RNA-binding protein 1

Induced

MSI2

musashi RNA-binding protein 2

Induced

MLH3
MRPS7

Input
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL
MTMR9

GENE NAME

TYPE

myotubularin related protein 9

Input

mechanistic target of rapamycin (serine/threonine
kinase)

Induced

major vault protein

Induced

MYH11

myosin, heavy chain 11, smooth muscle

Induced

MYH9

myosin, heavy chain 9, non-muscle

Induced

NAGK

N-acetylglucosamine kinase

Induced

NCOA3

nuclear receptor coactivator 3

Induced

NDFIP1

Nedd4 family interacting protein 1

Induced

NDFIP2

Nedd4 family interacting protein 2

Induced

MTOR
MVP

NEDD4
NEDD8
NMI

neural precursor cell expressed, developmentally downregulated 4, E3 ubiquitin protein ligase
neural precursor cell expressed, developmentally downregulated 8

Induced
Induced

N-myc (and STAT) interactor

Induced

NOTCH1

notch 1

Induced

NOTCH2

notch 2

Induced

NOTCH3

notch 3

Induced

NR3C1

nuclear receptor subfamily 3, group C, member 1
(glucocorticoid receptor)

Induced

NRAS

neuroblastoma RAS viral (v-ras) oncogene homolog

Induced

NRG1

neuregulin 1

NSF
NSMCE2

Input

N-ethylmaleimide-sensitive factor

Induced

NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO
ligase

Induced

NUBP2

nucleotide binding protein 2

Input

NUDT21

nudix (nucleoside diphosphate linked moiety X)-type
motif 21
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

NUP153

nucleoporin 153kDa

Induced

NXF1

nuclear RNA export factor 1

Induced

OAS3

2'-5'-oligoadenylate synthetase 3, 100kDa

Induced

poly(A) binding protein, cytoplasmic 4 (inducible form)

Induced

poly (ADP-ribose) polymerase 1

Induced

PABPC4
PARP1
PBK
PCNA

TYPE

PDZ binding kinase

Input

proliferating cell nuclear antigen

Induced

platelet-derived growth factor receptor, beta polypeptide

Induced

PEX19

peroxisomal biogenesis factor 19

Induced

PEX5

peroxisomal biogenesis factor 5

Induced

PFAS

phosphoribosylformylglycinamidine synthase

PDGFRB

Input

PIK3C2A

phosphatidylinositol-4-phosphate 3-kinase, catalytic
subunit type 2 alpha

Induced

PIP5K1A

phosphatidylinositol-4-phosphate 5-kinase, type I, alpha

Induced

PLK1

polo-like kinase 1

Induced

PLK2

polo-like kinase 2

Induced

PLK3

polo-like kinase 3

Induced

PLK4

polo-like kinase 4

Induced

PLK5

polo-like kinase 5

Induced

PML

promyelocytic leukemia

Induced

PMP22
POLB
POLR1C

peripheral myelin protein 22

Input

polymerase (DNA directed), beta

Induced

polymerase (RNA) I polypeptide C, 30kDa

Induced
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

POMZP3

POM121 and ZP3 fusion

Input

PPP2CA
PPP3CA
PPP3CC
PRDX1

protein phosphatase 2, catalytic subunit, alpha
isozyme
protein phosphatase 3, catalytic subunit, alpha
isozyme
protein phosphatase 3, catalytic subunit, gamma
isozyme

Induced
Induced
Input

peroxiredoxin 1

Induced

protein kinase, cAMP-dependent, catalytic, alpha

Induced

PRKCA

protein kinase C, alpha

Induced

PRKCB

protein kinase C, beta

Induced

PRKCD

protein kinase C, delta

Induced

PRKCZ

protein kinase C, zeta

Induced

PRKD1

protein kinase D1

Induced

PRKDC

protein kinase, DNA-activated, catalytic polypeptide

Induced

PROCR

protein C receptor, endothelial

PSMA2

proteasome subunit alpha 2

Induced

PSMA3

proteasome subunit alpha 3

Induced

PSMA4

proteasome subunit alpha 4

Induced

PSMA7

proteasome subunit alpha 7

Induced

PSMA8

proteasome subunit alpha 8

Induced

PSMB1

proteasome subunit beta 1

Induced

PSMB2

proteasome subunit beta 2

Induced

PSMB4

proteasome subunit beta 4

Induced

PSMD4

proteasome 26S subunit, non-ATPase 4

Induced

PRKACA
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL
PSMD6

GENE NAME

TYPE

proteasome 26S subunit, non-ATPase 6

Induced

PTEN

phosphatase and tensin homolog

PTK2

protein tyrosine kinase 2

Induced

PTMA

prothymosin, alpha, prothymosin alpha-like

Induced

PTPN1

protein tyrosine phosphatase, non-receptor type 1

Induced

PTPN11

protein tyrosine phosphatase, non-receptor type 11

Induced

PWP1

PWP1 homolog, endonuclein

Input

Input

RAB11A

RAB11A, member RAS oncogene family

Induced

RAB11B

RAB11B, member RAS oncogene family

Induced

RAB11FI
P2

RAB11 family interacting protein 2 (class I)

RAB7A

Input

RAB7A, member RAS oncogene family

Induced

RAC3

ras-related C3 botulinum toxin substrate 3 (rho family,
small GTP binding protein Rac3)

Induced

RAD23B

RAD23 homolog B, nucleotide excision repair protein

Induced

RAD51 recombinase

Induced

RAF1

Raf-1 proto-oncogene, serine/threonine kinase

Induced

RAN

RAN, member RAS oncogene family

Induced

RAD51

RANGRF

RAN guanine nucleotide release factor

Input

RASA1

RAS p21 protein activator (GTPase activating protein) 1

RBM3

RNA binding motif (RNP1, RRM) protein 3

RBX1

ring-box 1, E3 ubiquitin protein ligase

Induced

RIPK1

receptor (TNFRSF)-interacting serine-threonine kinase
1

Induced

RNMTL1

RNA methyltransferase like 1

Induced
Input

Input

173

APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

RPL17

ribosomal protein L17

Induced

RPL5

ribosomal protein L5

Induced

RPS20

ribosomal protein S20

Induced

RPS23

ribosomal protein S23

Induced

RPS27A

ribosomal protein S27a

Induced

ribosomal protein S7

Induced

RPTOR

regulatory associated protein of MTOR, complex 1

Induced

RQCD1

RCD1 required for cell differentiation1 homolog (S.
pombe)

Induced

RUVBL1

RuvB-like AAA ATPase 1

Induced

S100A1

S100 calcium binding protein A1

Induced

S100A3

S100 calcium binding protein A3

Input

S100B

S100 calcium binding protein B

Induced

SACS

sacsin molecular chaperone

RPS7

Input

SEC23A

Sec23 homolog A, COPII coat complex component

Induced

SGTA

small glutamine-rich tetratricopeptide repeat (407)containing, alpha

Induced

SHANK-associated RH domain interactor

Induced

SIN3A

SIN3 transcription regulator family member A

Induced

SIRT1

sirtuin 1

Induced

SKP1

S-phase kinase-associated protein 1

Induced

SHARPI
N

SLC9A3
R1

solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 3
solute carrier family 9, subfamily A (NHE3, cation
proton antiporter 3), member 3 regulator 1

SMAD1

SMAD family member 1

SLC25A3

Induced
Induced
Induced
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

SMAD 2

SMAD family member 2

Induced

SMAD 3

SMAD family member 3

Induced

SMAD 4

SMAD family member 4

Induced

SMC1A

structural maintenance of chromosomes 1A

SMS

TYPE

Input

spermine synthase

Induced

SMAD specific E3 ubiquitin protein ligase 1

Induced

synuclein, alpha (non A4 component of amyloid
precursor)

Induced

SNRPA

small nuclear ribonucleoprotein polypeptide A

Induced

SPTAN1

spectrin, alpha, non-erythrocytic 1

Induced

SRC proto-oncogene, non-receptor tyrosine kinase

Induced

SSU72 homolog, RNA polymerase II CTD
phosphatase

Induced

STAT5A

signal transducer and activator of transcription 5A

Induced

STUB1

STIP1 homology and U-box containing protein 1, E3
ubiquitin protein ligase

Induced

SMURF1
SNCA

SRC
SSU72

STX2

syntaxin 2

Input

SUMO1

small ubiquitin-like modifier 1

Induced

SUMO2

small ubiquitin-like modifier 2

Induced

SUMO3

small ubiquitin-like modifier 3

Induced

TCP1

t-complex 1

Induced

TERT

telomerase reverse transcriptase

Induced

TFE3

transcription factor binding to IGHM enhancer 3

TJP1

tight junction protein 1

Induced

TLR4

toll-like receptor 4

Induced
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APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

TNFRSF1A

tumor necrosis factor receptor superfamily, member
1A

Induced

TNFSF9

tumor necrosis factor (ligand) superfamily, member 9

Input

TNPO1

transportin 1

Input

TOM1L1

target of myb1 like 1 membrane trafficking protein

Induced

TOMM40

translocase of outer mitochondrial membrane 40
homolog (yeast)

Induced

TOP2A

topoisomerase (DNA) II alpha

Induced

TOP2B

topoisomerase (DNA) II beta

Induced

TOP3B

topoisomerase (DNA) III beta

Induced

tumor protein p53

Induced

tumor protein p53 binding protein 1

Induced

translocated promoter region, nuclear basket protein

Induced

TRAF1

TNF receptor-associated factor 1

Induced

TRAF2

TNF receptor-associated factor 2

Induced

TTC28

tetratricopeptide repeat domain 28

TP53
TP53BP1
TPR

Input

TUBA1A

tubulin, alpha 1a

Induced

TUBA4A

tubulin, alpha 4a

Induced

TUBGCP2

tubulin, gamma complex associated protein 2

Input

TUBGCP4

tubulin, gamma complex associated protein 4

Induced

Thioredoxin

Induced

ubiquitin A-52 residue ribosomal protein fusion
product 1

Induced

UBB

ubiquitin B

Induced

UBC

ubiquitin C

Induced

TXN
UBA52
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

UBE2D1

ubiquitin-conjugating enzyme E2D 1

Induced

UBE2D2

ubiquitin-conjugating enzyme E2D 2

Induced

ubiquitin-conjugating enzyme E2I

Induced

UBE2L3

ubiquitin-conjugating enzyme E2L 3

Induced

UBE2N

ubiquitin-conjugating enzyme E2N

Induced

UBE2V2

ubiquitin-conjugating enzyme E2 variant 2

Induced

ubiquitin-like 4A

Induced

UBQLN1

ubiquilin 1

Induced

UBQLN2

ubiquilin 2

Induced

UBQLN4

ubiquilin 4

Induced

UBQLNL

ubiquilin-like

Induced

UBR4

ubiquitin protein ligase E3 component n-recognin 4

Induced

UBR7

ubiquitin protein ligase E3 component n-recognin 7
(putative)

Induced

UBXN7

UBX domain protein 7

Induced

UCHL3

ubiquitin carboxyl-terminal esterase L3 (ubiquitin
thiolesterase)

Induced

UIMC1

ubiquitin interaction motif containing 1

USP10

ubiquitin specific peptidase 10

Induced

USP14

ubiquitin specific peptidase 14 (tRNA-guanine
transglycosylase)

Induced

USP34

ubiquitin specific peptidase 34

Induced

USP39

ubiquitin specific peptidase 39

Induced

USP7

ubiquitin specific peptidase 7 (herpes virus-associated)

Induced

USP8

ubiquitin specific peptidase 8

Induced

UBE2I

UBL4A

TYPE
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

USP9X

ubiquitin specific peptidase 9, X-linked

Input

UVRAG

UV radiation resistance associated

VIM
VPS16
VPS33B
WASL

Vimentin

Induced
Input

vacuolar protein sorting 16 homolog (S. cerevisiae)
vacuolar protein sorting 33 homolog B (yeast)

Induced
Input

Wiskott-Aldrich syndrome-like

Induced

WDHD1

WD repeat and HMG-box DNA binding protein 1

Induced

WDR48

WD repeat domain 48

Induced

WRN

Werner syndrome, RecQ helicase-like

Input

WWP1

WW domain containing E3 ubiquitin protein ligase 1

Induced

WWP2

WW domain containing E3 ubiquitin protein ligase 2

Induced

XIAP
XRCC5
XRCC6

X-linked inhibitor of apoptosis, E3 ubiquitin protein
ligase
X-ray repair complementing defective repair in Chinese
hamster cells 5 (double-strand-break rejoining)
X-ray repair complementing defective repair in Chinese
hamster cells 6

Induced
Induced
Induced

YAP1

Yes-associated protein 1

Induced

YBX1

Y box binding protein 1

Induced

YEATS domain containing 4

Induced

YKT6 v-SNARE homolog (S. cerevisiae)

Induced

YEATS4
YKT6
YWHAB
YWHAE
YWHAH

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, epsilon
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, eta
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Induced
Induced

APPENDIX II
Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members.

SYMBOL

GENE NAME

TYPE

YWHAZ

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, zeta

ZC3H14

zinc finger CCCH-type containing 14

Input

ZEB1

zinc finger E-box binding homeobox 1

Input

ZYX

Zyxin

Induced

Induced
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APPENDIX II
Supplementary Table II-4: G1-X-G2 Analysis-Induced EGFRI Resistance Network
Members that interact with CK2α or CK2α’ within one edge. Table members were
generated using the 85 independent Ensembl IDs identified by the FS analysis. Table
members generated by the STRING analysis considering the scenario G1-X-G2 where
G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be upregulated
in EGFRI resistant NSCLC cells and X is any other node that connects them. Table
members are from the complete network of 385 proteins that interact with CK2α or CK2α’
within one edge.

SYMBOL

GENE NAME

TYPE

AKT1

v-akt murine thymoma viral oncogene homolog 1

Induced

APC

adenomatous polyposis coli

Induced

ARRB2

arrestin, beta 2

Induced

BRCA1

breast cancer 1, early onset

Induced

calmodulin 1 (phosphorylase kinase, delta),
calmodulin 2 (phosphorylase kinase, delta)

Induced

caveolin 1, caveolae protein, 22kDa

Induced

CDC37

cell division cycle 37

Induced

CDH1

cadherin 1, type 1

Induced

CDK1

cyclin-dependent kinase 1

Induced

cyclin-dependent kinase inhibitor 1A (p21, Cip1)

Induced

CALM1:CALM2
CAV1

CDKN1A
CHUK

conserved helix-loop-helix ubiquitous kinase

Input

CREBBP

CREB binding protein

Induced

CSNK2A1

casein kinase 2, alpha 1 polypeptide

Induced

CSNK2A2

casein kinase 2, alpha prime polypeptide

Induced

CTNNB1

catenin (cadherin-associated protein), beta 1,
88kDa

Induced

dishevelled segment polarity protein 2

Induced

H2AFX

H2A histone family, member X

Induced

HDAC1

histone deacetylase 1

Induced

heat shock protein 90kDa alpha (cytosolic), class
A member 1

Induced

DVL2

HSP90AA1
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Supplementary Table II-4 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one edge. Table members
were generated using the 85 independent Ensembl IDs identified by the FS analysis.
Table members generated by the STRING analysis considering the scenario G1-X-G2
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them.
Table members are from the complete network of 385 proteins that interact with CK2α or
CK2α’ within one edge.

SYMBOL

GENE NAME

TYPE

HSP90AB1

heat shock protein 90kDa alpha (cytosolic), class B
member 1

Induced

HSP90B1

heat shock protein 90kDa beta (Grp94), member 1

Induced

HSPA4

heat shock 70kDa protein 4

Induced

IGFBP3

insulin-like growth factor binding protein 3

Induced

IRS1

insulin receptor substrate 1

Induced

ITCH

itchy E3 ubiquitin protein ligase

Induced

MAP1LC3A microtubule-associated protein 1 light chain 3 alpha

Induced

MAPT

microtubule-associated protein tau

Induced

MYH9

myosin, heavy chain 9, non-muscle

Induced

PBK

PDZ binding kinase

Input

PML

promyelocytic leukemia

Induced

PRKDC

protein kinase, DNA-activated, catalytic polypeptide

Induced

PSMA3

proteasome subunit alpha 3

Induced

PSMA4

proteasome subunit alpha 4

Induced

PTEN

phosphatase and tensin homolog

PTPN1

protein tyrosine phosphatase, non-receptor type 1

Induced

RPL5

ribosomal protein L5

Induced

SIN3A

SIN3 transcription regulator family member A

Induced

SIRT1

sirtuin 1

Induced

SNCA

synuclein, alpha (non A4 component of amyloid
precursor)

Induced
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Supplementary Table II-4 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one edge. Table members
were generated using the 85 independent Ensembl IDs identified by the FS analysis.
Table members generated by the STRING analysis considering the scenario G1-X-G2
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them.
Table members are from the complete network of 385 proteins that interact with CK2α or
CK2α’ within one edge.

SYMBOL GENE NAME
SRC

TYPE

SRC proto-oncogene, non-receptor tyrosine kinase

Induced

TOP2A

topoisomerase (DNA) II alpha

Induced

TOP2B

topoisomerase (DNA) II beta

Induced

TP53

tumor protein p53

Induced

UBC

ubiquitin C

Induced

WD repeat domain 48

Induced

WDR48
XRCC5
XRCC6

X-ray repair complementing defective repair in
Chinese hamster cells 5 (double-strand-break
rejoining)
X-ray repair complementing defective repair in
Chinese hamster cells 6
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Induced
Induced

APPENDIX II
Supplementary Table II-5: G1-X-G2 Analysis-Induced EGFRI Resistance Network
Members that interact with CK2α or CK2α’ within one or two edges. Table members
were generated using the 85 independent Ensembl IDs identified by the FS analysis.
Table members generated by the STRING analysis considering the scenario G1-X-G2
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them.
Table members are from the complete network of 385 proteins that interact with CK2α or
CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

ACACB

acetyl-CoA carboxylase beta

Induced

ACTA1

actin, alpha 1, skeletal muscle

Induced

ACTA2

actin, alpha 2, smooth muscle, aorta

Input

ADCY9

adenylate cyclase 9

Input

ADSS

adenylosuccinate synthase

Induced

AKT1

v-akt murine thymoma viral oncogene homolog 1

Induced

AKT2

v-akt murine thymoma viral oncogene homolog 2

Induced

ALDH1B1

aldehyde dehydrogenase 1 family, member B1

Input

ANGEL2

angel homolog 2 (Drosophila)

Input

ANXA6

annexin A6

Input

AP2A1

adaptor-related protein complex 2, alpha 1 subunit

Induced

adenomatous polyposis coli

Induced

androgen receptor

Induced

APC
AR
ARHGEF40
ARRB2
ATM
ATP5C1
ATP5G1
AURKA
BABAM1

Rho guanine nucleotide exchange factor (406) 40

Input

arrestin, beta 2

Induced

ATM serine/threonine kinase

Induced

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1
ATP synthase, H+ transporting, mitochondrial Fo
complex, subunit C1 (subunit 9)

Induced
Input

aurora kinase A

Induced

BRISC and BRCA1 A complex member 1

Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

BARD1

BRCA1 associated RING domain 1

BCCIP

BRCA2 and CDKN1A interacting protein

BCL2

B-cell CLL/lymphoma 2

Induced

BIRC2

baculoviral IAP repeat containing 2

Induced

BIRC3

baculoviral IAP repeat containing 3

Induced

Bloom syndrome, RecQ helicase-like

Induced

BRCA1

breast cancer 1, early onset

Induced

BRCC3

BRCA1/BRCA2-containing complex, subunit 3

BLM

BRE
BTRC
C1QBP
CAD
CALM1:C
ALM2

brain and reproductive organ-expressed (TNFRSF1A
modulator)
beta-transducin repeat containing E3 ubiquitin protein
ligase
complement component 1, q subcomponent binding
protein
carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase
calmodulin 1 (phosphorylase kinase, delta), calmodulin
2 (phosphorylase kinase, delta)

Induced
Input

Input
Induced
Induced
Input
Induced
Induced

CALM2

calmodulin 2 (phosphorylase kinase, delta)

CAMK1

calcium/calmodulin-dependent protein kinase I

CAPZA1

capping protein (actin filament) muscle Z-line, alpha 1

Induced

CAPZB

capping protein (actin filament) muscle Z-line, beta

Induced

CASP8

caspase 8, apoptosis-related cysteine peptidase

Induced

caveolin 1, caveolae protein, 22kDa

Induced

Cbl proto-oncogene, E3 ubiquitin protein ligase

Induced

cyclin D1

Induced

CAV1
CBL
CCND1
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Induced
Input

APPENDIX II
Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL
CCT4

GENE NAME

TYPE

chaperonin containing TCP1, subunit 4 (delta)

Induced

CD2AP

CD2-associated protein

Induced

CDC37

cell division cycle 37

Induced

CDH1

cadherin 1, type 1

Induced

CDK1

cyclin-dependent kinase 1

Induced

CDK2

cyclin-dependent kinase 2

Induced

CDKN1A

cyclin-dependent kinase inhibitor 1A (p21, Cip1)

Induced

CDKN1B

cyclin-dependent kinase inhibitor 1B (p27, Kip1)

Induced

cofilin 1 (non-muscle)

Induced

CHAF1A

chromatin assembly factor 1, subunit A (p150)

Induced

CHORDC
1

cysteine and histidine-rich domain (CHORD)
containing 1

Induced

CHUK

conserved helix-loop-helix ubiquitous kinase

Input

CKAP5

cytoskeleton associated protein 5

Induced

CNOT4

CCR4-NOT transcription complex, subunit 4

Induced

COPS5

COP9 signalosome subunit 5

Induced

COX15

cytochrome c oxidase assembly homolog 15 (yeast)

CFL1

CREBBP

CREB binding protein

Input
Induced

CRTAP

cartilage associated protein

Input

CSE1L

CSE1 chromosome segregation 1-like (yeast)

Induced

CSNK2A1

casein kinase 2, alpha 1 polypeptide

Induced

CSNK2A2

casein kinase 2, alpha prime polypeptide

Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL GENE NAME
CTNNB1

TYPE

catenin (cadherin-associated protein), beta 1, 88kDa

Induced

CTSL

cathepsin L

CUL1

cullin 1

CUTC

cutC copper transporter

Input

DARS2

aspartyl-tRNA synthetase 2, mitochondrial

Input

DAZAP1

DAZ associated protein 1

Induced

DCP2

decapping mRNA 2

Induced

DIP2C

disco-interacting protein 2 homolog C

Input

DIX domain containing 1

Input

DIXDC1

Input
Induced

DKC1

dyskeratosis congenita 1, dyskerin

Induced

DLG1

discs, large homolog 1 (Drosophila)

Induced

DOCK10

dedicator of cytokinesis 10

Input

DPYSL3

dihydropyrimidinase-like 3

Input

DVL2
EEF1A1
EGFR
EIF2AK2

dishevelled segment polarity protein 2

Induced

eukaryotic translation elongation factor 1 alpha 1

Induced

epidermal growth factor receptor
eukaryotic translation initiation factor 2-alpha kinase 2

Input
Induced

EIF3A

eukaryotic translation initiation factor 3, subunit A

EIF4A3

eukaryotic translation initiation factor 4A3

Induced

ELAVL1

ELAV like RNA binding protein 1

Induced

E1A binding protein p300

Induced

EP300
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

EPN1

epsin 1

Induced

EPS15

epidermal growth factor receptor pathway substrate 15

Induced

ERBB2

erb-b2 receptor tyrosine kinase 2

Induced

ERBB3

erb-b2 receptor tyrosine kinase 3

Induced

ERBB4

erb-b2 receptor tyrosine kinase 4

Induced

ERP44

endoplasmic reticulum protein 44

Induced

ESR1

estrogen receptor 1

Induced

exosome component 10

Induced

family with sequence similarity 175, member A

Induced

family with sequence similarity 175, member B

Induced

FANCA

Fanconi anemia, complementation group A

Induced

FANCG

Fanconi anemia, complementation group G

Induced

FANCM

Fanconi anemia, complementation group M

Induced

FASTKD
1

FAST kinase domains 1

Input

FBXL15

F-box and leucine-rich repeat protein 15

Input

FBXW7

F-box and WD repeat domain containing 7, E3 ubiquitin
protein ligase

Induced

GAPDH

glyceraldehyde-3-phosphate dehydrogenase

Induced

GDA

guanine deaminase

Induced

GLRX

glutaredoxin (thioltransferase)

GNS

glucosamine (N-acetyl)-6-sulfatase

Induced

Gephyrin

Induced

EXOSC1
0
FAM175
A
FAM175
B

GPHN
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

GRSF1

G-rich RNA sequence binding factor 1

Induced

H2AFV

H2A histone family, member V

Induced

H2AFX

H2A histone family, member X

Induced

HDAC1

histone deacetylase 1

Induced

HECW2

HECT, C2 and WW domain containing E3 ubiquitin
protein ligase 2

Induced

HES1

hes family bHLH transcription factor 1

Induced

HGS

hepatocyte growth factor-regulated tyrosine kinase
substrate

Induced

HIST3H3

histone cluster 3, H3

Induced

HNRNPA
1

heterogeneous nuclear ribonucleoprotein A1

Induced

HNRNPF

heterogeneous nuclear ribonucleoprotein F

Induced

HRAS

Harvey rat sarcoma viral oncogene homolog

Induced

HS1BP3

HCLS1 binding protein 3

Input

HSP90A
A1
HSP90A
B1
HSP90B
1
HSPA12
A

heat shock protein 90kDa alpha (cytosolic), class A
member 1
heat shock protein 90kDa alpha (cytosolic), class B
member 1

HSPA4

heat shock 70kDa protein 4

Induced

HSPA5

heat shock 70kDa protein 5 (glucose-regulated protein,
78kDa)

Induced

HSPA9

heat shock 70kDa protein 9 (mortalin)

Induced

HSPB1

heat shock 27kDa protein 1

Induced

heat shock protein 90kDa beta (Grp94), member 1
heat shock 70kDa protein 12A
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Induced
Induced
Induced
Input

APPENDIX II
Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL
HTT
HUWE1
ID2

GENE NAME

TYPE

Huntingtin

Induced

HECT, UBA and WWE domain containing 1, E3
ubiquitin protein ligase
inhibitor of DNA binding 2, dominant negative helixloop-helix protein

Induced
Input

IGBP1

immunoglobulin (CD79A) binding protein 1

Induced

IGF1R

insulin-like growth factor 1 receptor

Induced

IGFBP3

insulin-like growth factor binding protein 3

Induced

IKBKAP

inhibitor of kappa light polypeptide gene enhancer in Bcells, kinase complex-associated protein

Induced

IMPA1
INVS
IQGAP1

inositol(myo)-1(or 4)-monophosphatase 1

Input

Inversin

Input

IQ motif containing GTPase activating protein 1

Induced

IRS1

insulin receptor substrate 1

Induced

IRS2

insulin receptor substrate 2

Induced

IRS4

insulin receptor substrate 4

Induced

ITCH

itchy E3 ubiquitin protein ligase

Induced

KCTD9

potassium channel tetramerization domain containing 9

KEAP1

kelch-like ECH-associated protein 1

Induced

KRAS

Kirsten rat sarcoma viral oncogene homolog

Induced

KYNU

Kynureninase

LAMTOR
3

Input

Input

late endosomal/lysosomal adaptor, MAPK and MTOR
activator 3

Induced

LDHA

lactate dehydrogenase A

Induced

LIG3

ligase III, DNA, ATP-dependent

Input

LIN7C

lin-7 homolog C (C. elegans)

Induced

LRRK2

leucine-rich repeat kinase 2

Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

MAD2L1

MAD2 mitotic arrest deficient-like 1 (yeast)

Induced

MAGOH

mago homolog, exon junction complex core
component

Induced

MAP1LC3A

microtubule-associated protein 1 light chain 3 alpha

Induced

MAP3K1

mitogen-activated protein kinase kinase kinase 1, E3
ubiquitin protein ligase

Induced

MAP3K3

mitogen-activated protein kinase kinase kinase 3

Induced

MAP3K5

mitogen-activated protein kinase kinase kinase 5

Induced

MAP4K4

mitogen-activated protein kinase kinase kinase
kinase 4

Induced

MAPK1

mitogen-activated protein kinase 1

Induced

MAPT

microtubule-associated protein tau

Induced

MAP/microtubule affinity-regulating kinase 2

Induced

MAVS

mitochondrial antiviral signaling protein

Induced

MDC1

mediator of DNA-damage checkpoint 1

Induced

MET proto-oncogene, receptor tyrosine kinase

Induced

MARK2

MET
MID1IP1
MLH3

TYPE

MID1 interacting protein 1

Input

mutL homolog 3

Induced

mitochondrial ribosomal protein S7

Induced

MSH2

mutS homolog 2

Induced

MSI1

musashi RNA-binding protein 1

Induced

MSI2

musashi RNA-binding protein 2

Induced

MRPS7

MTMR9
MTOR
MVP
MYH11

myotubularin related protein 9

Input

mechanistic target of rapamycin (serine/threonine
kinase)

Induced

major vault protein

Induced

myosin, heavy chain 11, smooth muscle

Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

MYH9

myosin, heavy chain 9, non-muscle

Induced

NAGK

N-acetylglucosamine kinase

Induced

NCOA3

nuclear receptor coactivator 3

Induced

NDFIP1

Nedd4 family interacting protein 1

Induced

NDFIP2

Nedd4 family interacting protein 2

Induced

NEDD4
NEDD8
NMI

neural precursor cell expressed, developmentally downregulated 4, E3 ubiquitin protein ligase
neural precursor cell expressed, developmentally downregulated 8

Induced
Induced

N-myc (and STAT) interactor

Induced

NOTCH1

notch 1

Induced

NOTCH2

notch 2

Induced

NOTCH3

notch 3

Induced

NR3C1

nuclear receptor subfamily 3, group C, member 1
(glucocorticoid receptor)

Induced

NRAS

neuroblastoma RAS viral (v-ras) oncogene homolog

Induced

N-ethylmaleimide-sensitive factor

Induced

NSF
NSMCE2
NUDT21
NUP153

NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO
ligase
nudix (nucleoside diphosphate linked moiety X)-type
motif 21

Induced
Induced

nucleoporin 153kDa

Induced

NXF1

nuclear RNA export factor 1

Induced

OAS3

2'-5'-oligoadenylate synthetase 3, 100kDa

Induced

poly(A) binding protein, cytoplasmic 4 (inducible form)

Induced

poly (ADP-ribose) polymerase 1

Induced

PABPC4
PARP1
PBK
PCNA

PDZ binding kinase

Input

proliferating cell nuclear antigen
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Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL
PDGFRB

GENE NAME

TYPE

platelet-derived growth factor receptor, beta polypeptide

Induced

PEX19

peroxisomal biogenesis factor 19

Induced

PEX5

peroxisomal biogenesis factor 5

Induced

PFAS

phosphoribosylformylglycinamidine synthase

Input

PIK3C2A

phosphatidylinositol-4-phosphate 3-kinase, catalytic
subunit type 2 alpha

Induced

PIP5K1A

phosphatidylinositol-4-phosphate 5-kinase, type I, alpha

Induced

PLK1

polo-like kinase 1

Induced

PLK2

polo-like kinase 2

Induced

PLK3

polo-like kinase 3

Induced

PLK4

polo-like kinase 4

Induced

PML

promyelocytic leukemia

Induced

polymerase (DNA directed), beta

Induced

POLR1C

polymerase (RNA) I polypeptide C, 30kDa

Induced

POMZP3

POM121 and ZP3 fusion

PPP2CA

protein phosphatase 2, catalytic subunit, alpha isozyme

Induced

PPP3CA

protein phosphatase 3, catalytic subunit, alpha isozyme

Induced

PPP3CC

protein phosphatase 3, catalytic subunit, gamma
isozyme

POLB

PRDX1

Input

Input

peroxiredoxin 1

Induced

protein kinase, cAMP-dependent, catalytic, alpha

Induced

PRKCA

protein kinase C, alpha

Induced

PRKCB

protein kinase C, beta

Induced

PRKCD

protein kinase C, delta

Induced

PRKCZ

protein kinase C, zeta

Induced

PRKD1

protein kinase D1

Induced

PRKACA
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

PRKDC

protein kinase, DNA-activated, catalytic polypeptide

Induced

PROCR

protein C receptor, endothelial

PSMA2

proteasome subunit alpha 2

Induced

PSMA3

proteasome subunit alpha 3

Induced

PSMA4

proteasome subunit alpha 4

Induced

PSMA7

proteasome subunit alpha 7

Induced

PSMA8

proteasome subunit alpha 8

Induced

PSMB1

proteasome subunit beta 1

Induced

PSMB2

proteasome subunit beta 2

Induced

PSMB4

proteasome subunit beta 4

Induced

PSMD4

proteasome 26S subunit, non-ATPase 4

Induced

PSMD6

proteasome 26S subunit, non-ATPase 6

Induced

Input

PTEN

phosphatase and tensin homolog

PTK2

protein tyrosine kinase 2

Induced

PTMA

prothymosin, alpha, prothymosin alpha-like

Induced

PTPN1

protein tyrosine phosphatase, non-receptor type 1

Induced

PTPN11

protein tyrosine phosphatase, non-receptor type 11

Induced

PWP1

PWP1 homolog, endonuclein

Input

Input

RAB11A

RAB11A, member RAS oncogene family

Induced

RAB11B

RAB11B, member RAS oncogene family

Induced

RAB7A

RAB7A, member RAS oncogene family

Induced

RAC3

ras-related C3 botulinum toxin substrate 3 (rho family,
small GTP binding protein Rac3)

Induced

RAD23B

RAD23 homolog B, nucleotide excision repair protein

Induced

RAD51 recombinase

Induced

RAD51
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

RAF1

Raf-1 proto-oncogene, serine/threonine kinase

Induced

RAN

RAN, member RAS oncogene family

Induced

RANGRF

RAN guanine nucleotide release factor

Input

RASA1

RAS p21 protein activator (GTPase activating protein) 1

RBM3

RNA binding motif (RNP1, RRM) protein 3

RBX1

ring-box 1, E3 ubiquitin protein ligase

Induced

RIPK1

receptor (TNFRSF)-interacting serine-threonine kinase
1

Induced

RPL17

ribosomal protein L17

Induced

RPL5

ribosomal protein L5

Induced

RPS20

ribosomal protein S20

Induced

RPS23

ribosomal protein S23

Induced

RPS27A

ribosomal protein S27a

Induced

ribosomal protein S7

Induced

RPTOR

regulatory associated protein of MTOR, complex 1

Induced

RQCD1

RCD1 required for cell differentiation1 homolog (S.
pombe)

Induced

RUVBL1

RuvB-like AAA ATPase 1

Induced

S100A1

S100 calcium binding protein A1

Induced

S100B

S100 calcium binding protein B

Induced

SACS

sacsin molecular chaperone

RPS7

Induced
Input

Input

SEC23A

Sec23 homolog A, COPII coat complex component

Induced

SGTA

small glutamine-rich tetratricopeptide repeat (407)containing, alpha

Induced

SHANK-associated RH domain interactor

Induced

SIN3A

SIN3 transcription regulator family member A

Induced

SIRT1

sirtuin 1

Induced

SHARPI
N
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL
SKP1
SLC25A3
SLC9A3R
1

GENE NAME

TYPE

S-phase kinase-associated protein 1
solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 3
solute carrier family 9, subfamily A (NHE3, cation
proton antiporter 3), member 3 regulator 1

Induced
Induced
Induced

SMAD1

SMAD family member 1

Induced

SMAD 2

SMAD family member 2

Induced

SMAD 3

SMAD family member 3

Induced

SMAD 4

SMAD family member 4

Induced

SMC1A

structural maintenance of chromosomes 1A

SMS

Input

spermine synthase

Induced

SMAD specific E3 ubiquitin protein ligase 1

Induced

synuclein, alpha (non A4 component of amyloid
precursor)

Induced

SNRPA

small nuclear ribonucleoprotein polypeptide A

Induced

SPTAN1

spectrin, alpha, non-erythrocytic 1

Induced

SRC proto-oncogene, non-receptor tyrosine kinase

Induced

SSU72 homolog, RNA polymerase II CTD
phosphatase

Induced

STAT5A

signal transducer and activator of transcription 5A

Induced

STUB1

STIP1 homology and U-box containing protein 1, E3
ubiquitin protein ligase

Induced

SMURF1
SNCA

SRC
SSU72

STX2

syntaxin 2

Input

SUMO1

small ubiquitin-like modifier 1

Induced

SUMO2

small ubiquitin-like modifier 2

Induced

SUMO3

small ubiquitin-like modifier 3

Induced

TCP1

t-complex 1

Induced

TERT

telomerase reverse transcriptase

Induced
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

TYPE

TJP1

tight junction protein 1

Induced

TLR4

toll-like receptor 4

Induced

tumor necrosis factor receptor superfamily, member
1A

Induced

TNFRSF1
A
TNPO1

transportin 1

TOM1L1

target of myb1 like 1 membrane trafficking protein

Induced

TOMM40

translocase of outer mitochondrial membrane 40
homolog (yeast)

Induced

TOP2A

topoisomerase (DNA) II alpha

Induced

TOP2B

topoisomerase (DNA) II beta

Induced

TOP3B

topoisomerase (DNA) III beta

Induced

tumor protein p53

Induced

tumor protein p53 binding protein 1

Induced

translocated promoter region, nuclear basket protein

Induced

TRAF1

TNF receptor-associated factor 1

Induced

TRAF2

TNF receptor-associated factor 2

Induced

TTC28

tetratricopeptide repeat domain 28

TP53
TP53BP1
TPR

Input

Input

TUBA1A

tubulin, alpha 1a

Induced

TUBA4A

tubulin, alpha 4a

Induced

TUBGCP
2
TUBGCP
4

tubulin, gamma complex associated protein 2

Input

tubulin, gamma complex associated protein 4

Induced

Thioredoxin

Induced

ubiquitin A-52 residue ribosomal protein fusion product
1

Induced

UBB

ubiquitin B

Induced

UBC

ubiquitin C

Induced

TXN
UBA52
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL

GENE NAME

UBE2D1

ubiquitin-conjugating enzyme E2D 1

Induced

UBE2D2

ubiquitin-conjugating enzyme E2D 2

Induced

ubiquitin-conjugating enzyme E2I

Induced

UBE2L3

ubiquitin-conjugating enzyme E2L 3

Induced

UBE2N

ubiquitin-conjugating enzyme E2N

Induced

UBE2V2

ubiquitin-conjugating enzyme E2 variant 2

Induced

ubiquitin-like 4A

Induced

UBQLN1

ubiquilin 1

Induced

UBQLN2

ubiquilin 2

Induced

UBQLN4

ubiquilin 4

Induced

UBQLNL

ubiquilin-like

Induced

UBR4

ubiquitin protein ligase E3 component n-recognin 4

Induced

UBR7

ubiquitin protein ligase E3 component n-recognin 7
(putative)

Induced

UBXN7

UBX domain protein 7

Induced

UCHL3

ubiquitin carboxyl-terminal esterase L3 (ubiquitin
thiolesterase)

Induced

UIMC1

ubiquitin interaction motif containing 1

USP10

ubiquitin specific peptidase 10

Induced

USP14

ubiquitin specific peptidase 14 (tRNA-guanine
transglycosylase)

Induced

USP34

ubiquitin specific peptidase 34

Induced

USP39

ubiquitin specific peptidase 39

Induced

USP7

ubiquitin specific peptidase 7 (herpes virusassociated)

Induced

USP8

ubiquitin specific peptidase 8

Induced

UBE2I

UBL4A

TYPE

USP9X

ubiquitin specific peptidase 9, X-linked

UVRAG

UV radiation resistance associated
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APPENDIX II
Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance
Network Members that interact with CK2α or CK2α’ within one or two edges.

SYMBOL
VIM
VPS16
VPS33B
WASL

GENE NAME

TYPE

Vimentin

Input

vacuolar protein sorting 16 homolog (S. cerevisiae)
vacuolar protein sorting 33 homolog B (yeast)

Induced
Input

Wiskott-Aldrich syndrome-like

Induced

WDHD1

WD repeat and HMG-box DNA binding protein 1

Induced

WDR48

WD repeat domain 48

Induced

WRN

Werner syndrome, RecQ helicase-like

Input

WWP1

WW domain containing E3 ubiquitin protein ligase 1

Induced

WWP2

WW domain containing E3 ubiquitin protein ligase 2

Induced

XIAP
XRCC5
XRCC6

X-linked inhibitor of apoptosis, E3 ubiquitin protein
ligase
X-ray repair complementing defective repair in Chinese
hamster cells 5 (double-strand-break rejoining)
X-ray repair complementing defective repair in Chinese
hamster cells 6

Induced
Induced
Induced

YAP1

Yes-associated protein 1

Induced

YBX1

Y box binding protein 1

Induced

YEATS domain containing 4

Induced

YKT6 v-SNARE homolog (S. cerevisiae)

Induced

YEATS4
YKT6
YWHAB
YWHAE
YWHAH
YWHAZ

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, epsilon
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, eta
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, zeta

Induced
Induced
Induced
Induced

ZC3H14

zinc finger CCCH-type containing 14

Input

ZEB1

zinc finger E-box binding homeobox 1

Input

ZYX

Zyxin

Induced
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APPENDIX II
Supplementary Table II-6: G1-X-G2 Analysis-Induced EGFRI Resistance Network
Members that do not interact with CK2α or CK2α’. Table members were generated
using the 85 independent Ensembl IDs identified by the FS analysis. Table members
generated by the STRING analysis considering the scenario G1-X-G2 where G1 and G2
are from the original list of 85 Ensembl IDs of mRNA found to be upregulated in EGFRI
resistant NSCLC cells and X is any other node that connects them. Table members are
from the complete network of 385 proteins that do not interact with CK2α or CK2α’ within
one or two edges.

SYMBOL

GENE NAME

TYPE

ARHGEF9

Cdc42 guanine nucleotide exchange factor 9

Input

DHRS4
DHRS4L2
DHRS4L1

dehydrogenase/reductase (SDR family) member 4,
dehydrogenase/reductase (SDR family) member 4
like 2, dehydrogenase/reductase (SDR family)
member 4 like 1

Input

EGF

epidermal growth factor

Induced

FANCF

Fanconi anemia, complementation group F

Input

FBXO31

F-box protein 31

Input

GAB1
GNG11
KNG1
LDHAL6B
MINOS1

GRB2-associated binding protein 1
guanine nucleotide binding protein (G protein),
gamma 11

Induced
Input

kininogen 1

Induced

lactate dehydrogenase A-like 6B

Induced

mitochondrial inner membrane organizing system 1

Induced

NRG1

neuregulin 1

Input

NUBP2

nucleotide binding protein 2

Input

PLK5
PMP22

polo-like kinase 5

Induced

peripheral myelin protein 22

Input

RAB11 family interacting protein 2 (class I)

Input

RNMTL1

RNA methyltransferase like 1

Input

S100A3

S100 calcium binding protein A3

Input

transcription factor binding to IGHM enhancer 3

Input

tumor necrosis factor (ligand) superfamily, member 9

Input

RAB11FIP2

TFE3
TNFSF9
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Supplementary Table II-7: Induced network members sorted by putative collective
activity of community members. Communities of genes were determined from the
induced network using the cluster_walktrap function in igraph v1.0.1 (Described in
Appendix IV) (385, 386).
Supplementary Table II-7, Community #1: (Putative hallmark/functions: genomic
instability, replicative immortality)

SYMBOL
ATM

GENE NAME

TYPE

ATM serine/threonine kinase

Induced

BRCA1 associated RING domain 1

Induced

BLM

Bloom syndrome, RecQ helicase-like

Induced

BRE

brain and reproductive organ-expressed (TNFRSF1A
modulator)

Induced

chromatin assembly factor 1, subunit A (p150)

Induced

dyskeratosis congenita 1, dyskerin

Induced

family with sequence similarity 175, member A

Induced

FANCA

Fanconi anemia, complementation group A

Induced

FANCF

Fanconi anemia, complementation group F

Input

FANCG

Fanconi anemia, complementation group G

Induced

FANCM

Fanconi anemia, complementation group M

Induced

H2AFX

H2A histone family, member X

Induced

HES1

hes family bHLH transcription factor 1

Induced

LIG3

ligase III, DNA, ATP-dependent

BARD1

CHAF1A
DKC1
FAM175A

Input

MDC1

mediator of DNA-damage checkpoint 1

Induced

MLH3

mutL homolog 3

Induced

MSH2

mutS homolog 2

Induced

NSE2/MMS21 homolog, SMC5-SMC6 SUMO ligase

Induced

PARP1

poly (ADP-ribose) polymerase 1

Induced

PCNA

proliferating cell nuclear antigen

Induced

POLB

polymerase (DNA directed), beta

Induced

NSMCE2
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Supplementary Table II-7, Community #1 (continued): (Putative hallmark/functions:
genomic instability, replicative immortality)

SYMBOL

GENE NAME

TYPE

POLR1C

polymerase (RNA) I polypeptide C, 30kDa

Induced

PWP1

PWP1 homolog, endonuclein

RAD51

RAD51 recombinase

SMC1A

structural maintenance of chromosomes 1A

SUMO2

small ubiquitin-like modifier 2

Induced

SUMO3

small ubiquitin-like modifier 3

Induced

TOP2A

topoisomerase (DNA) II alpha

Induced

TOP2B

topoisomerase (DNA) II beta

Induced

TOP3B

topoisomerase (DNA) III beta

Induced

tumor protein p53 binding protein 1

Induced

TP53BP1

Input
Induced

UIMC1

ubiquitin interaction motif containing 1

WDHD1

WD repeat and HMG-box DNA binding protein 1

WRN
XRCC5
XRCC6

Werner syndrome, RecQ helicase-like
X-ray repair complementing defective repair in Chinese
hamster cells 5 (double-strand-break rejoining)
X-ray repair complementing defective repair in Chinese
hamster cells 6
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APPENDIX II
Supplementary Table II-7, Community #2: (Putative hallmark/functions: growth
signal autonomy, invasion and metastasis, proteomic instability, EGFRI
RESISTANCE MECHANISMS)

SYMBOL

GENE NAME

TYPE

DVL2

dishevelled segment polarity protein 2

Induced

EGF

epidermal growth factor

Induced

ERBB2

erb-b2 receptor tyrosine kinase 2

Induced

ERBB3

erb-b2 receptor tyrosine kinase 3

Induced

ERBB4

erb-b2 receptor tyrosine kinase 4

Induced

FBXL15

F-box and leucine-rich repeat protein 15

Input

inhibitor of DNA binding 2, dominant negative helix-loop-helix
protein

Input

ID2
ITCH

itchy E3 ubiquitin protein ligase

Induced

KRAS

Kirsten rat sarcoma viral oncogene homolog

Induced

LIN7C

lin-7 homolog C (C. elegans)

Induced

NDFIP1

Nedd4 family interacting protein 1

Induced

NDFIP2

Nedd4 family interacting protein 2

Induced

NEDD4

neural precursor cell expressed, developmentally downregulated 4, E3 ubiquitin protein ligase

Induced

NOTCH1

notch 1

Induced

NOTCH2

notch 2

Induced

NOTCH3

notch 3

Induced

NRAS

neuroblastoma RAS viral (v-ras) oncogene homolog

Induced

NRG1

neuregulin 1

RASA1

RAS p21 protein activator (GTPase activating protein) 1

Induced

SMAD specific E3 ubiquitin protein ligase 1

Induced

WWP1

WW domain containing E3 ubiquitin protein ligase 1

Induced

WWP2

WW domain containing E3 ubiquitin protein ligase 2

Induced

SMURF1

Input
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Supplementary Table II-7, Community #3: (Putative hallmark/functions: genomic
instability, deregulating cellular energetics)

SYMBOL GENE NAME

TYPE

GRSF1

G-rich RNA sequence binding factor 1

Induced

MRPS7

mitochondrial ribosomal protein S7

Induced

RNMTL1

RNA methyltransferase like 1

Input

USP39

ubiquitin specific peptidase 39

Induced

Supplementary Table II-7, Community #4: (Putative hallmark/functions: growth
signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS)

SYMBOL

GENE NAME

TYPE

AKT1

v-akt murine thymoma viral oncogene homolog 1

Induced

AKT2

v-akt murine thymoma viral oncogene homolog 2

Induced

adaptor-related protein complex 2, alpha 1 subunit

Induced

adenomatous polyposis coli

Induced

AP2A1
APC

ARHGEF40 Rho guanine nucleotide exchange factor (406) 40
ARRB2

Input

arrestin, beta 2

Induced

BCL2

B-cell CLL/lymphoma 2

Induced

CAV1

caveolin 1, caveolae protein, 22kDa

Induced

Cbl proto-oncogene, E3 ubiquitin protein ligase

Induced

CDC37

cell division cycle 37

Induced

EGFR

epidermal growth factor receptor

CBL

EIF2AK2

Input

eukaryotic translation initiation factor 2-alpha kinase 2

Induced

EPN1

epsin 1

Induced

EPS15

epidermal growth factor receptor pathway substrate 15

Induced

GAB1

GRB2-associated binding protein 1

Induced
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions:
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS)

SYMBOL
GAPDH

GENE NAME

TYPE

glyceraldehyde-3-phosphate dehydrogenase

Induced

GLRX

glutaredoxin (thioltransferase)

HGS

hepatocyte growth factor-regulated tyrosine kinase
substrate

Induced

Harvey rat sarcoma viral oncogene homolog

Induced

HRAS
HSP90AA1
HSP90AB1

heat shock protein 90kDa alpha (cytosolic), class A
member 1
heat shock protein 90kDa alpha (cytosolic), class B
member 1

HSP90B1

heat shock protein 90kDa beta (Grp94), member 1

HSPA12A

heat shock 70kDa protein 12A

Input

Induced
Induced
Induced
Input

HSPA4

heat shock 70kDa protein 4

Induced

HSPA5

heat shock 70kDa protein 5 (glucose-regulated
protein, 78kDa)

Induced

HSPB1

heat shock 27kDa protein 1

Induced

Huntingtin

Induced

insulin-like growth factor 1 receptor

Induced

IRS1

insulin receptor substrate 1

Induced

IRS2

insulin receptor substrate 2

Induced

IRS4

insulin receptor substrate 4

Induced

HTT
IGF1R

KCTD9

potassium channel tetramerization domain
containing 9

LRRK2

leucine-rich repeat kinase 2

Induced

microtubule-associated protein 1 light chain 3 alpha

Induced

MAP3K3

mitogen-activated protein kinase kinase kinase 3

Induced

MAP3K5

mitogen-activated protein kinase kinase kinase 5

Induced

MAPK1

mitogen-activated protein kinase 1

Induced

MAPT

microtubule-associated protein tau

Induced

MAP/microtubule affinity-regulating kinase 2

Induced

MAP1LC3A

MARK2
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions:
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS)
SYMBOL
MET

GENE NAME

TYPE

MET proto-oncogene, receptor tyrosine kinase

Induced

mechanistic target of rapamycin (serine/threonine
kinase)

Induced

major vault protein

Induced

PDGFRB

platelet-derived growth factor receptor, beta polypeptide

Induced

PRKACA

protein kinase, cAMP-dependent, catalytic, alpha

Induced

PRKCA

protein kinase C, alpha

Induced

PRKCB

protein kinase C, beta

Induced

PRKCD

protein kinase C, delta

Induced

PRKCZ

protein kinase C, zeta

Induced

PRKD1

protein kinase D1

Induced

protein tyrosine kinase 2

Induced

PTPN1

protein tyrosine phosphatase, non-receptor type 1

Induced

PTPN11

protein tyrosine phosphatase, non-receptor type 11

Induced

Raf-1 proto-oncogene, serine/threonine kinase

Induced

regulatory associated protein of MTOR, complex 1

Induced

synuclein, α (non A4 component of amyloid precursor)

Induced

SRC proto-oncogene, non-receptor tyrosine kinase

Induced

STAT5A

signal transducer and activator of transcription 5A

Induced

STUB1

STIP1 homology and U-box containing protein 1, E3
ubiquitin ligase

Induced

TTC28

tetratricopeptide repeat domain 28

MTOR
MVP

PTK2

RAF1
RPTOR
SNCA
SRC

Input

TUBA1A

tubulin, alpha 1a

Induced

TUBA4A

tubulin, alpha 4a

Induced

USP8

ubiquitin specific peptidase 8

Induced

YAP1

Yes-associated protein 1

Induced

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, beta

Induced

YWHAB
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions:
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS)

YWHAE
YWHAH
YWHAZ

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, epsilon
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, eta
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, zeta

Induced
Induced
Induced

Supplementary Table II-7, Community #5: (Putative hallmark/functions: invasion
and metastasis, proteomic instability, replicative immortality)

SYMBOL

GENE NAME

TYPE

ACTA1

actin, alpha 1, skeletal muscle

Induced

ACTA2

actin, alpha 2, smooth muscle, aorta

Input

ADSS

adenylosuccinate synthase

Induced

CALM1
CALM2

calmodulin 1 (phosphorylase kinase, delta),
calmodulin 2 (phosphorylase kinase, delta)

Induced

CALM2

calmodulin 2 (phosphorylase kinase, delta)

Induced

CAMK1

calcium/calmodulin-dependent protein kinase I

Input

CAPZA1

capping protein (actin filament) muscle Z-line, alpha 1

Induced

CAPZB

capping protein (actin filament) muscle Z-line, beta

Induced

CD2AP

CD2-associated protein

Induced

CFL1

cofilin 1 (non-muscle)

Induced

DLG1

discs, large homolog 1 (Drosophila)

Induced

EEF1A1

eukaryotic translation elongation factor 1 alpha 1

Induced

EIF3A

eukaryotic translation initiation factor 3, subunit A

Input

ELAVL1

ELAV like RNA binding protein 1

Induced

H2AFV

H2A histone family, member V

Induced

HECW2

HECT, C2 and WW domain containing E3 ubiquitin
protein ligase 2

Induced
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Supplementary Table II-7, Community #5 (continued): (Putative hallmark/functions:
invasion and metastasis, proteomic instability, replicative immortality)

SYMBOL

GENE NAME

HNRNPA1

heterogeneous nuclear ribonucleoprotein A1

Induced

heterogeneous nuclear ribonucleoprotein F

Induced

HSPA9

heat shock 70kDa protein 9 (mortalin)

Induced

IQGAP1

IQ motif containing GTPase activating protein 1

Induced

MYH11

myosin, heavy chain 11, smooth muscle

Induced

MYH9

myosin, heavy chain 9, non-muscle

Induced

HNRNPF

NUDT21
PIK3C2A
PRDX1
SGTA
SLC25A3
SPTAN1

TYPE

nudix (nucleoside diphosphate linked moiety X)-type
motif 21
phosphatidylinositol-4-phosphate 3-kinase, catalytic
subunit type 2 alpha
peroxiredoxin 1

Induced
Induced
Induced

small glutamine-rich tetratricopeptide repeatcontaining, alpha
solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 3

Induced
Induced

spectrin, alpha, non-erythrocytic 1

Induced

SSU72 homolog, RNA polymerase II CTD
phosphatase

Induced

TJP1

tight junction protein 1

Induced

TXN

Thioredoxin

Induced

UBC

ubiquitin C

Induced

VIM

Vimentin

Input

Wiskott-Aldrich syndrome-like

Induced

WDR48

WD repeat domain 48

Induced

YBX1

Y box binding protein 1

Induced

YEATS domain containing 4

Induced

SSU72

WASL

YEATS4
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Supplementary Table II-7, Community #6: (Putative hallmark/functions: invasion
and metastasis, growth and proliferation, cytoskeletal requirements)

SYMBOL

GENE NAME

TYPE

C1QBP

complement component 1, q subcomponent binding
protein

Input

CKAP5

cytoskeleton associated protein 5

Induced

MAD2L1

MAD2 mitotic arrest deficient-like 1 (yeast)

Induced

MINOS1

mitochondrial inner membrane organizing system 1

Induced

PLK2

polo-like kinase 2

Induced

PLK3

polo-like kinase 3

Induced

PLK4

polo-like kinase 4

Induced

PLK5

polo-like kinase 5

Induced

TOMM40

translocase of outer mitochondrial membrane 40
homolog (yeast)

Induced

TUBGCP2

tubulin, gamma complex associated protein 2

Input

TUBGCP4

tubulin, gamma complex associated protein 4

Induced

Supplementary Table II-7, Community #7: (Putative hallmark/functions: evasion of
growth suppressors, proteomic instability, evasion of apoptosis)

SYMBOL
ACACB

GENE NAME

TYPE

acetyl-CoA carboxylase beta

Induced

BRISC and BRCA1 A complex member 1

Induced

BRCC3

BRCA1/BRCA2-containing complex, subunit 3

Input

CAD

carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase

Induced

CCT4

chaperonin containing TCP1, subunit 4 (delta)

Induced

COP9 signalosome subunit 5

Induced

cullin 1

Induced

dihydropyrimidinase-like 3

Input

BABAM1

COPS5
CUL1
DPYSL3
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Supplementary Table II-7, Community #7 (continued): (Putative hallmark/functions:
evasion of growth suppressors, proteomic instability, evasion of apoptosis)

SYMBOL
ERP44

GENE NAME

TYPE

endoplasmic reticulum protein 44

Induced

FAM175B

family with sequence similarity 175, member B

Induced

HUWE1

HECT, UBA and WWE domain containing 1, E3
ubiquitin protein ligase

Induced

immunoglobulin (CD79A) binding protein 1

Induced

IGBP1
IKBKAP
NEDD8
NUBP2

inhibitor of kappa light polypeptide gene enhancer in
B-cells, kinase complex-associated protein
neural precursor cell expressed, developmentally
down-regulated 8

Induced
Induced

nucleotide binding protein 2

Input

2'-5'-oligoadenylate synthetase 3, 100kDa

Induced

poly(A) binding protein, cytoplasmic 4 (inducible form)

Induced

PFAS

phosphoribosylformylglycinamidine synthase

Input

PLK1

polo-like kinase 1

Induced

PPP2CA

protein phosphatase 2, catalytic subunit, alpha
isozyme

Induced

PSMD4

proteasome 26S subunit, non-ATPase 4

Induced

RAD23B

RAD23 homolog B, nucleotide excision repair protein

Induced

RPL17

ribosomal protein L17

Induced

RPL5

ribosomal protein L5

Induced

RPS20

ribosomal protein S20

Induced

RPS23

ribosomal protein S23

Induced

RPS27A

ribosomal protein S27a

Induced

ribosomal protein S7

Induced

Sec23 homolog A, COPII coat complex component

Induced

SIN3A

SIN3 transcription regulator family member A

Induced

TCP1

t-complex 1

Induced

ubiquitin A-52 residue ribosomal protein fusion product
1

Induced

OAS3
PABPC4

RPS7
SEC23A

UBA52
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Supplementary Table II-7, Community #7 (continued): (Putative hallmark/functions:
evasion of growth suppressors, proteomic instability, evasion of apoptosis)

SYMBOL
UBB

GENE NAME

TYPE

ubiquitin B

Induced

UBE2D1

ubiquitin-conjugating enzyme E2D 1

Induced

UBE2D2

ubiquitin-conjugating enzyme E2D 2

Induced

UBE2L3

ubiquitin-conjugating enzyme E2L 3

Induced

UBE2V2

ubiquitin-conjugating enzyme E2 variant 2

Induced

ubiquitin-like 4A

Induced

UBQLN1

ubiquilin 1

Induced

UBQLN2

ubiquilin 2

Induced

UBQLN4

ubiquilin 4

Induced

UBQLNL

ubiquilin-like

Induced

ubiquitin protein ligase E3 component n-recognin 4

Induced

UBXN7

UBX domain protein 7

Induced

UCHL3

ubiquitin carboxyl-terminal esterase L3 (ubiquitin
thiolesterase)

Induced

USP10

ubiquitin specific peptidase 10

Induced

USP14

ubiquitin specific peptidase 14 (tRNA-guanine
transglycosylase)

Induced

USP34

ubiquitin specific peptidase 34

Induced

USP7

ubiquitin specific peptidase 7 (herpes virus-associated)

Induced

ubiquitin specific peptidase 9, X-linked

Input

Zyxin

Induced

UBL4A

UBR4

USP9X
ZYX
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Supplementary Table II-7, Community #8: (Putative hallmark/functions: tumor
promoting inflammation, evasion of apoptosis)

SYMBOL

GENE NAME

TYPE

BIRC2

baculoviral IAP repeat containing 2

Induced

BIRC3

baculoviral IAP repeat containing 3

Induced

CASP8

caspase 8, apoptosis-related cysteine peptidase

Induced

MAP3K1
MAP4K4

mitogen-activated protein kinase kinase kinase 1, E3
ubiquitin protein ligase
mitogen-activated protein kinase kinase kinase
kinase 4

Induced
Induced

MAVS

mitochondrial antiviral signaling protein

Induced

RIPK1

receptor (TNFRSF)-interacting serine-threonine
kinase 1

Induced

SHANK-associated RH domain interactor

Induced

toll-like receptor 4

Induced

TNFRSF1A

tumor necrosis factor receptor superfamily, member
1A

Induced

TNFSF9

tumor necrosis factor (ligand) superfamily, member 9

Input

TRAF1

TNF receptor-associated factor 1

Induced

TRAF2

TNF receptor-associated factor 2

Induced

UBE2N

ubiquitin-conjugating enzyme E2N

Induced

X-linked inhibitor of apoptosis, E3 ubiquitin protein
ligase

Induced

SHARPIN
TLR4

XIAP
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Supplementary Table II-7, Community #9: (Putative hallmark/functions: proteomic
instability, evasion of apoptosis)

SYMBOL
CNOT4

GENE NAME

TYPE

CCR4-NOT transcription complex, subunit 4

Induced

N-ethylmaleimide-sensitive factor

Induced

PSMA2

proteasome subunit alpha 2

Induced

PSMA3

proteasome subunit alpha 3

Induced

PSMA4

proteasome subunit alpha 4

Induced

PSMA7

proteasome subunit alpha 7

Induced

PSMA8

proteasome subunit alpha 8

Induced

PSMB1

proteasome subunit beta 1

Induced

PSMB2

proteasome subunit beta 2

Induced

PSMB4

proteasome subunit beta 4

Induced

PSMD6

proteasome 26S subunit, non-ATPase 6

Induced

RQCD1

RCD1 required for cell differentiation1 homolog (S.
pombe)

Induced

sacsin molecular chaperone

Input

NSF

SACS
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Supplementary Table II-7, Community #10: (Putative hallmark/functions: genomic
instability)

SYMBOL
EIF4A3

GENE NAME

TYPE

eukaryotic translation initiation factor 4A3

EXOSC10 exosome component 10

Induced
Induced

MAGOH

mago homolog, exon junction complex core component

Induced

NUP153

nucleoporin 153kDa

Induced

NXF1

nuclear RNA export factor 1

Induced

RAN

RAN, member RAS oncogene family

Induced

RAN guanine nucleotide release factor

Input

RNA binding motif (RNP1, RRM) protein 3

Input

SNRPA

small nuclear ribonucleoprotein polypeptide A

Induced

TNPO1

transportin 1

Input

translocated promoter region, nuclear basket protein

Induced

RANGRF
RBM3

TPR

Supplementary Table II-7, Community #11: (Putative hallmark/functions: evasion of
growth suppressors, evasion of apoptosis)

SYMBOL GENE NAME

TYPE

ANXA6

annexin A6

Input

IMPA1

inositol(myo)-1(or 4)-monophosphatase 1

Input

S100B

S100 calcium binding protein B

Induced
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APPENDIX II
Supplementary Table II-7, Community #12: (Putative hallmark/functions: growth
signal autonomy, evasion of growth suppressors)

SYMBOL

GENE NAME

TYPE

phosphatidylinositol-4-phosphate 5-kinase, type I,
alpha
protein phosphatase 3, catalytic subunit, alpha
isozyme
protein phosphatase 3, catalytic subunit, gamma
isozyme

PIP5K1A
PPP3CA
PPP3CC

Induced
Induced
Input

RAB11A

RAB11A, member RAS oncogene family

Induced

RAB11B

RAB11B, member RAS oncogene family

Induced

RAB11 family interacting protein 2 (class I)

Input

RAB11FIP2

Supplementary Table II-7, Community
deregulating cellular energetics)

SYMBOL
ATP5C1
ATP5G1

COX15
LAMTOR3

(Putative

GENE NAME

hallmark/functions:

TYPE

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1
ATP synthase, H+ transporting, mitochondrial Fo
complex, subunit C1 (subunit 9)

Supplementary Table II-7, Community
deregulating cellular energetics)

SYMBOL

#13:

#14:

(Putative

GENE NAME

Induced
Input

hallmark/functions:

TYPE

cytochrome c oxidase assembly homolog 15 (yeast)

Input

late endosomal/lysosomal adaptor, MAPK and MTOR
activator 3

Induced
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APPENDIX II
Supplementary Table II-7, Community #15: (Putative hallmark/functions: tumor
promoting inflammation)

SYMBOL GENE NAME

TYPE

MTMR9

myotubularin related protein 9

Input

NMI

N-myc (and STAT) interactor

Induced

POM121 and ZP3 fusion

Input

POMZP3

Supplementary Table II-7, Community #16: (Putative hallmark/functions: tumor
promoting inflammation, angiogenesis, tumor microenvironment influence)

SYMBOL

GENE NAME

TYPE

CTSL

cathepsin L

Input

KNG1

kininogen 1

Induced

Supplementary Table II-7, Community
deregulating cellular energetics)

SYMBOL
BCCIP

#17:

(Putative

hallmark/functions:

GENE NAME

TYPE

BRCA2 and CDKN1A interacting protein

Input

cysteine and histidine-rich domain (CHORD) containing 1

Induced

guanine deaminase

Induced

KYNU

Kynureninase

Input

LDHA

lactate dehydrogenase A

Induced

SMS

spermine synthase

Induced

CHORDC1
GDA
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Supplementary Table II-7, Community
deregulating cellular energetics)

SYMBOL
DARS2
DCP2

#18:

(Putative

GENE NAME

hallmark/functions:

TYPE

aspartyl-tRNA synthetase 2, mitochondrial

Input

decapping mRNA 2

Induced

Supplementary Table II-7, Community #19: (Putative hallmark/functions: growth
signal autonomy, invasion and metastasis, genomic instability)

SYMBOL
AR

GENE NAME

TYPE

androgen receptor

Induced

AURKA

aurora kinase A

Induced

BRCA1

breast cancer 1, early onset

Induced

beta-transducin repeat containing E3 ubiquitin protein
ligase

Induced

cyclin D1

Induced

CDH1

cadherin 1, type 1

Induced

CDK1

cyclin-dependent kinase 1

Induced

CDK2

cyclin-dependent kinase 2

Induced

CDKN1A

cyclin-dependent kinase inhibitor 1A (p21, Cip1)

Induced

CDKN1B

cyclin-dependent kinase inhibitor 1B (p27, Kip1)

Induced

conserved helix-loop-helix ubiquitous kinase

Input

CREBBP

CREB binding protein

Induced

CSNK2A1

casein kinase 2, alpha 1 polypeptide

Induced

CSNK2A2

casein kinase 2, alpha prime polypeptide

Induced

CTNNB1

catenin (cadherin-associated protein), beta 1, 88kDa

Induced

EP300

E1A binding protein p300

Induced

ESR1

estrogen receptor 1

Induced

BTRC
CCND1

CHUK
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APPENDIX II
Supplementary
Table
II-7,
Community
#19
(continued):
(Putative
hallmark/functions: growth signal autonomy, invasion and metastasis, genomic
instability)

SYMBOL

GENE NAME

TYPE

FBXO31

F-box protein 31

Input

FBXW7

F-box and WD repeat domain containing 7, E3 ubiquitin
protein ligase

Induced

HDAC1

histone deacetylase 1

Induced

HIST3H3

histone cluster 3, H3

Induced

KEAP1

kelch-like ECH-associated protein 1

Induced

NCOA3

nuclear receptor coactivator 3

Induced

NR3C1

nuclear receptor subfamily 3, group C, member 1
(glucocorticoid receptor)

Induced

PBK

PDZ binding kinase

Input

PML

promyelocytic leukemia

Induced

protein kinase, DNA-activated, catalytic polypeptide

Induced

PTEN

phosphatase and tensin homolog

Input

PTMA

prothymosin, alpha, prothymosin alpha-like

Induced

RAC3

ras-related C3 botulinum toxin substrate 3 (rho family,
small GTP binding protein Rac3)

Induced

RBX1

ring-box 1, E3 ubiquitin protein ligase

Induced

RuvB-like AAA ATPase 1

Induced

SIRT1

sirtuin 1

Induced

SKP1

S-phase kinase-associated protein 1

Induced

SMAD1

SMAD family member 1

Induced

SMAD 2

SMAD family member 2

Induced

SMAD 3

SMAD family member 3

Induced

SMAD 4

SMAD family member 4

Induced

SUMO1

small ubiquitin-like modifier 1

Induced

TERT

telomerase reverse transcriptase

Induced

TP53

tumor protein p53

Induced

PRKDC

RUVBL1
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APPENDIX II
Supplementary
Table
II-7,
Community
#19
(continued):
(Putative
hallmark/functions: growth signal autonomy, invasion and metastasis, genomic
instability)

UBE2I

ubiquitin-conjugating enzyme E2I

Induced

ZEB1

zinc finger E-box binding homeobox 1

Input

Supplementary Table II-7, Community #20: (Putative hallmark/functions: genomic
instability, proteomic instability)

SYMBOL GENE NAME

TYPE

RAB7A

RAB7A, member RAS oncogene family

Induced

UVRAG

UV radiation resistance associated

Induced

VPS16

vacuolar protein sorting 16 homolog (S. cerevisiae)

Induced

vacuolar protein sorting 33 homolog B (yeast)

Input

VPS33B

Supplementary Table II-7, Community #21: (Putative hallmark/functions: growth
signal autonomy, deregulating cellular energetics, Endo/Exocytosis)

SYMBOL GENE NAME

TYPE

STX2

syntaxin 2

Input

YKT6

YKT6 v-SNARE homolog (S. cerevisiae)

Induced
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APPENDIX II
Supplementary Table II-7, Community #22: (Putative hallmark/functions: growth
signal autonomy, proteomic instability)

SYMBOL GENE NAME

TYPE

CRTAP

cartilage associated protein

Input

TOM1L1

target of myb1 like 1 membrane trafficking protein

Induced

Supplementary Table II-7, Community #23: (Putative hallmark/functions: posttranslational gene regulation, proteomic instability)

SYMBOL GENE NAME
DAZAP1

TYPE

DAZ associated protein 1

Induced

MSI1

musashi RNA-binding protein 1

Induced

MSI2

musashi RNA-binding protein 2

Induced

zinc finger CCCH-type containing 14

Input

ZC3H14

Supplementary Table II-7, Community #24: (Putative hallmark/functions: genomic
instability)

SYMBOL
CSE1L
SLC9A3R1

GENE NAME

TYPE

CSE1 chromosome segregation 1-like (yeast)

Induced

solute carrier family 9, subfamily A (NHE3, cation proton
antiporter 3), member 3 regulator 1

Induced
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APPENDIX II
Supplementary Table II-7, Community #25: (Putative
deregulating cellular energetics, proteomic instability)

hallmark/functions:

SYMBOL

GENE NAME

ALDH1B1

aldehyde dehydrogenase 1 family, member B1

Input

ubiquitin protein ligase E3 component n-recognin 7
(putative)

Induced

UBR7

TYPE

Supplementary Table II-7, Community
deregulating cellular energetics)

SYMBOL
GNS

GENE NAME

(Putative

hallmark/functions:

TYPE

glucosamine (N-acetyl)-6-sulfatase

LDHAL6B lactate dehydrogenase A-like 6B
NAGK

#26:

N-acetylglucosamine kinase

Induced
Induced
Induced
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APPENDIX II
Supplementary Table II-7, Proteins with no community affiliation:

SYMBOL

GENE NAME

TYPE

PROCR

protein C receptor, endothelial

Input

GNG11

guanine nucleotide binding protein (G protein), gamma
11

Input

Cdc42 guanine nucleotide exchange factor (406) 9

Input

dedicator of cytokinesis 10

Input

Inversin

Input

disco-interacting protein 2 homolog C

Input

S100A1

S100 calcium binding protein A1

Induced

ADCY9

adenylate cyclase 9

Input

HS1BP3

HCLS1 binding protein 3

Input

PMP22

peripheral myelin protein 22

Input

transcription factor binding to IGHM enhancer 3

Input

dehydrogenase/reductase (SDR family) member 4,
dehydrogenase/reductase (SDR family) member 4 like
2, dehydrogenase/reductase (SDR family) member 4
like 1

Input

MID1IP1

MID1 interacting protein 1

Input

ANGEL2

angel homolog 2 (Drosophila)

Input

PEX19

peroxisomal biogenesis factor 19

Induced

S100A3

S100 calcium binding protein A3

Input

cutC copper transporter

Input

IGFBP3

insulin-like growth factor binding protein 3

Induced

DIXDC1

DIX domain containing 1

Input

FASTKD1

FAST kinase domains 1

Input

PEX5

peroxisomal biogenesis factor 5

Induced

GPHN

Gephyrin

Induced

ARHGEF9
DOCK10
INVS
DIP2C

TFE3
DHRS4:D
HRS4L2:
DHRS4L1

CUTC
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APPENDIX II
Supplementary Figure II-1: NSCLC cells most sensitive to CX-4945 have decreased
CSNK2B expression. U133A Affymetrix signal intensity values for (A) CSNK2A1
(Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at), (B)
CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated from
untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko, 2006
#238]. Values for each gene set were normalized to corresponding expression in Small
Airway Epithelial Cells (SAEC) and is shown as percent change.

A
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APPENDIX II
Supplementary Figure II-1 (continued): NSCLC cells most sensitive to CX-4945 have
decreased CSNK2B expression. U133A Affymetrix signal intensity values for (A)
CSNK2A1 (Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at),
(B) CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated
from untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko,
2006 #238]. Values for each gene set were normalized to corresponding expression in
Small Airway Epithelial Cells (SAEC) and is shown as percent change.
B
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APPENDIX II
Supplementary Figure II-1 (continued): NSCLC cells most sensitive to CX-4945 have
decreased CSNK2B expression. U133A Affymetrix signal intensity values for (A)
CSNK2A1 (Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at),
(B) CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated
from untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko,
2006 #238]. Values for each gene set were normalized to corresponding expression in
Small Airway Epithelial Cells (SAEC) and is shown as percent change.
C
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APPENDIX III

APPENDIX III: SUPPLEMENTARY FIGURES FOR CHAPTER 5

Supplementary Figure III-1: Comparison of CX-4945 treatment on erlotinib
response. A549 and PC9 samples treated only with ± 1µM CX-4945 from Figures 3 and
5 to determine the impact of 7-day incubation of CX-4945 on erlotinib sensitivity in cells
not modulated with TGFβ, LY-2109761, or SB-431542. Unpaired t-test comparing
untreated and CX-4945 treated curves indicates that the differences between the curves
are not significant.

Copyright © Madeline Krentz Gober, 2017
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